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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1. NATURAL PRODUCTS: 
Chemical substances biosynthesized in the living system i.e. plants, animals and microbes are called as 
natural products. 
Natural products are mainly divided into two major classes:  
 
1.1.1. PRIMARY METABOLITES:  
Primary metabolites are the biochemical’s which are utilized by the basic metabolic pathways required for 
life. They play enormous cellular functions such as absorption of nutrients, generation of energy, growth 
and development of organism. They have a broad species distribution which encompasses many phyla 
and more than one kingdom e.g. carbohydrates, lipids, amino acids and nucleic acids1,2 which are the 
essential macromolecules of life.3 
 
1.1.2. SECONDARY METABOLITES: 
Contradictorily, the secondary metabolites are nonessential and are not vital for the survival of organism. 
Furthermore, secondary metabolites typically have a narrow species distribution. Secondary metabolites 
display a broad range of functions. These include pheromones; the social signaling molecules between the 
individuals of the same species, signaling molecules that magnetize and activate symbiotic organisms, 
agents which sequester, solubilize and transport nutrients (siderophores etc.) across cell membrane and 
defensive weapons like repellants, venoms, toxins etc. that are used against competitors, prey, and 
predators.4 Secondary metabolites are not essential to survival but do increase the competitiveness of the 
producer5 within its environment, because of their ability to modulate biochemical and signal transduction 
pathways. General structural classes of secondary metabolites include alkaloids, phenyl propanoids, 
polyketides, and terpenoids, peptides, fatty acids etc. 
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1.2. MEDICINES IN FOLKLORE: 
Natural products have been recognized since ancient ages as a source of medicine in the form of 
traditional medicines, remedies, potions, and oil for the treatment of human diseases. History of 
medicines dates back practically to the dawn of human civilization. The ancient civilizations of the 
Chinese, Indians and North Africans provide written evidence for the use of natural products as drugs. 
Before the 20th century, crude and semi-pure extracts from plants, animals, microbes and minerals 
represented the only available medication to treat the illness. The earliest record of use of natural products 
as medicines was documented in 2600 B.C. The clay tablets in cuneiform from Mesopotamia depict the 
use of oils from Cupressus sempervirens (Cypress) and Commiphora species (myrrh) to treat cough, cold 
and inflammation, which are still being used. The Ebers papyrus (2900 B.C.) is an Egyptian 
pharmaceutical record, which documents over 700 plant based drugs ranging from gargles, pills, and 
infusions to ointments. The Chinese Materia Medica (1100 B.C.), Shennong Herbal (~ 100 B.C., 365 
drugs) and the Tang Herbal (659 A. D., 850 drugs) are the documented records of the uses of natural 
products.6 Ayurveda is the traditional healing modality of the Vedic culture from India. Ayurveda is said 
to be 2000 to 5000 years old which claims the use of plant extracts to cure different human diseases e.g. 
Alghi maurorum Medik (Camel thorns) aids in the treatment of anorexia, constipation, dermatosis, 
epistaxis, fever, leprosy, and obesity.7 The Konkani peoples from south western India use to treat asthama 
by smoking  the plants; whilst the Romans  used to have the plant for nasal polyps.8 The steam-produced 
charcoal of the fungus Piptoporus betulinus was used as an antiseptic and disinfectant.9 The red algae 
Chodrus crispus and Mastocarpus stellatus were sources of beverages, which were popular as a folk cure 
for colds, sore throats, and chest infections including tuberculosis. The alga was also used for kidney 
trouble and burns when boiled with milk or water.10, 11  
In the 20th century, the receptor theory of drug action revolutionized the thinking in the use of drugs. The 
effect of drug in the human body is mediated by the specific interaction of the drug molecules with 
biological macromolecules. This breakthrough led to the beginning of new era in the discovery of new 
drugs, as the extracts from the natural sources have replaced pure, isolated chemicals and since then it 
became the standard treatments for diseases. The isolation of morphine from sticky mixture of alkaloids 
(including codeine, morphine, noscapine, thebaine, and papaverine) by Friedrich Serturner from Papaver 
somniferum in 1806, and digoxin, a heart stimulant originating from flower Digitalis lanata were the 
classical example of isolation of bioactive ingredient and elucidation of their structures. The evolution in 
synthetic chemistry led to the chemical synthesis of these compounds, since then natural products have 
been extensively screened for their medical purposes. 
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1.3. CRUCIAL ROLE OF NATURAL PRODUCTS IN DRUG DISCOVERY: 
The reward of half of the 2015 Nobel Prize in medicine or physiology to Drs. Satoshi Omura and William 
C. Campbell for their discovery and development of antiparasitic avermectin B1a, B1b (1) and ivermectin 
B1a, B1b (2) complexes (figure-1), with the other half being awarded to Prof. Youyou Tu for her discovery 
and development of antimalerial drug artemisinin (3) (figure-2) highlights the imperative role of natural 
products in drug discovery. 
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Figure-1: Avermectin/Ivermectin complex. 
 
Nature’s biosynthetic machinery continues to provide unique structural diversity in comparison to 
standard and/or combinatorial synthesis. The investigation of natural products brings out a variety of lead 
structures, which may be used as a template for the development of new therapeutic agents. Complex 
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natural scaffolds gains some more advantages over synthetic scaffolds; indeed, the following 
characteristics of the natural products make them the favorable leads in drug discovery: 
 
1.3.1. CHEMICAL DIVERSITY:  
It has been recognized that the natural products structures have the characteristic of high chemical and 
structural diversity. In fact, about 40% of the chemical scaffolds found in the natural products are absent 
in the today’s medicinal chemistry. As a result of the natural selection process, natural products possess a 
unique and vast chemical diversity with optimal interaction with biological macromolecules. 
The studies by Feher and Schmid12 reveal that natural products typically have a greater number of chiral 
centers and native steric complexity, with bridgehead tetrahedral carbon atoms, rings and chiral centers 
than either synthetic drugs or combinatorial libraries. 
Moreover, the drugs and combinatorial molecules bears significant number of nitrogen, sulphur, and 
halogen containing groups, whereas natural products contain more oxygen atoms.12  
Natural products contains less number of aromatic ring atoms and heavy metal atoms compared to 
synthetic drugs and combinatorial libraries, nevertheless, the natural products incurs prominent molecular 
rigidity with more number of solvated hydrogen bond donors and acceptors.  
Natural product libraries also have a broader distribution of physicochemical properties such as molecular 
weight, octanol-water distribution coefficient and ring diversity compared to synthetic counterparts. In 
fact, the currently marked drugs bears less than one fifth of the ring systems found in natural products.12 
 
1.3.2. BIOCOMPATIBILITY: 
Another important advantage with natural products is that they are biologically evolved. Moreover, the 
typical biosynthesis of natural products involves repeated interaction of biosynthetic intermediates with 
the modulating enzymes, and the actual biological function of many natural products comprises binding 
to the other macromolecules such as nucleic acids, proteins, enzymes, receptors, ion channels and 
carbohydrates etc. One can assume that the ability of natural products to bind with other macromolecules 
is biologically validated. It is a disregarded fact that most of the natural products carries an advanced 
binding structural motifs compared with synthetics, most likely due to the sterically complexity and 
typical spatial arrangement of atoms in natural products scaffolds.13 
Pertaining to this chemo-diversity and bio-specificity, natural products have proven to be the richest 
source of lead compounds for new drug development.  
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Figure-2: Representative examples of natural product drugs, modulating different targets. 
 
Indeed, 1355 New Chemical Entities (NCEs) have been reported in the years 1981-2010, of which 540 
(40%) NCEs were either natural products or derivatives of natural products. In particular, 63 of the 99 
(64%) small molecules anticancer drugs and 78 of the 104 (75%) antibiotics developed from 1981-2010 
have emerged from natural products. The representative examples include, artemisinin (antimalarial) (3) 
and lovastatin (cholesterol lowering agent) (4) (figure-2).14 Thus, the natural products can be sensed as a 
population of privileged structures selected by evolutionary pressures to interact with a wide variety of 
proteins and other biological targets to elicit specific biological response, an analogy based on the fact 
that natural products have become effective drugs in a wide variety of therapeutic indications. 
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1.4. HISTORICALLY IMPORTANT NATURAL PRODUCTS: 
Natural products, including plants, animals and minerals have been the most successful source of 
potential drug leads. Indeed, clinical, pharmacological and chemical studies of these traditional 
medicines, which were predominantly derived from plants, were the basis of early medicine. The well 
known example to date would be the anti-inflammatory agent; acetylsalicylic acid (aspirin) (5) derived 
from the natural product, salicin isolated from the bark of willow tree Salix alba L.15 Morphine (6) as 
mentioned earlier was a commercially important drug, first reported in 1803. The antimalarial drug 
quinine (7) isolated from the bark of Cinchona succirubra, has been approved by US FDA in 2004. Prior 
to this approval, it had been used for centuries to treat malaria, fever, indigestion, mouth and throat 
disease and cancer.15 The L-histidine derived alkaloid, Pilocarpine (8), found in Pilocarpus jaborandi 
has been used as a drug in the treatment of chronic angle glaucoma and acute angle-closure glaucoma for 
over 100 years. In 1994, an oral formulation of pilocarpine (8) was approved by FDA to treat dry mouth 
(xerostomia) which is a side effect of head and neck cancer radiation therapy. Pilocarpine (8) is also used 
as an stimulant for the sweat glands to measure the concentration of sodium and chloride ions in the 
sweat, which is used in the diagnosis of cystic fibrosis16 (figure-3). 
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Figure -3: Acetylsalicylic acid (5), Morphine (6), Quinine (7) and Pilocarpine (8). 
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1.5. SOURCES OF NATURAL PRODUCTS: 
Origins of natural products can be broadly divided into four parts. 
1.5.1. NATURAL PRODUCTS FROM MICROORGANISMS 
1.5.2. NATURAL PRODUCTS FROM PLANTS 
1.5.3. NATURAL PRODUCTS FROM MARINE SOURCES 
1.5.5. NATURAL PRODUCTS FROM ANIMALS 
 
1.5.1. NATURAL PRODUCTS FROM MICROORGANISMS:  
Microorganisms particularly fungi have been a part of human life for thousands of years. They have a 
capacity to produce a wide variety of bioactive complex organic molecules which are used in microbial 
warfare. Microbial secondary metabolites were unexplored as a source of potential drugs until the 
discovery of antibacterial filtrate “penicillin G” (9) by Fleming in 1928. Re-isolation and clinical studies 
by Chain, Florey, and co-workers in the early 1940s, followed by commercialization of synthetic 
penicillins revolutionized the drug discovery.17a-f Following the success of penicillin, industry and 
academic research groups assembled and screened large number of microbial cultures in order to discover 
new antibiotics. The outcome of research was enormous, which led to the discovery of structurally 
divergent antibiotics such as chloramphenicol (10), cephalosporin C (11), chlortetracycline (12), 
streptomycin (13), and erythromycin (14). All of these compounds, or derivatives thereof, are still in 
use as drugs today. The key breakthrough in drug discovery was the use of mechanism based screening 
for bioassay guided fractionation. One of the compounds identified in early 1970s using mechanism based 
screening methods was the HMG-CoA reductase inhibitor mevastatin (15) from Penicillium citrium. 
Mevastatin (15) was also reported as an antifungal agent from P. brevicompactum. Later mevastatin 
(15) and lovastatin (3) were found to be lead structures for a series of antilipidemic drugs collectively 
known as“statins”18,19 
N
S
H
N
O
OH
O
O
Ph
9
 
O2N
OH
HN
OH
CHCl2
O10
 
8 
 
N
H
N
O
O
OH
O
S
COOH
OAc
11
 
Cl
OH O
H
OH
OH
O O
NH2
OH
H
NOH
12
 
 
O
O
O OH
CHO
O
OH
H
N
HN
OH
MeHN
OH
HO
HO
HO
H2N
NH NH
NH2
13
 
OH
O
O
O
O
OH
OHOH
O
O
HO
NMe2
OMe
OH14
 
O
O
O OH
O
15
 
 
Figure-4: Structures of Penicillin G (9), Chloramphenicol (10), Cephalosporin C (11), Chlortetracycline 
(12), Streptomycin (13), Erythromycin (14) and Mevastatin (15). 
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1.5.2. NATURAL PRODUCTS FROM PLANTS: 
Human civilizations from different parts of the world have well documented the medicinal uses of plants 
from decades. Plants ecosystem have evolved and adapted over millions of years to withstand against 
insects, phytopathogenic microorganisms i.e. bacteria, fungi, and environmental changes. The wide 
distribution of plant species encompassing the world prepares them to produce unique, structurally 
diverse secondary metabolites. Their ethnopharmacological properties have been used as a primary source 
of medicines for early drug discovery.21, 22 According to the World Health Organization (WHO), 80% of 
people still rely on plant-based traditional medicines for primary health care22 and 80% of 122 plant 
derived drugs were related to their original ethnopharmacological purpose.23 The knowledge associated 
with traditional medicine (complementary or alternative herbal products) has promoted further 
investigations of medicinal plants as a potential medicines and has led to the isolation of many natural 
products that have become well known pharmaceuticals. 
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Figure-5: Paclitaxel (16). 
The most widely used breast cancer drug is paclitaxel (Taxol ®) (16), isolated from the bark of Taxus 
brevifolia (pacific yew). In 1962 the US department of agriculture first collected the bark as part of their 
exploratory plant screening program at the National Cancer Institute (NCI). It has received the FDA 
approvals for several uses as a anticancer drug in 1992.24 Another example of anticancer compound 
currently used in anticancer therapy is ingenol-3-angelate (17) a derivative of the polyhydroxy 
diterpenoid ingenol isolated from the sap of Euphorbia peplus.25 A gel formulation of the drug has been 
approved by the US Food and Drug Administration (FDA) and by the European Medicines Agency 
(EMA) for the topical treatment of actinic keratosis.  
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Figure -6: Ingenol-3-angelate (17), Podophyllotoxin (18). 
 
Podophyllotoxin (abbreviated as PPT, 18) also known as podofilox, is a lignan extracted from the roots 
and rhizomes of Podophyllum species. It is used on the skin as a topical treatment of external genital 
warts, caused by some types of the human papilomavirus (HPV), and other warts. PPT and its synthetic 
derivatives display a wide selection in medical applications such as purgative, vesicant, antirheumatic, 
antiviral, and antitumor agents.26 
 
1.5.3. NATURAL PRODUCTS FROM MARINE SOURCES: 
The majority of the currently marketed drugs are of terrestrial origins. However, the mining of novel 
sources, such as the marine environment, which covers 70% of the earth’s surface and represents the 
largest unexplored wealthy resource, have opened the avenues for chemical and biological novelties. A 
comparative analysis by Kong and co-workers showed that marine natural products are superior to the 
terrestrial one in terms of chemical diversity.27 In the deep sea under extreme environmental conditions 
like high temperature (more than 400 °C in hydrothermal vent), extreme pH and pressure and in presence 
of high levels of abiotic chemicals such as H2S, high densities of biologically diverse communities with 
distinct metabolism were observed. Hence, the marine environment represents a unique resource that 
encloses a massive biological diversity, which will potentially lead to unique biologically active 
compounds that we can translate into novel medicines.28a  
Natural products from filter-feeding marine invertebrates and in particular, sponges, have proven to be a 
rich source of structurally unique pharmacologically active compounds, with over 16,000 molecules 
isolated so far with a continuing pace of discovery of hundreds of novel bioactive molecules per year. All 
classes of pharmaceuticals have been represented in this discovery process, including antiprotozoals, 
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pesticides, TGF-beta inhibitors and cationic channel blockers, anticancer, cytotoxic, antiviral, anti-
inflammatory and antibacterial compounds. The important biosynthetic pathways found in sponges which 
give rise to these compounds include the terpenoids, fatty acid, polyketide, alkaloid, isoprenoid, and non-
ribosomal protein synthase pathways.28 b-c 
As of 2015, the following five marine-derived drugs are approved in the market29a 
1) Ziconotide (Prialt; 19) possesses a potent analgesic effect, which is mediated through a completely 
novel mechanism of action; it reversibly blocks N-type voltage-sensitive calcium channels, inhibiting the 
activity of a subset of neurons including pain-sensing primary nociceptors.29b It is synthetic form of ω-
conotoxin peptide derived from the toxin of cone snail species Conus magnus. Ziconotide represents the 
first N type calcium-channel blocker and the first marine-derived peptide drug which hits the market.30 
Moreover, the discovery of this novel mechanism of action proved the key role of N-type calcium 
channels in signal-regulation innociceptive neurons, and further validated those channels as drug 
targets.29b, 30 Interestingly, ziconotide is 1000-times more potent than morphine and it is not addictive in 
nature, which is common side effect of opiate based therapies.31  
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Figure-7: Ziconotide (Prialt; 19).  
2) Cytarabine: FDA approved in 1969 as anticancer drug, 
3) Vidarabine: FDA approved in 1976 as antiviral drug. 
4) Trabectedin (Yondelis®) is the first marine derived anticancer agent to get approval in the EU and is 
recently approved (October-2015) by US FDA for the treatment of soft tissue sarcoma and relapsed 
ovarian cancer,29a 
5) Eribulin mesylate (Halaven; 20) was recently approved marine originated drug for the treatment of 
metastatic breast cancer and may be used off-label for certain solid tumors, including those from prostate 
cancer, and non-small lung cancer tumors. It acts by a novel microtubule-targeting mechanism, where it 
aggregates in tubulin and selectively blocks microtubule growth in a fashion that is discrete from other 
12 
 
antimitotic drugs.32 Eribulin is a synthetic analogue of halichondrin B (21), which was isolated from 
several sponges, including Halichondria okadai (Japan); Axinella species from the western pacific, 
Phakellia carteri from the Eastern Indian Ocean. Halochondrin B (21) was originally discovered by 
Hirata and Uemura from the Meijo University in Nagoya, Japan in the waters of Miura Penisula, south of 
Tokyo.33  
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Figure-8: Eribulin mesylate (Halaven; 20), Halochondrin B (21). 
 
There are about 12 marine natural products derived drugs on their way to hit the market, the examples 
include anticancer agent bryostatin 1 (25), the dolastatin derivatives soblidotin (auristatin PE; TZT-1027) 
and the synthadotin (tasidotin; ILX-651).29a 
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1.5.4. NATURAL PRODUCTS FROM ANIMALS: 
Animals often have been a source of new lead compounds. According to Van Oosten et. al. the UniProt 
protein database contains over 5,000 bioactive peptides derived from animal venoms and toxins, 
rendering this a significant resource for drug discovery and development.34 The major components of 
most venom are peptides and proteins that are often protease-resistant due to their disulfide-rich 
architectures. Some of these toxins have become valuable as pharmacological tools and/or therapeutics 
due to their extremely high specificity and potency for particular molecular targets. There are currently 
six FDA-approved drugs derived from venom peptides or proteins. Venom-derived drugs have been 
approved for treatment of a wide range of pathophysiological conditions, including chronic pain, diabetes 
and hypertension. Numerous venom-derived peptides and proteins are in clinical trials or undergoing 
preclinical development for an even wider range of medical conditions including cancer, chronic pain, 
congestive heart failure, myocardial infarction, stroke and autoimmune diseases such as multiple 
sclerosis.35  
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Figure-9: Captopril (22), Epibatidine (23), Tirofiban (24) 
 
The era of venom based drug discovery has began in 1970s with the discovery of captopril (22) from the 
venom of Brazilian pit viper Bothrops jaracaca. Captopril (22) is an antihypertensive drug which is an 
inhibitor of angiotensin converting enzyme.36 Epibatidine (23), obtained from the skin of an ecuadorian 
poisonous frog is ten times more potent than morphine.37 Tirofiban (24) is an antiplatelet drug. 
Tirofiban (24) is a synthetic, non-peptide inhibitor acting at glycoprotein (GP) IIb/IIIa receptors in 
human platelets. It therefore constitutes an anticoagulant, specifically an inhibitor of platelet aggregation. 
It is a modified version of an anticoagulant found in the venom of the saw-scaled viper Echis carinatus.38 
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1.6. NATURAL PRODUCTS AND HIGH THROUGHPUT SCREENING: 
Automated testing of large collection (libraries) of compounds against a specific biological target such as 
enzyme or receptors is called as High throughput screening (HTS). This technique is very useful in 
identifying natural products (and also synthetic) molecules as potential drug leads. The natural product 
libraries might be composed of crude extracts (10-100 compounds), semi-pure mixtures (5-10 
compounds) or alternatively, single purified natural compounds. The latter follows the same screening 
process as that of synthetic pure libraries. However, in the first case, diversity of natural product library 
samples adds two additional levels of complexity to screening process. The first is that once a response 
for the sample is detected in screening, one or more rounds of chemical purification and biological assay 
might be necessary for indentifying the active principle of the mixture. The second hurdle is that the 
complexity of crude or semi-pure natural samples, and the chemical nature of many of the components 
found in them, often challenges the robustness of HTS technology. For example in case of the kinase 
assays, as the relative concentration of each component in a sample are not precisely known, the outcome 
of the HTS screening may vary depending on the concentration of the active component. Indeed, the 
highly abundant components can exhibit inhibition as result of non specific binding, perturbation of assay 
pH or other physicochemical properties. Furthermore, natural product samples may contain compounds 
that either fluoresce or absorb or at excitation or emission wavelengths of the fluorophore (e.g. 
fluorescein), or by light scattering of insoluble components, which therefore affect the readout of the 
assay.39  
Effective strategy that helps to alleviate these disturbances, as well as shorten the time required for 
isolation of active ingredient is the implementation of purified or fractionated samples for screening, from 
the original crude extract.40a-b The samples produced by the fractionation process are less complex for use 
in screening. The result of this procedure is that the final isolation of the active component is simplified, 
typically requiring one additional purification step. Simplification of the mixture results in relative 
increase in concentration of minor component, thereby enhancing the opportunity to uncover the novel 
bioactive metabolites. HTS analysis of natural compounds libraries using mass spectrometry has been 
successfully used to obtain the significant results. For example electron spray ionization fourier transform 
ion cyclotron resonance mass spectrometry (ESI-FTICR) screening against RNA targets.41 These and 
other developments make it likely that future lead generation through the screening of natural products 
need not be limited by HTS technology. 
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1.7. NATURAL PRODUCT BASED MOLECULAR LIBRARIES: 
Taking into account the chemical diversity and biochemical specificity of the natural compounds, they 
should not be viewed as stand-alone approach distinct from combinatorial synthesis. Combination of both 
the approaches i.e. use of combinatorial synthesis for generation of natural product based libraries will be 
much more effective strategy. Number of strategies can be adopted through which the unique molecular 
diversity of natural products can be leveraged in the design of combinatorial libraries. 
The target oriented synthesis can be adapted to elaborate the structural modifications on the existing 
bioactive natural scaffolds in a parallel, systemic fashion in order to improve its inherent biological 
activity or physicochemical properties (drug-like properties). This can be performed either by semi-
synthetic modifications of the parent molecule, or by fully synthetic methods. This strategy was used by 
Waldmann et al., who developed a potent, selective inhibitor of TIE2 receptor tyrosine kinase by parallel 
synthesis of a small (74 molecules) focused library based on nakijiquinone C.42 Earlier in 1990s several 
natural product scaffolds have been effectively utilized such as yohimbine43 and paclitaxel44 for solid-
phase synthesis of focused libraries. Ellman et. al. performed an elegant study on vancomycin; the biaryl 
template of vancomycin was combinatorially derivatized by split-and-mix library synthesis to discover 
analogues with improved selectivity for vancomycin- resistant bacterial strains45a-b (figure-10). 
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Figure-10: Screening of Vancomycin peptides for differential binding against D-Ala-D-Ala and D-Ala-D-
Lactate. 
 
Another distinct approach is the diversity-oriented synthesis, which can be pursued with privileged 
structural motifs of natural-product scaffolds to synthesize combinatorial libraries capable of binding a 
wide range of targets.46 The diversity-oriented synthesis approach successfully produced high-quality 
screening libraries by solid-phase synthesis based on natural product benzopyran scaffolds.47a-b Later, 
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refinements have made it possible to rapidly synthesize diversity-oriented small-molecule microarray 
libraries to produce molecules that bind Hap3p, a subunit of the Hap2/3/4/5p transcription factor complex 
and HIV protease. The combinatorial generation of analogues is relatively straightforward, providing a 
concise route to the skeleton is available. For example the fumitremorgin48 and fumiquinazoline alkaloids 
were synthetically assembled on solid phase from tryptophan,49, 50 resulting in the discovery of unnatural 
analogues that are cell-cycle inhibitors and antagonists of the breast cancer resistance protein, a multidrug 
resistant transporter (figure-11). 
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Figure-11: Assembling of natural products scaffolds from tryptophan.  
 
Researchers have also demonstrated that it is possible to synthesize diversity-oriented natural products 
libraries by chemical recombination of complex fragments obtained by chemical degradation of diverse 
bioactive natural products.51 
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1.8. SYNTHESIS OF NATURAL PRODUCTS: 
1.8.1. COMBINATORIAL BIOSYNTHESIS: 
The advances in the synthetic organic chemistry have achieved the synthesis of complex natural 
compounds in recent years. However, the inherent structural complexity of the natural compounds limits 
the applications of current synthetic techniques for the modification of complex natural products to 
generate libraries with significant structural diversity. The combinatorial biosynthesis employs the use of 
genetic engineering to produce novel “unnatural” natural product analogs, generating the libraries with 
distinct chemical diversity and improved medicinal activity. The promising feature of the combinatorial 
biosynthesis is its ability to incorporate the variety of functional groups in the natural scaffolds which are 
difficult to introduce using traditional chemical synthesis.  
Combinatorial biosynthesis usually involves three major strategies: 
1.8.1.1. PRECURSOR DIRECTED COMBINATORIAL BIOSYNTHESIS 
1.8.1.2. ENZYME LEVEL COMBINATORIAL BIOSYNTHESIS 
1.8.1.3. PATHWAY LEVEL COMBINATORIAL BIOSYNTHESIS 
 
1.8.1.1. PRECURSOR DIRECTED COMBINATORIAL BIOSYNTHESIS: 
The biosynthetic machinery utilizes the diverse building blocks to generate a structural diversity in natural 
products. The precursor directed biosynthesis takes the advantage of enzyme ability to incorporate the 
miscellaneous non native substrates to produce various natural product analogs. The growing culture of 
the engineered microorganism is fed with different non natural organic molecules, which are incorporated 
in the biosynthetic pathway to produce the novel secondary metabolites. 
 
  
 
 
 
 
 
 
 
Figure-12: Precursor -directed biosynthesis.  
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Harvey et. al.52 developed a strategy combining the precursor directed biosynthesis with colony bioassay 
to rapidly discover new macrolide antibiotics. A culture of engineered Escherichia coli HYL3 strain is fed 
with a synthetic precursor that mimics the natural diketide intermediate in biosynthesis of macrolides to 
generate the library of alkynyl and alkenyl-substituted erythromycin analogues. Escherichia coli HYL3 
strain contains a plasmids expressing module 2-6 of the mPKS (modular type -1 polyketide synthase) 6-
deoxyerythronolide B synthase (DEBS), and proteins for sugar biosynthesis and glycosyl transfer. 
Subsequently, the precursors were incorporated into the corresponding glycosylated macrolides. The 
newly generated analogs were screened against the Bacillus subtilis in a single colony assay. Using this 
approach the authors have obtained equipotent and orthogonally functional analogs as a promising lead 
structures for antibiotic drug development.52 
Precursor directed biosynthesis can also be applied to the natural products whose precursor are known but 
the characterization of the biosynthetic enzyme is not detailed. Although the technique has an immense 
advantage of producing the compounds biosynthetically, it has also got some shortcomings such as 
challenging fermentation process, inefficient incorporation of the precursors, and the scale. 
 
1.8.1.2. ENZYME LEVEL COMBINATORIAL BIOSYNTHESIS: 
1.8.1.2.1. SWAPPING OF ENTIRE DOMAINS, MODULES, AND SUBUNITS:  
 
 
Figure-13: Domain swapping.  
 
PKSs (polyketide synthetases) and NRPSs (non-ribosomal polyketide synthetases) have got the 
sequentially organized modules, each module comprised of a set of catalytic domains and subunits 
required to complete ne cycle of chain extension. These enzymes utilize the stepwise biosynthesis 
strategy for the synthesis of polyketides. These modular structures make them favorable choice for the 
combinatorial biosynthesis. The entire domain, modules or subunits are exchanged with other domains to 
generate a library of hybrid molecules. A large combinatorial library of 61 6-deoxyerythronolide B (6-
DEB) analogs was constructed by substituting the AT (Acyl tranferase) domains and the β-carbon 
New analogs 
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processing domains of erythromycin mPKS with their respective counterparts from the rapamycin 
Mpks.53 Module and domain sweeping of daptomycin synthetase (NRPs) led to fruitful combinatorial 
biosynthesis of analogs. Subunit and module exchanges between related cyclic lipopeptide A54145 and 
calcium dependent antibiotic (CDA), coupled with modification of glutamine (Gln) at position 12 and 
variations in lipid side chain, generated a combinatorial library of 72 compounds, many of which were 
active antibacterial agents.54a-c 
 
1.8.1.2.2. SITE SPECIFIC MUTAGENESIS:  
 
 
 
Figure-14: Site specific mutagenesis. 
 
Most of the times due to denaturation of proteins native structure and thus of their function, very often 
domain sweeping leads to insoluble protein expression, impaired activities and reduced product yields. 
Moreover, the drastic structural changes may also affect the down streaming of intermediates from 
catalytic domain. Site specific mutagenesis enables one point change i.e. substitution of one amino acid 
residue at a time, which is less invasive and renders effective way for enzyme modulation. The selected 
module of monensin PKS was subjected to mutagenesis to disable the reductive domains such as 
ketoreductase (KR), dehydratases and enoylreductases (ER). Inactivation of the reductive domains led to 
a library of 22 premonensin redox derivatives.55 The ER20-A, -B, -C derivatives exhibited increased 
antibacterial activity against Pseudomonas aeruginosa and also showed activity against B. subtilis, 
against which the native premonensin exhibited poor activity.55 Introduction of S2107A mutation into the 
AT domain of sixth module of the mPKS 6-deoxyerythronolide B synthase (DEBS), the substrate 
specificity of AT switched to fluoromalonyl CoA from methylmalonyl CoA.56 As the fluorine has a great 
impact on the physicochemical properties such has lipophilicity, acidity, basicity, and metabolic stability, 
this study has opened new avenues for the synthesis of fluorinated analogs of natural compounds.57 
 
 
New analogs 
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1.8.1.2.3. DIRECTED EVOLUTION: 
 
Figure-15: Directed evolution strategy. 
 
Directed evolution, is another enzyme engineering approach which uses saturation mutagenesis. The 
microorganisms are randomly mutagenised to obtain chimeric variants which are having ability to 
produce structural analogues of the natural product. The saturation mutagenesis of the active site residues 
of A domain of AdmK gene involved in hybrid NRPS/PKS pathway was employed for the biosynthesis 
of andrimid derivatives.58 
 
1.8.1.3. PATHWAY LEVEL COMBINATORIAL BIOSYNTHESIS: 
 
Figure-16: Pathway-level recombination. 
 
In a well characterized host using modern techniques of genetic engineering it is possible to express 
heterologously biosynthetic genes from different species. In 1985, Hopwood et. al.59 reported the first 
attempt to produce the hybrid antibiotic, mederrhodin A by interchanging and combining of genes from 
multiple species to generate combinatorial pathways. Since then, especially in the field of drug discovery 
hybrid pathways have been widely used for the production of natural products. For example, plant 
secondary metabolites triterpene saponins which are having versatile biological activity were 
heterologously expressed using biosynthesis approach in recombinant yeast strains. Recombinant strains 
expressing the combination of β-amyrin synthase, cytochrome P450 reductase, β-amyrin oxidases 
New analogs 
New analogs 
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CYP93E2 and CYP72A61v2 or the β-amyrin synthase, cytochrome P450 reductase, β-amyrin oxidases 
CYP716A12 and CYP72A68v2, were able to produce soyasapogenol B and gypsogenic acid 
respectively.60  
(Figure-13 to 16 were taken from- Ang. Drug Des. Devel. Ther. 2015, 9, 823) 
 
1.8.2. TOTAL SYNTHESIS: 
To conduct the biological investigation of natural compounds and develop them further into a suitable 
lead compounds, it is mandatory to have sufficient quantities of the natural products. The quantity 
available from the natural sources limits the use of these compounds. Furthermore, large scale isolation of 
compounds from natural sources is a tedious process, which involves repeated extraction and purification 
steps. In fact, large amount of the natural resources will be destructed to obtain milligram quantities, 
which is economically and environmentally not viable. The most practical solution to this problem is the 
chemical synthesis of the natural compounds. But, the inbuilt structural complexity of the natural 
products makes it a tough task for the synthetic organic chemists. However, recent advances in organic 
synthesis made it possible to chemically synthesize a large variety of natural products. Researchers from 
academia and industries have developed enormous methodologies to achieve the total synthesis of diverse 
natural products, which are well documented in the literature.61, 62 Chemical syntheses has empowered the 
uninterrupted and large-scale supply of rare bioactive scaffolds and subsequently eased the 
pharmacological evaluation (i.e. target identification, mechanism of action and developing preliminary 
structure activity relationship) of the compounds. The natural lead compounds were further simplified to 
more potent analogs based pharmacophoric models. For example, in 1960s a group of macrolide lactones 
called bryostatins were isolated from a species of bryozoan, Bugula neritina, by George Pettit.63 In 1988 
Wender et. al. proposed a pharmacophoric model of bryostatin 1 (25), a potent inhibitor of protein kinase 
C.64 This model was used to investigate the functional groups required for its biological activity. In the 
past years number of simplified analogues (e.g. 26, 27) were synthesized which were found to be more 
potent and structurally less complex65a-d (figure-13). 
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Figure-13: Total synthesis approach for simplifying the natural product. 
 
1.8.3. MUTASYNTHESIS:  
The term mutasynthesis was coined by Rinehart66 in late 1970s but this approach was first described by 
Birch in 1963.67 Mutasynthesis can be considered as an extension of precursor-directed biosynthesis. The 
genes responsible for the biosynthesis of particular precursor are silenced using random mutagenesis, thus 
the mutant strains obtained can only be able to produce the natural compound when fed with the 
precursor; usually the synthetic building blocks. Depending on the number of building blocks 
supplemented variety of new natural compounds can be produced.  
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Figure-14: Mutasynthesis of neomycin analogue. 
 
Mutasynthesis gains some advantages over precursor-directed biosynthesis mainly because of boycotting 
the substrate competition with natural precursor. One of the earliest applications of mutasynthesis was the 
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biosynthesis of unnatural analogues of the aminoglycosides-aminocyclitol antibiotic neomycin B (28). 
The random mutagenesis of antibiotic producer strain Streptomyces fradiae yielded a mutant which was 
only able to produce the antibiotic in presence of aminocyclitol precursor deoxystreptamine (29). The 
mutant strain was supplemented with synthetic precursor’s streptamine (30) and epistreptamine (31), 
which were utilized in the biosynthetic pathways to produce novel neomycin analogues, hybrimycin A2 
(32) and hybrimycin B2 (33).68 
 
1.8.4. SEMI-SYNTHESIS: 
Total synthesis of natural products offers a great advantage of obtaining the complex natural compounds 
in small quantities for initial biological studies. But, the large scale synthesis of structurally too-complex 
molecules remains a tough challenge, particularly low yields; number of steps and multiple protection-
deprotections make the chemical synthesis less efficient and economically impracticable. One of the 
prominent solutions to this problem is semi-synthesis of natural products or advanced intermediates, 
which later can be converted into the target molecule by chemical synthesis. Semi-synthesis and 
derivatization of natural products plays a key role in natural product based drug discovery in almost all 
disease area.69 Owing to intrinsic structural complexicity of natural molecules, chemical derivatization of 
compounds obtained from the natural sources to develop structure-activity relationships and prepare 
analogs with improved biological and physicochemical properties in the only feasible option.  
Ground-breaking discoveries in the field of genomics and structural biology have deepened the 
understanding of natural product biosynthetic pathways. Genetic manipulations of these pathways are 
being utilized to generate unnatural natural products. In fact, this process is relatively slow and requires 
deep understanding of the latent biosynthetic pathways. Combination of microbial metabolic potential 
with biochemical and genetic knowledge can be applied to natural product biosynthesis by developing a 
semi-synthetic process by means of direct fermentation of engineered microorganisms. The direct 
fermentation is being used for the production of anticancer drug epirubicin (34, figure-15) and 
antiparasitic drug ivermectin70a-c (1, 2, figure-1). 
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Figure-15: Structure of epirubicin (34) 
 
Semi-synthesis of anti-malarial drug artemisinin (4) is another classical example of combination of 
chemical synthesis with metabolic engineering. Currently artemisinin-based therapy is the most effective 
treatment against the fatal malaria. Extraction of artemisinin from plant Artemisia annua and the chemical 
synthesis are not sufficient enough to supply the requisite quantity of artemisinin at low cost, needed for 
large-scale treatment in growing world. To circumvent the supply problem, the genes required for the 
production of the artemisinin precursor, artemisinic acid (35) have been heterologously expressed in an 
engineered strain of the yeast Saccharomyces cerevisiae. Artemisinic acid (35) obtained from the 
fermentation process was transformed in to artemisinin (4) using two simple chemical steps71a-b (figure-
16). 
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Figure-16: Production of artemisinin (4). 
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1.8.5. BIOMIMETIC SYNTHESIS: 
Biomimetic synthesis is a branch of natural product synthesis which involves the synthetic sequence for a 
target molecule imitating the biosynthetic pathways. The term biomimetic synthesis was coined by Nobel 
laureate Sir Robert Robinson72 in 1917. Biomimetic sequence utilizes series of reactions which are 
passing through intermediate structures which closely resembles to those occur during biosynthesis of 
target molecule from its innate source. It is a comprehensive term for both the testing of a proposed 
biosynthetic pathway by designing the reaction sequence parallel to the proposed one and also to study 
reaction sequence intended for synthetic goal designed to mimic one or more enzymatic transformations 
of the already established biosynthetic pathway. The results obtained from the biomimetic reactions have 
also proved the bio-catalytic role of enzyme in biosynthesis. For example, the reactions which require the 
drastic condition such as high temperature, specialized reagents or those who proceeds with poor 
selectivity are often cited as an evidence of in vivo enzyme catalysis. 
Biomimetic synthesis has gained a promising application in the total synthesis on natural compounds. The 
reactions are elegant and usually are highly efficient in terms of stereo and regio selectivity. The earliest 
example of a biomimetic synthesis is Robinson's synthesis of the alkaloid tropinone (38) starting from 
succinaldehyde, methylamine and acetone dicarboxylic acid.72  
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Figure-17: Biomimetic synthesis of tropinone (38) 
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In 1997 Corey et. al. published the elegant biomimetic synthesis of the tetracyclic marine sesterterpene 
scalarenedial (45). The synthetic strategy involves the concomitant formation of all four carbocyclic 
rings starting from a chiral oxirane, mimicking the cyclase catalyzed cyclisation of linear polyenes.73 
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Figure-18: Corey’s biomimetic synthesis of scalarenedial (45). 
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1.9. SUMMARY: 
Mother Nature is serving the human kind via the elegant synthesis of privileged structures called as 
“natural products”. The intrinsic chemical diversity offered by natural compounds make them the favorite 
choice in the search of highly specific and potent modulator of biological macromolecules. They could 
serve as promising leads to address poorly populated and underexplored chemical space. Biological 
screening of crude extracts obtained from natural sources finds difficulties mainly because of the complex 
nature of the extract. However, simplification of crude extracts using fractionation techniques furnish 
semi pure natural product fractions and the fractions obtained have enhanced concentration of minor (and 
may be active one) component, which makes the bio-assay screening simpler. Libraries generated from 
semi pure natural product fractions can be used directly in HTS screening reducing the time and money 
and efforts. Moreover, advanced approaches in separation and structure elucidation have further brought 
down the prime hurdles in screening mixture of complex molecules which has accelerated the pace of 
natural product based drug discovery. In depth understanding of evolutionary specificity and 
biocompatibility gained by secondary metabolites has delineated their role in mediating the cellular 
response. Total synthesis, semi-synthesis and biosynthesis of natural products have played a crucial role 
in contributions made by natural products in drug discovery and chemical biology. The genetic 
information being gathered from genomic mining of microbial sources will be the key in future to 
produce the novel skeleton of natural products. The advances in genomics, metabolic engineering and 
chemical synthesis hold great promise to exploit the unearthed chemical diversity in search of new drugs. 
  Advances in chemical synthesis has revolutionized the structural diversification and in turn 
modulation of biological activity of complex natural products to obtain more potent and structurally 
simpler analogs. Therefore many researchers from academia and industry have dedicated research 
programs to prepare compounds which mimic the unique structural properties of natural products.74 One 
of the major hurdles in bringing the natural product based complex molecules to market is the “supply 
problem”. However, the combination of synthetic chemistry and biosynthesis holds to meet the challenges 
of difficulties of material supply and structural modifications.75 Highly efficient syntheses of complex 
natural products by Baran et. al. show the coupling of potent and appealing natural products using the 
skills of synthetic organic chemistry.76 In today’s scenario, it seems that there is no complex molecule 
which cannot be synthesized in the laboratory. 
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CHAPTER-2 
SCOPE OF THE THESIS 
Concerns are being raised worldwide over ever-growing anti-microbial resistance (AMR). The 
evolutionary inevitable mechanisms in bacteria and other pathogens make them resistant to the current 
therapies. The innate capacity of microbes to mutate makes our drugs ineffective. In ability to treat the 
drug resistant microbial infections has already caused an estimated 700,000 deaths yearly and if left 
unchecked is predicted to cause ten million deaths annually and may cost up to US $ 100 trillion by 
2050.1  
Antibiotic resistance is a global threat irrespective of level of income of different countries as resistance 
originating in one part of the world spreads easily with the speed and volume of intercontinental travel 
today. The mixing of different microbial strains from different territories enables the sharing of genetic 
information among them creating new resistant strains. International human mobility and food trade 
accelerates the spread of AMR across different species from microbes in animals to those in humans.2 
 Any use of antibiotics even though appropriate contributes to the growing resistance, but abuse or 
overuse of antibiotics in few parts of the world has worsen the scenario which is enough to counter the 
achievements gained to combat AMR elsewhere.3 The availability of antibiotics without prescription and 
even in many cases frequent unnecessary prescription practices facilitates the misuse of antimicrobials. In 
developed and developing countries excessive use of antibiotics is a major challenge but it is also a fact 
that in the poorer countries essential and effective life saving antibiotics are inaccessible. Poor supply of 
newer and relatively more expensive drugs and depriving efficacy of older and cheaper antibiotics also 
counts for increasing resistance.4 The development of new drugs is a time taking process and requires 
high cost. Even though if new drugs are launched there are no strategies to minimize the unwanted use to 
maintain long term efficiency. An inefficient and costly diagnosis also affects the physician’s ability to 
prescribe appropriate antibiotic or not to prescribe at all.5  
Many of the modern healthcare treatments depend heavily on the use of antibiotics. In fact, most of the 
times post-surgery patients are treated with prophylactic antibiotics to reduce the risk of bacterial 
infections. If antibiotics do not stay in, workforce surgeries would become far more dangerous and will be 
risky to undertake. Modern cancer chemotherapy and organ transplants result in immunosupression 
making the patient more vulnerable to infection. Thus, without effective antibiotics it is impossible to 
imagine both and the chemotherapy will become life threatening.  
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The pace at which we are discovering the new antibiotics is much slower than the rising antibiotic 
resistance. The relentless increasing drug resistance has outstripped the discovery of new antimicrobial 
agents and there is urgent need for new antibiotic drugs with novel mechanism of action. The global 
health system will be paralyzed without effective antimicrobials, specifically the antibiotics. 
To overcome AMR crisis, research in the following five key areas needs to be accelerated to conceive 
new antibiotic leads into effective drugs:6 
1. In depth understanding of evolutionary mechanisms. 
2. Molecular level knowledge of antibiotic mode of action and resistance. 
3. Development of new chemical and genetic probes. 
4. Amalgamation of structural biology into antibiotic discovery. 
5. Discovery of new antimicrobial chemical scaffolds. 
Along with the rise in antibiotic resistance, cancer is one of the leading causes of human illness and 
deaths. Despite of technological advances, cancer has become very prevalent and there is significant rise 
in number of new cancer cases. Plethora of antitumor agents has been developed based on detailed 
analysis of their structures and mechanism. Severe side effects and recurrence of tumors often reduce the 
efficacy of chemotherapeutic agents and limits their use. Despite of their severe toxicity, chemotherapy, 
irradiation and immunotherapy have become the standard line of treatment. Thus, there a constant need of 
newer anticancer agents being more specific and having reduced side effects. One of the key strategies to 
develop efficient anticancer agents is the study of anticancer agents derived from natural sources. The 
anticancer agents derived from nature have proven to be effective against a wide variety of cancers.7 In 
fact, since 1930s to 2014 77% of the FDA approved anticancer drugs are either natural products, their 
derivatives or natural product inspired molecules.8 
Since their discovery, natural products have served as a rich source of lead structures, predominantly as 
antibiotics and antitumor agents. The widespread presence of natural products as drugs may be attributed 
to the evolution of secondary metabolites as bioactive molecules which conferred the selectional 
advantages to the producer. Although they display relatively complex chemical scaffolds and rich 
functional groups, natural products are logical starting points for the discovery of new drugs. As 
mentioned earlier (chapter-1), total synthesis of natural compounds has a profound impact in discovery 
and development of novel bioactive molecules. The natural chemical scaffolds have become the 
inspiration for the development of modern medicines. Total synthesis is one of the very viable and 
economical options in the initial phase of developing new drug like molecules from natural resources.  
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The aim of my Ph.D work is the total synthesis of novel antimicrobial natural compounds, investigation 
of their mechanism of action and preparation of analogues to understand the pharmacophoric functional 
groups in the molecule.  
In chapter 3, we describe the total synthesis approach to the antibiotic promysalin. Promysalin represents 
a structurally novel lead of antibiotic molecule. The structural features and species specific antibiotic 
activity of promysalin prompted us to undertake the total synthesis of this unprecedented chemical 
scaffold.  
Chapter 4 deals with the mechanistic investigation of promysalin and synthesis of its analogues to study 
structure activity relationships. Promysalin and analogues were screened against number of gram + and 
gram - microorganisms. These results revealed that promysalin is a broad spectrum antibiotic. We also 
investigated the mechanism of action of promysalin and we found that promysalin exerts its antibacterial 
effect by disrupting the cell membrane. 
Chapter 5 underscores my contribution towards the total synthesis of Leopolic acid A. 
Chapter 6 highlights the total synthesis of resormycin. The developed synthesis in turn could be 
extended for the synthesis of androprostamine A and B.  These natural compounds are peptides which 
show herbicidal, antifungal and anticancer activity. Pertaining to the promising biological activity of these 
structures, they can serve as leads for the development of new bioactive molecules.  
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CHAPTER 3 
TOTAL SYNTHESIS OF PROMYSALIN 
3.1. MYRISTIC ACID METABOLITES: 
Fatty acids play a significant role in the cell metabolism of living organisms. They act as a metabolic fuel; 
constitute important components of cell membrane, and also act as secondary messenger and gene 
regulator. Fatty acids are backbones of several natural products isolated mainly form microbial sources. 
Fatty acid metabolites display broad range of bioactivity such as antifungal, antibacterial, 
immunosuppressant, cytotoxic, anti-inflammatory etc. Myristic acid (2), one of the sufficiently 
hydrophobic fatty acids, is a biosynthetic precursor of a number of secondary metabolites, some of which 
are depicted in figure-1.  
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Figure-1: Natural products derived from myristic Acid. 
Lyngbic acid (3) was isolated from the lipid extract of marine cyanobacteria Lyngbya majuscula (Moore 
et al. 1978).1 Later Gerwick demonstrated that (3) has antibacterial activity against the gram positive 
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strains of S. aureus and B. subtilis. Moreover, (3) also obstructs the CqsS-mediated quorum sensing 
signalling pathways in Vibrio harveyi.2 In 2000, Hermitamide A (4), and B (5), the two amide derivative 
of Lyngbic acid were reported by Gerwick et al. from the same cyanobacteria.3 These compounds 
exhibited immunosuppressive activity and also block the voltage gated sodium ion channels.4 In addition, 
they were found cytotoxic to neuro-2a neuroblastoma cells and also active in brine shrimp toxicity assay.3 
The malyngamides are a class of N-substituted amides of methoxy myristic acid and exhibit a wide range 
of bioactivities such as anti-inflammatory, anti-feedant, cytotoxicity to marine animals, anti-leukemic, 
anti-tumor, antifungal, anti-HIV, and most often antineoplastic activities.5 The tripeptide Malyngamide X 
(6) displays remarkable antimalarial and antitubercular activity.5 
Among the natural products containing a myristic moiety, a salicylate metabolite promysalin (1, Fig. 1), 
has recently aroused great interest in the field of antibiotics mainly because of its distinctive biological 
profile. 
3.2. SYNTHESIS OF PROMYSALIN: 
3.2.1. INTRODUCTION: 
The narrow region of the soil immediately adjacent to the roots is described as rhizosphere. The 
rhizosphere microbiome is inhabited with a blend of neutral, beneficial and pathogenic (to plants and 
humans) microorganisms i.e. bacteria, viruses and fungi. Pseudomonas species are the most prevalent in 
rhizosphere and are extensively studied for their bio-control activity. Competition with other soil and 
rhizosphere microbes, especially phytopathogenic fungi, for space and vital resources led to the 
development of an evolutionary mechanism which enforced them to produce metabolites with specific 
bio-activities assisting survival of the producer. These metabolites possess diverse functions: they can act 
as biosurfactants,6 antibiotics,7 siderophores,8 and virulence factors.9 A plethora of new secondary 
metabolites has been identified via the characterization of the chemical compounds used in this bacterial 
“pathowars”. These compounds have become the richest source of new molecular frameworks for the 
development of new leads in medicine and agriculture. Pseudomonas are well known producers of 
diverse class of antibiotics including phenazines, phloroglucinols, pyoluteorin, pyrrolonitrin, and cyclic 
lipopeptides.10 Usually the production of secondary metabolites is triggered by environmental signals that 
activate the Gac/Rsm signal transduction pathways. The antagonism between two Pseudomonas species is 
usually reconciled by production of narrow spectrum bacteriocins or protein toxins.11 For example the 
antagonism among two Pseudomonas syringae mediated by 3-methylarginine renders the unusual case of 
a secondary metabolite targeting other Pseudomonas.12 
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In 2011, Li. et al.13 isolated a novel type of amphipathic metabolite, promysalin (1, Figure 1) 
biosynthesized by Pseudomonas putida RW10S1strain in the rice root rhizosphere. Promysalin displayed 
unusual intragenus antagonism towards other Pseudomonas, which is a typical characteristic of 
bacteriocins but an uncommon property of secondary metabolites. Promysalin was found to be a narrow 
spectrum antibiotic, which selectively inhibited the growth of other Pseudomonas strains and other gram 
negative bacteria. This molecule has attracted the attention because of its unique species specific 
bioactivity, especially against the multidrug resistant opportunistic human pathogen Pseudomonas 
aeruginosa, restraining the bacterial proliferation at sub-micromolar concentration.13 Interestingly, the 
compound did not show any antibacterial effect against gram +ve equivalents. However, along with the 
narrow spectrum of antagonistic properties, promysalin contributes to the biofilm formation and also 
facilitates the swarming and surface colonization of the producer. 
The molecule is assembled of salicylic acid, 2,8-dihydroxymyristamide and a 5-carboxy-2-pyrroline- 
moiety. The two unique moieties (2-pyrroline-5-carboxylic acid and 2.8-dihydroxymyristamide) are 
unprecedented in a secondary metabolite. The distinctive biological profile of the molecule suggests 
another physiological function for a salicylic acid derivative in bacteria. The role of salicylic acid as a 
signalling molecule in plant defence system against invading phytopathogens and its ability to interfere 
with bacterial quorum sensing deserves further investigation of promysalin.13 Li. et al.13 have proposed a 
biosynthetic pathways based on bioinformatics studies and characterization of intermediates from 
mutants. The structure of promysalin was confirmed using spectroscopic analysis. The recent studies by 
Wuest et al.14 have revealed that promysalin is able to disperse established biofilms and obstruct 
pyoverdine synthesis. In quest of discovering new antibiotic scaffolds to cope with escalating antibiotic 
resistance, promysalin could serve as a promising lead molecule. Owing to tempting structural features 
and remarkable bioactivity, we decided to develop a stereoselective synthetic approach to 1.  
3.2.2. RETROSYNTHETIC ANALYSIS: 
Scheme-1 outlines the retrosynthetic strategy developed towards promysalin. The target compound 1 
could be easily accessed by esterification of the appropriately protected salicyldehydroproline core (A) 
with the dihydroxymyristamide framework (B). 
We envisioned that the fragment A could be efficiently obtained using Yu’s14 strategy of one pot 
reductive elimination of a lactam. The lactam in turn could be generated by aroylation of the appropriate 
L-pyroglutamate ester with suitably O-protected salicyloyl chloride. The stereoselective introduction of 
C-2 and C-8 alcohol functions in myristamide chain could be established using proline-catalyzed 
MacMillan asymmetric α-aminoxylation15 of the corresponding aldehydes. As the absolute configuration 
38 
 
of C-2 and C-8 was not assigned, using this strategy one can easily access both the stereoisomers by 
employing the relevant proline catalyst. 
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Scheme 1: Retrosynthesis of promysalin. PG = Protecting Group. 
3.2.3. SYNTHESIS OF THE SALICYLDEHYDROPROLINE CORE: 
Based on the proposed biosynthetic pathway, L-proline is the biosynthetic precursor of the 
dehydroproline moiety incorporated in the molecule. Assuming the (S)-configuration for natural amino 
acids, the (S)-configuration at C-16 was randomly chosen for the synthesis of an enantiopure 
distereoisomer.13  
3.2.3.1. INITIAL APPROACH: 
The synthesis of salicyldehydroproline core was commenced with the aroylation of L-pyroglutamic acid 
tert-butyl ester 7 with O-acetyl salicyloyl chloride. Compound 10 was prepared in moderate yield 
following the sequence reported in Scheme-2. Unfortunately, the next step i.e. the reduction of lactam 
using lithium triethylborohydride, followed by TFAA and DIPEA mediated in situ elimination of 
lactamol, was found to be quite troublesome.14 Lactam 10 proved to be a tough substrate for reductive 
elimination. In fact, all the attempts with variation in temperature, solvents (THF, CH2Cl2, and toluene) 
and equivalents of reagents gave the enamide 11 in very poor yield, with concomitant formation of 
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products derived from the hydrolysis of the acetate group. The vulnerability of the acetate group under the 
reaction conditions enforced us to change the O-protecting groups of both pyroglutamate and salicylic 
acid cores.  
N
H
O
OtBu
O
NO
OtBu
O
O
OAc
N
OtBu
O
O
OAc
10
a b
117
 
Scheme-2: Initial reductive elimination attempt. Reagents and conditions: a) o-acetyl salicyloyl chloride, 
NEt3, Toluene, 80 °C, 5h, 53%, b) i) LiBHEt3, PhMe,  -78 °C, 1 h, ii) TFAA, DIPEA, Cat. DMAP, rt, 3h, 
11%. 
3.2.3.2. OPTIMIZATION OF REDUCTIVE ELIMINATION: 
In an alternate strategy we decided to aroylate ethyl-L-pyroglutamate with variably protected salicyloyl 
chlorides using an optimized protocol prior to lactam reduction. The substitution of acetate with allyl, 
benzyl or p-methoxybenzyl did not give conclusive results in the reductive elimination step. In fact, in all 
the cases the starting material got decomposed. However, protection of salicylate with 2-methoxymethyl 
(MEM) produced encouraging results. The chemoselective reduction of lactam and base promoted 
subsequent in situ elimination went smoothly, afforded enamide in acceptable yield. 
Having the optimized reaction conditions and protecting group in hand, we commenced the synthesis of 
pyrrolinecarboxylic acid (-)-14 as shown in scheme 3. Treatment of ethyl (S)-pyroglutamate 8 with 2-((2-
methoxyethoxy)methoxy)benzoic acid16 using Ghosez reagent (1-chloro-N,N,2-trimethyl-1-
propenylamine) and triethylamine in toluene17 gave salicyloyl lactam (+)-12 in 82% yield. The 
chemoselective reduction of pyroglutamate lactam (+)-12 with LiBHEt3 at -78 °C, followed by in situ 
dehydration of lactamol using TFAA and DIPEA14  produced the salicyloyl enamide (-)-13 in 62% yield. 
Lastly, the hydrolysis of ethyl ester using lithium hydroxide gave the desired intermediate (-)-14. 
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Scheme-3: Synthesis of salicyloyldehydroproline core. Reagents and conditions: a) i. 2-[(2-
methoxyethoxy)methoxy]benzoic acid, 1-chloro-N,N,2-trimethyl-1-propenylamine, CH2Cl2, 0°C to rt, 1 
h; ii. NEt3, toluene, 80°C, 3 h, 82%; b) LiBHEt3, toluene, -78 °C, 1 h, TFAA, DIPEA, cat. DMAP, -78 °C 
to rt, 3 h, 62%; c) LiOH, EtOH : H2O, 0°C to rt, 5 h, 97%. 
3.2.4. SYNTHESIS OF THE DIHYDROXYMYRISTAMIDE CHAIN: 
After successful synthesis of the dehydroproline core, we focused our attention on the synthesis of 
dihydroxymyristamide chain (B). Initial approaches are summarized in scheme-4. Octanal 9 was 
subjected to proline catalyzed α-aminoxylation, followed by Horner–Wadsworth–Emmons olefination 
reaction (HWE reaction) and subsequent Pd/C catalyzed hydrogenation of crude aminooxy intermediate 
15 to get the γ-hydroxy ester 16. Unfortunately, this sequence resulted either in low yields or formation of 
complex mixtures. Alternatively, deprotection of 15 immediately after workup using Cu(OAc)2 gave the 
α,β-unsaturated γ-hydroxy ester 17 in poor yield.  
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Scheme-4: Aminooxylation followed by HWE olefination strategy, Reagents and conditions: a) i. L-
proline, PhNO, DMSO, rt, 2 h; ii) DBU, LiCl, HWE salt, CH3CN, 0 °C to rt, 1 h; b) H2, Pd/C, EtOAc, rt, 
12 h, 17% (over two steps); c) Cu(OAc)2, EtOH, rt, 12 h, 25-30% (over two steps). 
Several attempts were made to improve the outcome of this reaction (Table-1). Unfortunately we did not 
obtain either 16 or 17 in acceptable yields, and on consequence we abandoned this strategy. 
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Sr. No 
Octanal 
(mmol) 
Nitroso- 
benzene 
(mmol) 
L-Proline 
(mmol) 
Solvent 
T (°C) 
 
Product formed (% Yield) 
 
1) 1 1.2 0.4 DMSO/CH3CN RT 16, 20% (After hydrogenation) 
2) 1 1 0.1 CH2Cl2 0 °C 17, 30 % (Using Cu(OAc)2 
3) 2 1 0.1 
DMSO 
RT Traces of 17 (Cs2CO3 is used as base.) 
4) 1.2 1 0.1 
DMSO 
RT Homodimerisation (Cs2CO3 is used as base.) 
5) 2 1 0.1 DMSO/ACN RT Homodimerisation is the major side reaction.  
6) 1 1 0.1 CH2Cl2 RT 17, 30 % (Using Cu(OAc)2 
7) 1.2 1 0.1 CH2Cl2 RT 17, 30 % (Using Cu(OAc)2 
8) 1.2 1 0.1 CHCl3 +4 °C 17, 25% (Using Cu(OAc)2 
9) 1.2 1 0.4 CHCl3 +4 °C 17, 27% (Using Cu(OAc)2 
 
Table-1: Optimization of aminoxylation followed by HWE Wittig and hydrogenation/ Cu(OAc)2 reaction 
sequence. 
Alternatively, instead of HWE olefination we decided to in situ reduce the aminooxyaldehyde to 
aminooxyalcohol. This approach for the synthesis of 18 from octanal is illustrated in scheme 5. L-proline 
catalyzed enantioselective α-oxyamination15 of octanal 9 using nitrosobenze as a source of oxygen in 
CHCl3 at +4 °C, and concomitant in situ reduction with NaBH4 gave an oxyamino alcohol which was 
immediately deprotected upon workup using Zn/AcOH in EtOH to obtain diol (+)-19 in good yield.  
The absolute configuration of diol (+)-19 was assigned to be (R), considering all literature reports18 for 
aminoxylation reaction. Moreover, the specific optical rotation value of (+)-19 ([α]D23 = +14.1 (c 1.00, 
MeOH) was in agreement with the reported literature19 value for antipode (S)-1,2 octanediol ([α]D23 = -
13.6 (c 1.00, MeOH, e.e. 97%), which affirms that we have synthesized the (R) enantiomer with more 
than 97% e.e.  
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Scheme 5: Synthesis of dihydroxymyristamide chain (B): Reagents and conditions: a) i. L-proline, 
PhNO, CHCl3, +4 °C, 2 h, then NaBH4, EtOH, 0 °C, 0.5 h; ii. Zn dust, EtOH : AcOH, rt, 1 h, 91% over 
two steps; b) PMB dimethylacetal, PPTS, CH2Cl2, 0 °C to rt, 2 h; c) DIBAL, CH2Cl2, -78 °C, 2 h, 72% 
over two steps; d) (COCl)2, DMSO, NEt3, CH2Cl2, -78 °C, 2 h, 94%; e) n-BuLi, TBSO(CH2)6P+Ph3Br-, 
THF,-78°C to rt, 2 h, 74%; f) TBAF, THF, 0 °C to rt, 1 h, 88%; g) (COCl)2, DMSO, NEt3, CH2Cl2, -
78°C, 1 h, 91%; h) i. L-proline, PhNO, CHCl3, + 4°C, 2 h, then NaBH4, EtOH, 0 °C, 0.5 h; ii. Zn dust, 
EtOH : AcOH, rt, 1 h, 77% over two steps; i) TBS-Cl, imidazole, CH2Cl2, rt, 6 h, 98%; j) TBDPS-Cl, 
imidazole, DMF, rt, 16 h, 98%; k) AcOH:THF:H2O, rt, 36 h, 92%; l) TEMPO, bis(acetoxy)iodobenzene, 
NaHCO3, ACN : H2O, 0 °C, 4 h, 70%; m) HBTU, HOBT, NH4Cl, DIPEA, DMF, 0 °C to rt, 1 h, 73%; n) 
H2, Pd/C, MeOH, rt, 12 h, 73%; o) (-)-14, EDC, DMAP CH2Cl2, rt, 16 h, 50%. 
Pyridinium P-toluenesulfonate (PPTS) catalyzed protection of diol (+)-19 with p-methoxybenzaldehyde 
afforded acetal 20, which upon reductive opening with DIBAL furnished PMB-alcohol (-)-21 in excellent 
yield.20 Oxidation of primary alcohol  using Swern21 protocol confered aldehyde  (+)-22 in 96 % yield. 
Wittig olefination22 of aldehyde (+)-22 with tert-butyldimethylsilyloxybutyl (triphenyl) phosphonium 
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bromide smoothly facilitated the chain elongation to construct myristamide framework. Silyl ether (+)-23 
was cleanly deprotected on treatment with TBAF23 at 0 °C offering the primary alcohol (+)-24  in 88% 
yield. The enantiomeric purity and absolute configuration of alcohol (+)-24 was assessed by measurement 
of optical rotation of corresponding (R)-tetradecane-1,8-diol ([α]D23 = -0.63 (c 1.1, CHCl3; lit.24 for (R) 
enantiomer [α]D23 = -0.48 (c 1.1, CHCl3, derived from opening of an epoxide with 94% e.e.25); lit.26 [α]D23 
= -0.6 (c 1.8, CHCl3) which was obtained upon hydrogenation of (+)-24. Again, another sequence of 
Swern oxidation and successive aminoxylation reaction established stereoselectively the C-2 hydroxy to 
afford diol (+)-26. The (R) configuration at this carbon could be safely assumed on the basis of the 
mechanism of the reaction.15 Attempted TEMPO27 catalyzed selective oxidation of diol (+)-26 to α-
hydroxycarboxylic acid gave a complex mixture of compounds. After several futile attempts of direct 
oxidation and protection deprotection, the selective protection of primary and secondary alcohol as TBS 
and TBDPS ether respectively, followed by regioselective deprotection of primary silyl ether was found 
to be the optimal choice. This sequence enabled us to install at C-2 functionality inert under deprotection 
of the OH at C-8. Thus, diol (+)-26 was treated sequentially with TBSCl and TBDPSCl, followed by 
selective desilylation of primary silyl ether using AcOH in THF/H2O28 to give alcohol (-)-29 in excellent 
yield. Oxidation of this alcohol using Widlanski29 protocol and subsequent amidation with NH4Cl in 
DMF30 provided myristamide (-)-31. Catalytic hydrogenation31 of the double bond using Pd/C proceed 
smoothly with concomitant deprotection of PMB, furnishing the key alcohol intermediate (-)-18 in 73% 
yield. Hassle free esterification of (-)-14 with alcohol (-)-18 using EDC and cat. DMAP gave fully 
protected promysalin (-)-32. Unfortunately, ester (-)-32 was found to be highly sensitive to acidic 
condition. One-pot deprotection of MEM and TBDPS ethers under acidic condition led to the formation 
of the unusual cyclized product 33, Scheme-6. 
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Scheme-6: Attempted global deprotection of MEM and TBDPS ether. a) THF:H2O, 2N HCl, 0 °C to rt, 
1h. 
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To circumvent this issue we went back to compound (-)-13, which was used as model substrate to 
optimize the MEM deprotection reaction. All attempts to remove 2-methoxyethoxymethyl ether with 
various reagents such as ZnBr2,32 PTSA,33 CBr4,34 montmorillonite K-10,35 TMS-OTf,36 or ethylene 
glycol solvolysis,37 were unsatisfactory and exclusively gave oxazinone 35 as a diastereomeric mixture. 
After several experiments, the MEM group was cleanly removed by treatment with TiCl4 at -20 °C38 
solely obtaining phenol (-)-34 without formation of any side products (Scheme-7).  
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 Scheme-7: Optimization of MEM deprotection. 
Pertaining to the sensitivity of dehydroproline core in acidic medium, the protecting groups were removed 
sequentially under mild, aprotic conditions. Thus, the careful treatment of (-)-32 with TiCl4 at -20 °C,38 
followed by TBAF mediated desilylation, gave promysalin (-)-1 with absolute configuration 2R, 8R, 16S 
(scheme-8). Fortunately, the spectroscopic data of the synthesized compound completely matched those 
of the natural product, thus confirming that we had synthesized the right diastereomer. 
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Scheme-8: Completion of total synthesis. a) i. TiCl4, -20 °C, 15 min; ii. TBAF, THF, 0 °C to rt, 2 h, 70% 
over two steps. 
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When we were in a final stage of this work, Wuest et. al.14 published an efficient total synthesis of all four 
diastereomers of promysalin. The absolute configuration of natural compound was assigned as (2R, 8R, 
16S) based on the biological screening. 
Wuest et al. have synthesized the myristamide fragment in more efficient manner starting from 5-
hexanoic acid over six steps in 45% overall yield. However, their strategy towards synthesis of 
salicyldehydroproline core seems to be less attractive, which needs seven steps from methyl salicylate to 
generate the dehydroproline acid. 
The amalgamation of both the strategies would probably offer the best route to achieve the convergent 
synthesis of promysalin. The combined strategy in turn could be the best solution for the generation of 
structurally diverse analogues for further SAR studies and to shed light on its unknown mode of action.14 
 
3.2.5. CONCLUSIONS: 
In conclusion, we designed and executed the total synthetis of Pseudomonas antibiotic promysalin in 
longest linear sequence of 16 steps with 3% overall yield. Key steps of our approach encompass an 
organocatalytic asymmetric α-hydroxylation of carbonyl compounds employed to fabricate the 
myristamide framework, and Superhydride® mediated reductive elimination of lactam to obtain the 
salicyldehydroproline fragment. The straightforward and modular nature of the synthesis will give easy 
access to the preparation of analogues for biological activity evaluation.  
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3.3. EXPERIMENTAL SECTION: 
3.3.1. GENERAL INFORMATION: 
All reagents and solvents were reagent grade or were purified by standard methods before use. Melting 
points were determined in open capillaries by a SMP3 apparatus and are uncorrected. 1H spectra were 
recorded on Bruker AMX 300 MHz and Bruker AV600 spectrometers. TMS was used as an internal 
standard and the chemical shifts are reported in parts per million (δ). The peak patterns are indicated as 
follows: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; m, multiplet; q, quartet. The coupling 
constants, J are reported in Hertz (Hz) and 13C NMR spectra were recorded on Bruker AMX 300 MHz 
and Bruker AV600 spectrometers. Optical rotations were measured with a Perkin Elmer 241 polarimeter. 
IR spectra were recorded on a Perkin Elmer 1310 spectrophotometer and reported in wave numbers (cm-
1). The elemental analyses were recorded with a CARLO ERBA EA 1108 instrument. The accurate mass 
spectra were recorded using Bruker Daltonics model Autoflex III, accurate mass MALDI TOF/TOF 
MS/MS.  Solvents were routinely distilled prior to use; anhydrous tetrahydrofuran (THF) and ether (Et2O) 
were obtained by distillation from sodium-benzophenone ketyl; dry methylene chloride was obtained by 
distillation from phosphorus pentoxide. All reactions requiring anhydrous conditions were performed 
under a positive nitrogen flow and all glassware were oven dried and/or flame dried. Isolation and 
purification of the compounds were performed by flash column chromatography on silica gel 60 (230-400 
mesh). Analytical thin-layer chromatography (TLC) was conducted on TLC plates (silica gel 60 F254, 
aluminium foil). Compounds on TLC plates were detected under UV light at 254 and 365 nm or were 
revealed spraying with 10 % phosphomolybdic acid (PMA) in ethanol. 
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3.3.2: EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA: 
3.3.2.1. tert-butyl (S)-1-(2-((2-acetoxy)benzoyl)-5-oxopyrrolidine-2-carboxylate.  
NO
OtBu
O
O
OAc
9
 
NEt3 (2.3 mL, 16.62 mmol) followed by O-acetyl salicyloyl chloride (1.98 g, 9.98 mmol, in toluene 6 mL 
) were added dropwise to a stirred solution of t-butyl L-pyroglutamate (1.54 g, 8.31 in toluene 16 mL, 0.5 
M) at 0 °C under N2 atmosphere. The reaction mixture was warmed to room temperature and stirred at 
80°C for 3 h. Sat. NaHCO3 (10 mL) was added and the organic layer was separated. The aqueous layer 
was extracted with EtOAc (2 x 15 mL). The combined organic extracts were washed with brine (15 mL), 
dried over anhydrous Na2SO4 and concentrated in vacuo. The purification using flash column 
chromatography in 0-17% EtOAc : Hexane furnished lactam 9 as a white solid (1.55 g, 53%). 
Rf  (40% EtOAc/Hexane) = 0.6. 
mp: 124-126 °C. 
1H NMR (300 MHz, CDCl3): δ 7.60 – 7.35 (2H, m); 7.33-7.09 (2H, m); 4.77 (1H, dd, J = 3.7, 9.5 Hz); 
2.81 – 2.63 (1H, m); 2.62 – 2.32 (2H, m); 2.26 (3H, s); 2.19 – 2.02 (1H, m); 1.49 (9H, m). 
13C NMR (150 MHz, CDCl3): δ 172.6, 169.4, 168.4, 166.2, 147.3, 131.3, 128.6, 127.6, 125.0, 122.3, 
82.1, 58.3, 31.1, 27.5 (× 3C), 21.2, 20.5. 
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3.3.2.2. tert-butyl (S)-1-(2-((2-acetoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate.  
N
OtBu
O
O
OAc
10
 
To a stirred solution of 9 (97 mg, 0.27 mmol) in dry toluene (1 mL) was added Superhydride® (0.33 mL, 
0.33 mmol, 1M in THF) at -78°C under N2 atmosphere. The solution was stirred for 1 h at -78°C, then 
DMAP (0.6 mg, 0.055 mmol) and DIPEA (0.26 mL, 1.59 mmol) were added, followed by very slow 
addition of TFAA (0.04 mL, 0.33 mmol). The reaction mixture was gradually warmed to room 
temperature and stirred for 3 h. Water (5 mL) was added. The aqueous layer was extracted with ethyl 
acetate (2 × 7 mL); the combined organic extracts were washed with brine (5 mL), dried over anhydrous 
Na2SO4 and concentrated in vacuo. The residue was purified using flash column chromatography with 0-
10 % acetone : hexane to give 10 (10 mg, 11%) as a gummy solid. 
Rf (20% acetone : hexane) = 0.4. 
1H NMR (300 MHz, CDCl3): δ 7.58-7.39 (2H, m), 7.34 -7.23 (1H, m), 7.65 (1H, d, J = 7.8 Hz), 6.19-6.27 
(1H, m), 5.11-5.00 (1H, m), 4.85 (dd, J = 3.6, 10.5 Hz, 1H), 3.19-2.98 (1H, m), 2.24-2.08 (1H, m), 2.30 
(3H, s), 1.50 (9H, s). 
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3.3.2.3. ethyl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-5-oxopyrrolidine-2-carboxylate. 
NO
OEt
O
O
OMEM
12
 
Ghosez’s reagent (1-chloro-N,N,2-trimethyl-1-propenylamine) (2.5 mL, 0.02 mol) was added dropwise to 
a solution of 2-((2-methoxyethoxy)methoxy)benzoic acid16 (4.1 g, 0.02 mol) in dry dichloromethane (40 
mL) at 0°C under N2 atmosphere. The reaction mixture was stirred at room temperature for 1 h. The 
solvent was removed in vacuo and the residue was dried under vacuum and used in the next step without 
purification. In another 2-necked dry flask was placed ethyl L-pyroglutamate (1.4 g, 9.2 mmol) in dry 
toluene (15 mL) and the solution was cooled to 0°C. To this was added NEt3 (3.2 mL, 0.02 mol) followed 
by dropwise addition of the crude acid chloride solution in toluene (15 mL). The reaction mixture was 
heated at 80 °C for 3 h, and then it was cooled to room temperature and quenched by addition of saturated 
aqueous NaHCO3 (30 mL). The organic layer was separated and the aqueous layer was extracted with 
ethyl acetate (2 × 100 mL). The combined organic extracts were washed with brine (30 mL), dried over 
anhydrous Na2SO4 and concentrated in vacuo. Purification of the residue by flash column 
chromatography with 0-18% acetone : hexane gave (+)-12 (2.75 g, 82%) as a yellow gummy solid. 
Rf  (20% acetone : hexane, double run) = 0.30. 
[α]D23 = +30.9 (c 1.0, CHCl3). 
νmax (thin film) : 3045, 1760, 1700, 1620, 1510, 1470, 1340, 1280, 1250, 1210, 1120, 1010, 750, 710 cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.40 (dd, J = 7.5, 7.5 Hz, 1H), 7.31 (d, J = 7.5 Hz, 1H), 7.21 (d, J = 7.5 
Hz, 1H), 7.05 (dd, J = 7.5, 7.5 Hz, 1H), 5.27 (d, J = 7.0 Hz, AB, 1H), 5.23 (d, J = 7.0 Hz, AB, 1H), 4.91 
(dd, J = 2.9, 9.5 Hz, 1H), 4.28 (q, J = 7.3 Hz, 2H), 3.80 (t, J = 4.5 Hz, 2H), 3.55 (t, J = 4.5 Hz, 2H), 3.38 
(s, 3H), 2.73-2.64 (m, 1H), 2.55-2.50 (m, 1H), 2.50-2.45 (m, 1H), 2.2-2.10 (m, 1H), 1.33 (t, J = 7.3 Hz, 
3H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 172.8, 170.9, 167.8, 154.5, 131.8, 128.4, 125.8, 121.6, 114.5, 93.9, 
71.6, 67.7, 61.7, 58.9, 58.2, 31.6, 21.7, 14.1 ppm.  
Elemental analysis calcd (%) for C18H23NO7: C 59.17, H 6.34, N 3.83; Found: C 59.38, H 6.32, N 3.84. 
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3.3.2.4. ethyl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
OEt
O
O
OMEM
13
 
To a stirred solution of (+)-12 (1.1 gm, 3.0 mmol) in dry toluene (22 mL) was added Superhydride ® (3.6 
mL, 3.6 mmol, 1 M in THF) at -78°C under N2 atmosphere. The solution was stirred for 1 h at -78°C, 
then DMAP (7 mg, 0.06 mmol) and DIPEA (2.8 mL, 0.02 mol) were added, followed by very slow 
addition of TFAA (0.5 mL, 3.6 mmol) over 5 min. The reaction mixture was gradually warmed to room 
temperature and stirred for 3 h. Water (30 mL) was added and the organic layer was separated. The 
aqueous layer was extracted with ethyl acetate (2 × 75 mL); the combined organic extracts were washed 
with brine (15 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified 
using flash column chromatography in 0-50 % ethyl acetate : hexane to give (-)-13 (650 mg, 62%) as 
yellow oil. 
Rf  (35% ethyl acetate : hexane) = 0.30.  
[α]D23 = -104.3 (c 1.00, CHCl3). 
νmax (liquid film): 3050-2800 (br), 1760, 1660, 1640, 1620, 1510, 1470, 1425, 1250, 1210, 1110, 1045, 
1000, 860, 780 cm-1.  
1H NMR (300 MHz, CDCl3): δ = 7.41-7.34 (m, 2H,), 7.23 (d, J = 7.8 Hz, 1H), 7.07 (dd, J = 7.8, 7.8 Hz, 
1H), 6.2 (m, 1H), 5.30 (s, 2H), 5.10-5.03  (m, 1H), 5.00 (dd, J = 3.6, 10.5 Hz, 1H), 4.27 (q, J = 7.2 Hz, 
2H), 3.86-3.81 (m, 2H,), 3.57-3.52 (m, 2H), 3.37 (s, 3H), 3.18-3.13 (m, 1H,), 2.74-2.69 (m, 1H), 1.33 (t, J 
= 7.2 Hz, 3H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 170.8, 164.9, 153.4, 131.2, 130.8, 128.8, 125.9, 122.1, 115.3, 108.5, 
93.7, 71.5, 67.9, 61.3, 59.0, 58.0, 34.1, 14.1 ppm. 
Elemental analysis calcd (%) for C18H23NO6: C 61.88, H 6.64, N 4.01; found: C 62.01, H 6.62, N 4.00. 
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3.3.2.5. (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylic acid. 
N
OH
O
O
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A solution of (-)-13 (920 mg, 2.6 mmol) in EtOH (22.5 mL) was cooled to 0 °C. To this was added 
dropwise a solution of LiOH (166 mg, 3.9 mmol) in water (11.25 mL). After complete addition the 
reaction mixture was warmed to room temperature and stirred for 5 h. EtOH was removed in vacuo, the 
aqueous layer was washed with 40% ethyl acetate in diethyl ether (2 × 25 mL), cooled to 0 °C and 
acidified using 5% citric acid. The product was extracted using 5% methanol: dichloromethane (3 × 100 
mL). The combined organic extracts were washed with brine (15 mL), dried over anhydrous Na2SO4 and 
concentrated to afford pyrrolinecarboxylic acid (-)-14 (809 mg, 97%) as a pale yellow gummy solid. 
Rf  (5% methanol : dichloromethane) = 0.35. 
[α]D23 = -97.6 (c 1.00, CHCl3). 
νmax (thin film) 3300-2900 (br), 1760, 1660, 1640, 1625, 1505, 1475, 1440, 1292, 1005, 760, 725 cm-1.  
1H NMR (600 MHz, CDCl3) δ = 7.38 (dd, J = 7.9, 7.9 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 7.9 
Hz, 1H), 7.05 (dd, J = 7.9, 7.9 Hz, 1H), 6.62 (brs, 1H), 6.09 (d, J = 2.2 Hz, 1H), 5.28-5.25 (m, 2H), 5.17-
5.22 (m, 1H), 5.08 (dd, J = 4.9, 10.1 Hz, 1H), 3.80-3.76 (m, 2H), 3.52 (t, J = 4.7 Hz, 2H), 3.34 (s, 3H), 
3.08-3.02 (m, 2H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 172.2, 167.1, 153.4, 131.8, 129.7, 128.8, 124.8, 122.1, 115.1, 111.2, 
93.7, 71.5, 68.0, 58.9, 53.4, 32.9 ppm.  
Elemental analysis calcd (%) for C16H19NO6: C 59.81, H 5.96, N 4.36, found: C 59.99, H 5.94, N 4.35. 
HRMS Accurate mass (ES+) calculated for C16H19NO6Na (M + Na)+ 344.11046, Found: 344.11114. 
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3.3.2.6. (R)-ethyl 4-hydroxydecanoate. 
C6H13
OH
EtO
O
16
 
To a stirring solution of nitrosobenzene (100 mg, 0.933 mmol), L-proline (42.9 mg, 0.373 mmol), in 
DMSO (4 mL) under N2 atmosphere, was added n-octanal (0.17 mL, 1.12 mmol) at room temperature. 
The reaction mixture was stirred at room temperature for 30 minutes, by this time the colour of the 
mixture changed from green to yellow. Reaction mixture was cooled to 0 °C; to this was added premixed 
mixture of DBU (0.41 mL, 2.79 mmol), LiCl (118 mg, 2.79 mmol), and triethyl phosphonoacetate in 
CH3CN (4 mL). After complete addition the ice bath was removed and the reaction mixture was stirred at 
room temperature for 1 h. Ice pieces were added and the CH3CN was removed in vacuo. The aqueous 
layer was extracted with ethyl acetate (2 x 10 mL), combined organic extracts were washed with brine (7 
mL), dried over anhydrous Na2SO4. The solvent was removed in vacuo; the crude aminooxy alcohol (350 
mg) was dissolved in ethyl acetate (7 mL), Pd/C (35 mg, 10% by crude weight) was added. The RB flask 
was evacuated and flushed with H2 (three times) and the reaction mixture was stirred overnight at room 
temperature under H2 atmosphere. The reaction mixture was filtered through celite bed and the residue 
was washed with ethyl acetate (10 mL). In vacuo concentration followed by flash column 
chromatography furnished γ-hydroxy ester 16 (37 mg, 20%) as a yellow oil. 
Rf  (7% EtOAc : Hexane) = 0.35. 
1H NMR (200 MHz, CDCl3) δ = 4.13 (q, J = 7.2 Hz, 2H), 3.67–3.52 (m, 1H), 2.50–2.39 (m, 2H), 1.99–
1.61 (m, 4H), 1.56–1.29 (m, 8H), 1.29–1.22 (m, 3H), 0.92 (d, J = 4.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ = 174.1, 80.9, 71.0, 60.2, 37.4, 32.1, 30.7, 29.5, 25.5, 22.5, 14.0, 13.9 
ppm. 
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3.3.2.7. (R, E)-ethyl 4-hydroxydec-2-enoate. 
C6H13
OH
EtO
O
17
 
To a stirring solution of nitrosobenzene (83 mg, 0.781 mmol), L-proline (34 mg, 0.296 mmol), in 
dichloromethane (2.7 mL) under N2 atmosphere, was added n-octanal (0.12 mL, 0.781 mmol) at 0 °C. 
The reaction mixture was stirred at 0 °C for 1.25 h, by this time the colour of the mixture changes from 
green to yellow. To this was added premixed and pre-cooled mixture of DBU (0.41 mL, 2.79 mmol), LiCl 
(118 mg, 2.79 mmol), and triethyl phosphonoacetate in dichloromethane (2.7 mL). After complete 
addition the ice bath was removed and the reaction mixture was stirred at room temperature for 1 h. Ice 
pieces were added and the dichloromethane was removed in vacuo. The aqueous layer was extracted with 
ethyl acetate (2 x 10 mL), combined organic extracts were washed with brine (7 mL), dried over 
anhydrous Na2SO4. The solvent was removed in vacuo; the crude aminooxy alcohol (285 mg) was 
dissolved in ethanol (9 mL), Cu(OAc)2 (28 mg, 0.156 mmol) was added. The reaction mixture was stirred 
at room temperature for 12 h. EtOH was removed in vacuo, the residue was taken in water (15 mL) and 
the aqueous layer was extracted with diethyl ether (2 x 10 mL). The combined organic extracts were 
washed with brine (8 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The purification 
using flash column chromatography in 10% EtOAc : Hexane yielded alcohol 17 (46 mg, 26%) as dark 
yellow oil.  
Rf  (7% EtOAc : Hexane) = 0.40. 
1H NMR (200 MHz, CDCl3) δ =  0.89 (t, J = 6.8 Hz, 3H), 1.21–1.41 (m, 11H), 1.56 (m, 2H), 1.99 (brs, 
1H), 4.19 (q, J = 7.2 Hz, 2H), 4.30 (m, 1H), 6.01 (dd, J = 15.6, 1.5 Hz, 1H), 6.93 (dd, J = 15.6, 4.9 Hz, 
1H). 
13C NMR (50 MHz, CDCl3): δ 14.1, 14.2, 22.6, 25.2, 29.1, 31.7, 36.6, 60.3, 71.0, 120.0, 150.3, 166.4. 
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3.3.2.8. (R)-octane-1,2-diol. 
C6H13HO
OH
19
 
A suspension of L-proline (322 mg, 2.8 mmol) in CHCl3 (30 ml) was cooled to 4 °C and stirred for 15 
min, then nitrosobenzene (3 g, 0.03 mol) was added in one portion. At this time the solution turned green. 
To this suspension was added octanal 9 (13.1 ml, 84.0 mmol) in one portion. The resulting solution was 
then stirred at 4 °C for 2 h and it turned yellow. The reaction mixture was then added dropwise to an 
ethanol (25 mL) suspension of NaBH4 (1.05 g, 0.03 mol) at 0 °C. After 30 min, the reaction was treated 
with saturated aqueous NaHCO3 (50 mL). The aqueous layer was extracted with dichloromethane (3 × 75 
mL); the combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. To a solution of the oxy-aniline adduct (14.6 g) in EtOH/AcOH (3:1, 156 mL), Zn 
dust (8.1 g, 0.12 mol) was added portionwise. The resulting suspension was stirred at room temperature 
for 1 h. The reaction mixture was filtered through a plug of celite and the residue was washed with 
ethanol (50 mL); the filtrate was concentrated in vacuo at a temperature <40 °C. The residue was 
dissolved in ethyl acetate (200 mL) and washed with saturated aqueous NaHCO3 solution (100 mL), brine 
(50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting yellow oil was 
purified using flash column chromatography (eluent: 20-50% ethyl acetate : hexane) to afford (R)-octane-
1,2-diol (+)-19 (3.7 g, 91%) as an off-white sticky solid. 
Rf  (50% ethyl acetate : hexane) = 0.35.  
[α]D23  = +14.1 (c 1.00, MeOH). 
νmax (liquid film) 3600-3300 (br), 3100, 1550, 1490, 1445, 1290, 1130, 950 cm-1.  
1H NMR (600 MHz, CDCl3) δ = 3.76-3.70 (m, 1H), 3.67 (dd, J = 3.2, 11.1 Hz, 1H), 3.45 (dd, J = 7.9, 
11.1 Hz, 1H), 2.50-2.35 (m, 2H), 1.49-1.26 (m, 10H), 0.90 (t, J = 7.0 Hz, 3H) ppm. 
13C NMR (150 MHz, CDCl3): δ = 72.3, 66.8, 33.2, 31.7, 29.3, 25.5, 22.6, 14.0 ppm.  
Elemental analysis calcd (%) for C8H18O2: C 65.71, H 12.41; found: C 65.50, H 12.44. 
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3.3.2.9. (R)-2-(4-methoxybenzyloxy)octan-1-ol. 
C6H13HO
OPMB
21
 
A solution of (R)-octane-1,2-diol (+)-19 (7.4 g, 0.05 mol), PPTS (254 mg, 1.1 mmol) in dry 
dichloromethane (126 mL) was cooled to 0 °C. 4-Methoxybenzaldehyde dimethylacetal (12.9 mL, 0.08 
mol) was added dropwise. The reaction mixture was stirred at room temperature for 2 h under N2 
atmosphere. Excess NEt3 (10 mL) was added, and then the reaction mixture was concentrated in vacuo. 
The product was filtered through a short pad of silica gel (neutralized with 5 % NEt3 in hexane) in 1% 
ethyl acetate: hexane to afford (R)-4-hexyl-2-(4-methoxyphenyl)-1,3-dioxolane 20. (16 g of crude 
compound, mixture of diastereomers.) as a yellow oil; Rf (5% ethyl acetate: hexane) = 0.55. Compound 
20 was unstable, thus it was used immediately in the next step without further purification. 
To a stirred solution of 20 (16.0 g, crude) in dry dichloromethane (300 mL), DIBAL (90.90 mL, 0.09 mol, 
1 M in dichloromethane) was added dropwise at -78 °C under N2 atmosphere and stirred for 2 h at -78 °C. 
The reaction mixture was gradually warmed to -20 °C over 1 h, methanol (5 mL) was added dropwise and 
the resulting solution was stirred for 5 min. Dilution with diethyl ether (150 mL) followed by addition of 
saturated aqueous solution of Rochelle’s salt (150 mL) gave a thick suspension which was stirred 
vigorously until the two layers become clear. The organic layer was separated; and the aqueous layer was 
extracted with ethyl acetate (3 × 150 ml). The combined organic extracts were washed with brine (100 
mL), dried over anhydrous Na2SO4 and concentrated in vacuo. Purification using flash column 
chromatography in 0-12% ethyl acetate: hexane gave (-)-21 (9.7 g, 72% over two steps) as a pale yellow 
oil. 
Rf  (15% ethyl acetate : hexane) = 0.46.  
[α]D23 = -17.5 (c 1.00, CHCl3).  
νmax (liquid film) 3650-3300 (br), 1640, 1620, 1540, 1495, 1370, 1205, 1100, 850 cm-1.  
1H NMR (600 MHz, CDCl3) δ = 7.30 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 4.58 (d, J = 11.4 Hz, 
AB, 1H), 4.49 (d, J = 11.4 Hz, AB, 1H), 3.74-3.68 (s, 3H), 3.70 (m, 1H), 3.55-3.48 (m, 2H), 2.00 (brs, 
1H), 1.70-1.62 (m, 1H), 1.55-1.48 (m, 1H), 1.39-1.25 (m, 8H), 0.91 (t, J = 7.2 Hz, 3H) ppm.  
13C NMR (150 MHz, CDCl3) δ =159.3, 130.6, 129.4 (× 2), 113.9 (× 2); 79.5, 71.2, 64.3, 55.3, 31.8, 30.8, 
29.5, 25.4, 22.6, 14.1 ppm. 
Elemental analysis calcd (%) for C16H26O3: C 72.14, H 9.84; found: C 72.39, H 9.81. 
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3.3.2.10. (R)-2-(4-methoxybenzyloxy)octanal. 
C6H13
OPMB
O
22
 
To a stirred solution of oxalyl chloride (8.8 mL, 0.10 mol) in dry dichloromethane (286 mL), was added 
DMSO (9.7 mL, 0.14 mol) in dry dichloromethane (143 mL) dropwise at -78 °C under N2 atmosphere. 
Stirring was continued for 15 min, then (-)-21 (9.1 g, 0.03 mol) in dry dichloromethane (143 mL) was 
added dropwise. After complete addition, the reaction mixture was stirred at -78 °C for 1 h, then NEt3 (47 
mL, 0.34 mol) was added dropwise. The reaction mixture was gradually warmed to 0 °C and stirred at 
this temperature until complete conversion was observed. The mixture was diluted with diethyl ether (50 
mL) and poured in cold sat. NaHCO3 (140 mL). The organic layer was separated and the aqueous layer 
was extracted with diethyl ether (3 × 100 mL). The combined organic extracts were washed with brine 
(75 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. Purification using flash column 
chromatography in 0-5% ethyl acetate : hexane gave aldehyde (+)-22 (8.5 g, 94%) as a colorless oil. 
Rf  (4% ethyl acetate : hexane) = 0.47.  
[α]D23 = +37.8 (c 0.75, MeOH);  
1H NMR (600 MHz, CDCl3)  δ = 9.63 (d, J = 2.3 Hz, 1H), 7.30 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.5 Hz, 
2H), 4.62 (d, J = 11.8 Hz, AB, 1H), 4.50 (d, J = 11.4 Hz, AB, 1H), 3.82 (s, 3H), 3.78-3.72 (m, 1H), 1.71-
1.63 (m, 2H), 1.49-1.20 (m, 8H), 0.91 (t, J = 7.1 Hz, 3H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 204.1, 159.5, 129.7 (×2), 129.4, 113.9 (×2), 83.2, 72.2, 55.2, 31.6, 30.0, 
29.0, 24.7, 22.5, 14.0 ppm.  
Elemental analysis calcd (%) for C16H24O3: C 72.69, H 9.15; found: C 72.92, H 9.12. 
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3.3.2.11. (R)-Z-8-(4-methoxybenzyloxy)tetradec-6-enyloxy)tert-butyldimethylsilane. 
23
C6H13PMBO
TBSO
 
To a stirred suspension of TBSO(CH2)6P+Ph3Br-22 (11.85 g, 0.021 mol) in anhydrous THF (76 mL) cooled 
to -78 °C, n-BuLi (12.35 mL, 0.02 mol, 1.6 M in hexane) was added. The brown red colored suspension 
obtained was stirred at -78 °C for 30 min under N2 atmosphere. Compound (+)-22 (4.0 g, 0.01mol) in 
anhydrous THF (76 mL) was added dropwise; on complete addition the solution turned pale yellow. The 
reaction mixture was stirred at -78 °C for 15 min, warmed to room temperature and stirred for 2 h. After 
addition of saturated NH4Cl (100 mL), the product was extracted with diethyl ether (3 × 100 mL). The 
combined organic extracts were washed with brine (30 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. Purification by flash column chromatography in 0-1% ethyl acetate: hexane 
yielded (+)-23 (5.2 g, 74%) as a colorless oil. 
Rf  (1% ethyl acetate : hexane) = 0.36.  
[α]D23 = +15.6 (c 1.00, CHCl3). 
νmax (liquid film) 3050, 1570, 1550, 1535, 1480, 1290, 1110, 860, 760, 730 cm-1.  
1H NMR (600 MHz, CDCl3)  δ = 7.24 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 5.59 (dt, J = 11.0, 7.3 
Hz, 1H), 5.29 (dd, J = 11.0, 9.4 Hz, 1H), 4.49 (d, J = 11.6 Hz, AB, 1H), 4.24 (d, J = 11.6 Hz, AB, 1H), 
4.12-4.02 (m, 1H), 3.80 (s, 3H), 3.60 (t, J = 6.4 Hz, 2H), 2.12-1.95 (m, 2H), 1.73-1.18 (m, 16H), 0.89 (m, 
12 H), 0.05 (s, 6H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 158.9, 133.1, 131.2 (×2), 129.2 (×2), 113.6 (×2), 73.8, 69.4, 63.1, 55.2, 
35.8, 32.7, 31.8, 29.6, 29.3, 27.8, 26.0 (×3), 25.5, 25.4, 22.6, 18.3, 14.1, -5.3 (×2) ppm.  
Elemental analysis calcd (%) for C28H50O3Si: C 72.67, H 10.89; found: C 72.40, H 10.92. 
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3.3.2.12. (R)-8-(4-methoxybenzyloxy)tetradec-6-en-1-ol. 
C6H13PMBO
HO
24
 
A solution of TBS ether (+)-23 (9.5 g, 0.02 mol) in anhydrous THF (82 mL) was cooled to 0 °C. TBAF 
(61 mL, 0.06 mol, 1M in THF) was added at 0 °C under N2 atmosphere. The reaction mixture was 
warmed to room temperature and stirred for 1 h. Saturated NH4Cl (125 mL) was added, and the organic 
layer was separated. The aqueous layer was extracted with ethyl acetate (3 × 150 mL), and the combined 
organic extracts were washed with brine (80 mL), dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified using flash column chromatography in 0-15% ethyl acetate : hexane to 
afford desired (+)-24 (6.3 g, 88%) as pale yellow oil.  
Rf  (15% ethyl acetate : hexane) = 0.41.  
[α]D23 = +20.0 (c 1.00, CHCl3).  
νmax (liquid film) 3600-3200 (br), 3090, 3020, 1640, 1530, 1480, 1320, 1290, 1280, 1105, 1050, 760 cm-1.    
1H NMR (300 MHz, CDCl3) δ = 7.26 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 5.61 (dt, J = 11.0, 7.3 
Hz, 1H), 5.31 (dd, J = 11.0, 9.5 Hz, 1H), 4.51 (d, J = 11.9 Hz, AB, 1H), 4.27 (d, J = 11.9 Hz, AB, 1H), 
4.15-4.05 (m, 1H), 3.82 (s, 3H), 3.65 (t, J = 6.4 Hz, 2H), 2.15-2.00 (m, 2H), 1.75-1.50 (m, 4H), 1.48-1.30 
(m, 12H), 0.88 (t, J = 7.0 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 158.9, 133.0, 131.2, 131.1, 129.2 (×2), 113.7 (×2), 73.8, 69.3, 62.8, 55.3, 
35.7, 32.6, 31.8, 29.5, 29.3, 27.8, 25.4, 25.4, 22.6, 14.1 ppm.  
Elemental analysis calcd (%) for C22H36O3: C 75.82, H 10.41; found: C 75.60, H 10.43. 
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3.3.2.13. (R)-8-(4-methoxybenzyloxy)tetradec-6-enal. 
C6H13PMBO
O
25
 
To a stirred solution of oxalyl chloride (4.7 mL, 0.05 mol) in dry dichloromethane (150 mL), a solution of 
DMSO (5.1 mL, 0.07 mol) in dry dichloromethane (75 mL) was added dropwise at -78 °C under N2 
atmosphere and stirred for 15 min. Tetradecenol (+)-24 (6.3 g, 0.02 mol) in dry dichloromethane (75 mL) 
was added dropwise. After complete addition, the reaction mixture was stirred at -78 °C for 1 h. After 
addition of NEt3 (25 mL, 0.18 mol), the reaction mixture was gradually warmed to 0 °C and stirred at this 
temperature until complete conversion was observed. The mixture was diluted with diethyl ether (50 mL) 
and poured in cold sat. NaHCO3 (80 mL), the organic layer was separated and aqueous layer was 
extracted with diethyl ether (3 × 150 mL). The combined organic extracts were washed with brine (50 
mL), dried over anhydrous Na2SO4 and concentrated in vacuo. Purification using flash column 
chromatography with 0-5% ethyl acetate: hexane gave (+)-25 (5.7 g, 91%) as a colorless oil. 
Rf  (3% ethyl acetate : hexane) = 0.44.  
[α]D23 = +17.8 (c 1.00, MeOH).  
1H NMR (300 MHz, CDCl3) δ = 9.78 (s, 1H), 7.25 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 5.59 (dt, 
J = 11.0, 7.3 Hz, 1H), 5.34 (dd, J = 11.0, 9.5 Hz, 1H), 4.51 (d, J = 11.3 Hz, AB, 1H), 4.26 (d, J = 11.3 Hz, 
AB, 1H), 4.012-4.02 (m, 1H), 3.82 (s, 3H), 2.44 (t, J = 7.3 Hz, 2H), 2.12-1.98 (m, 2H), 1.73-1.56 (m, 
4H), 1.49-1.35 (m, 4H), 1.32-1.18 (m, 6H), 0.89 (t, J = 7.0 Hz, 3H) ppm.  
13C NMR (75 MHz, MeOD) δ = 200.3, 159.4, 133.2, 130.7, 129.3, 129.1, 113.5, 113.3, 104.6, 73.4, 69.2, 
54.4, 35.5, 32.3, 31.8, 29.4, 29.1, 27.6, 25.2, 24.1, 22.5, 13.2 ppm.  
Elemental analysis calcd (%) for C22H34O3: C 76.26, H 9.89; found: C 75.98, H 9.87. 
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3.3.2.14. (2R,8R)-8-(4-methoxybenzyloxy)tetradec-6-ene-1,2-diol. 
C6H13PMBO
HO
OH
26
 
A suspension of L-proline (57.6 mg, 0.5 mmol) in CHCl3 (16.5 mL) was cooled to 4 °C and stirred for 15 
min, then nitrosobenzene (525 mg, 5 mmol) was added in one portion. At this time the solution turned 
green. To this suspension was added a solution of tetradecenal (+)-25 (3.4 g, 9.9 mmol) in CHCl3 (16.5 
mL) in one portion. The resulting solution was then stirred at 4 °C for 2 h. At this time the solution turned 
yellow. The reaction mixture was then added to an ethanol (50 mL) suspension of NaBH4 (374 mg, 9.9 
mmol)
 
at 0 °C. After 30 min. the reaction was treated with saturated aqueous NaHCO3 (125 mL). The 
aqueous layer was extracted with dichloromethane (3 × 150 mL). The combined organic extracts were 
washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The oxy-
aniline adduct (4.1 g) was dissolved in EtOH/AcOH (3:1, 30 mL) and Zn dust (1.2 g, 0.02 mol) was 
added portionwise. The resulting suspension was stirred at room temperature for 1 h. The reaction 
mixture was filtered through a plug of celite and the residue was washed with ethanol (25 mL). The 
filtrate was concentrated in vacuo at <40 °C. The residue was dissolved in ethyl acetate (200 mL) and 
washed with a saturated NaHCO3 solution (100 mL), brine (50 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The resulting yellow oil was purified using flash column 
chromatography with 20% - 50% ethyl acetate : hexane to afford 1,2 diol (+)-26 (2.78 g 77%) as a yellow 
oil. 
Rf  (40% ethyl acetate : hexane) = 0.36.  
[α]D23 = +18.9 (c 1.00, CHCl3). 
νmax (liquid film) 3600-3200 (br), 3090, 1640, 1540, 1482, 1090, 1070, 760, 730 cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.23 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 5.56 (dt, J = 11.0, 7.3 
Hz, 1H), 5.32 (dd, J = 11.0, 9.5 Hz, 1H), 4.49 (d, J = 11.4 Hz, AB, 1H), 4.25 (d, J = 11.4 Hz, AB, 1H), 
4.12-4.02 (m, 1H); 3.79 (s, 3H), 3.71-3.53 (m, 2H), 3.45-3.35 (m, 1H), 2.88 (brs, 1H), 2.26 (brs, 1H), 
2.15-1.95 (m, 2H), 1.73-1.15 (m, 14H), 0.87 (t, J = 7.0 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 159.1, 132.8, 131.6, 131.1, 129.4 (×2), 113.8 (×2), 73.9, 72.2, 69.5, 66.8, 
55.4, 35.8, 32.8, 31.9, 29.4, 27.8, 25.8, 25.5, 22.7, 14.2 ppm.  
Elemental analysis calcd (%) for C22H36O4: C 72.49, H 9.95, found: C 72.70, H 9.94. 
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3.3.2.15. (2R,8R)-Z-1-((tert-butyldimethylsilyl)oxy)-8-(4-methoxybenzyloxy)tetradec-6-en-2-ol. 
C6H13PMBO
TBSO
OH
27
 
To a stirred solution of tetradecene-1,2 diol (+)-26 (400 mg, 1.1 mmol) in dry dichloromethane (11 mL) 
was added imidazole (149 mg, 2.2 mmol), then TBSCl (215 mg, 1.4 mmol) was added portionwise at 0 
°C. The reaction mixture was warmed to room temperature and stirred for 6 h, then it was quenched by 
addition of ice; the aqueous layer was extracted with dichloromethane (2 × 30 mL). The combined 
organic extracts were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified using flash column chromatography (0 - 8% ethyl acetate : petroleum 
ether) to afford mono TBS ether (+)-27 (518 mg, 98%) as a colorless oil. 
Rf (5% ethyl acetate : petroleum ether) = 0.35.  
[α]D23 = +14.3 (c 1.00, CHCl3). 
νmax (liquid film) 3610, 3580-3400 (br), 1625, 1605, 1530, 1480, 1260, 1120, 1090, 1050, 850, 795 cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.26 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 5.61 (dt, J = 11.0, 7.3 
Hz, 1H), 5.33 (dd, J = 11.0, 9.5 Hz, 1H), 4.51 (d, J = 11.3 Hz, AB, 1H), 4.26 (d, J = 11.3 Hz, AB, 1H), 
4.12-4.02 (m, 1H), 3.82 (s, 3H), 3.69-3.59 (m, 2H), 3.40 (dd, J = 8.5, 10.4 Hz, 1H), 2.17-1.96 (m, 2H), 
1.74-1.11 (m, 14H), 0.92 (s, 9H), 0.89 (t, J = 7.0 Hz, 3H), 0.09 (s, 6H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 159.1, 132.9, 131.6, 131.2, 129.3 (×2), 113.8 (×2), 73.9, 71.7, 69.5, 67.3, 
55.4, 35.9, 32.5, 32.0, 29.4, 27.9, 26.0 (×3), 25.9, 25.5, 22.7, 18.4, 14.2, -5.2, -5.3 ppm.  
Elemental analysis calcd (%) for C28H50O4Si: C 70.24, H 10.53; found: C 70.01, H 10.54. 
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3.3.2.16. (R)-5-((R)-Z-6-((4-methoxybenzyl)oxy)dodec-4-en-1-yl)-2,2,8,8,9,9-hexamethyl-3,3-diphenyl-
4,7-dioxa-3,8-disiladecane. 
C6H13PMBO
TBSO
OTBDPS
28
 
A solution of mono TBS ether (+)-27 (518 mg, 1.1 mmol), imidazole (220 mg, 3.2 mmol) in dry DMF 
(5.4 mL) was cooled to 0 °C. TBDPS-Cl (0.42 mL, 1.6 mmol) was added dropwise at 0 °C. After 
complete addition, the reaction mixture was stirred at room temperature under N2 atmosphere for 12 h. 
TLC showed partial completion of reaction, thus other 302 mg (1.1 mmol of TBDPS-Cl were added and 
the mixture stirred for further 8 h. The reaction was quenched by addition of ice; the aqueous layer was 
extracted with diethyl ether (3 × 50 mL), then the combined organic extracts were washed with brine (30 
mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified using flash 
column chromatography with 0-3% ethyl acetate : petroleum ether to afford bis-silyl ether (+)-28 (773 
mg, 98%) as yellow oil. 
Rf  (2% ethyl acetate : hexane) = 0.47.  
[α]D23 = +5.5 (c 1.2, CHCl3).  
νmax (liquid film) 3100, 1630, 1520, 1480, 1265, 1120, 850, 720 cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.76-7.65 (m, 4H), 7.47-7.31 (m, 6H), 7.24 (d, J = 8.5 Hz, 2H), 6.87 (d, 
J = 8.5 Hz, 2H), 5.51 (dt, J = 11.0, 7.0 Hz, 1H), 5.27 (dd, J = 11.0, 9.5 Hz, 1H), 4.48 (d, J = 11.6 Hz, AB, 
1H), 4.21 (d, J = 11.6 Hz, AB, 1H), 4.011-4.01 (m, 1H), 3.81 (s, 3H), 3.85-3.71 (m, 1H), 3.53-3.38 (m, 
2H), 2.00-1.84 (m, 2H), 1.65-1.20 (m, 14H), 1.06 (s, 9H), 0.89 (t, J = 7.0 Hz, 3H), 0.83 (s, 9H), 0.06 (s, 
3H), 0.01 (s, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 159.1, 136.0 (×6), 134.6, 134.5, 133.3, 131.3, 129.7, 129.4, 127.6 (×5), 
113.7 (×2), 74.1, 73.6, 69.6, 66.3, 55.4, 35.9, 33.6, 32.0, 29.5, 28.1, 27.2 (×3), 26.0 (×3), 25.5, 24.8, 22.8, 
19.5, 18.4, 14.3, -5.3 (×2) ppm.  
Elemental analysis calcd (%) for C44H68O4Si2: C 73.69, H 9.56: found: C 73.50, H 9.55.  
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3.3.2.17. (2R,8R)-Z-2-((tert-butyldiphenylsilyl)oxy)-8-((4-methoxybenzyl)oxy)tetradec-6-en-1-ol. 
C6H13PMBO
HO
OTBDPS
29
 
A mixture of bis-silyl ether (+)-28 (698 mg, 0.9 mmol) in AcOH/ THF/ H2O 3: 1: 1 (36 mL) was stirred at 
room temperature for 36 h. The reaction was quenched by addition of saturated aq. K2CO3 (50 mL), 
followed by addition of solid K2CO3. The aqueous layer was extracted with ethyl acetate (2 × 50 mL). 
The combined organic extracts were washed with brine (30 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. Purification using flash column chromatography with 0-8% ethyl acetate : 
petroleum ether produced (-)-29 (500 mg, 92%) as a yellow oil. 
Rf  (5% ethyl acetate : petroleum ether) = 0.56.  
[α]D23 = -18.07 (c 1.3, CHCl3). 
νmax (liquid film) 3610, 3580-3300 (br), 1635, 1600, 1530, 1480, 1445, 1270, 1120, 840, 760, 730 cm-1.    
1H NMR (300 MHz, CDCl3): δ = 7.75-7.58 (m, 4H), 7.49-7.32 (m, 6H), 7.21 (d, J = 8.6 Hz, 2H), 6.85 (d, 
J = 8.6 Hz, 2H), 5.41 (dt, J = 11.2, 7.4 Hz, 1H), 5.24 (dd, J = 11.2, 9.6 Hz, 1H), 4.44 (d, J = 11.4 Hz, AB, 
1H), 4.18 (d, J = 11.4 Hz, AB, 1H), 4.07-3.95 (m, 1H), 3.79 (s, 3H,), 3.80-3.72 (m, 1H), 3.58-3.41 (m, 
2H), 1.91-1.73 (m, 2H), 1.66-1.13 (m, 14H), 1.07 (s, 9H), 0.87 (t, J = 7.0 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 159.1, 136.0 (×2), 135.8 (×2), 134.0, 133.8, 132.7, 131.5, 131.2, 129.9 
(×2), 129.3 (×2), 127.9 (×4), 113.8 (×2), 1C overlapped to the solvent signal, 74.0, 69.5, 66.0, 55.4, 35.8, 
33.3, 31.9, 29.4, 27.8, 27.2 (×4), 25.5, 22.7, 19.5, 14.2 ppm.  
Elemental analysis calcd (%) for C38H54O4Si: C 75.70, H 9.03; found: C 75.42, H 9.00.  
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3.3.2.18. (2R,8R)-Z-2-((tert-butyldiphenylsilyl)oxy)-8-((4-methoxybenzyl)oxy)tetradec-6-enoic acid. 
C6H13PMBO
HO
OTBDPS
30
O
 
A suspension of (-)-29 (340 mg, 0.6 mmol), NaHCO3 (141 mg, 1.7 mmol) in acetonitrile / water (3.4 
mL:3.4 mL) was cooled to 0 °C and stirred for 10 min. TEMPO (17 mg, 0.1 mmol), and 
bis(acetoxy)iodobenzene (451 mg, 1.4 mmol), were added in one portion and the solution was stirred at 0 
°C for 4 h. Saturated aq. NaHCO3 (20 mL) was added at 0 °C and the aqueous layer was extracted with 
ethyl acetate (2 × 50 mL). The combined organic extracts were washed with brine (15 mL), dried over 
anhydrous Na2SO4 and concentrated in vacuo. The crude oil was purified using flash column 
chromatography (0-20% ethyl acetate: petroleum ether) to furnish (+)-30 (259 mg, 70%) as a colorless 
oil. 
Rf  (20% ethyl acetate : hexane) = 0.43.  
[α]D23 = +5.9 (c 1.00, MeOH).  
νmax (liquid film) 3100-2800 (br), 1730, 1630, 1605, 1525, 1480, 1445, 1280, 1260, 1125, 845, 760, 720 
cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.70-7.53 (m, 4H), 7.51-7.31 (m, 6H), 7.20 (d, J = 8.2 Hz, 2H), 6.85 (d, 
J = 8.2 Hz, 2H), 5.48-5.38 (m, 1H), 5.27 (m, 1H), 4.43 (d, J = 11.4 Hz, AB, 1H), 4.340-4.32 (m, 1H), 
4.16 (d, J = 11.4 Hz, AB, 1H), 4.08-3.92 (m, 1H), 3.79 (s, 3H), 1.95-1.18 (m, 16H), 1.12 (s, 9H), 0.86 (t, 
J = 6.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 174.8, 159.1, 135.8 (×4), 135.4, 132.9, 132.4, 131.8, 131.1, 130.5, 130.3, 
129.3 (×2), 127.9 (×4), 113.8 (×2), 73.9, 72.9, 69.5, 55.4, 35.8, 34.3, 31.9, 29.8, 29.4, 27.4, 27.0 (×3), 
25.4, 22.7, 19.4, 14.2 ppm.  
Elemental analysis calcd (%) for C38H52O5Si: C 73.98, H 8.50; found: C 74.22, H 8.52. 
 
 
65 
 
3.3.2.19. (2R,8R)-Z-2-((tert-butyldiphenylsilyl)oxy)-8-((4-methoxybenzyl)oxy)tetradec-6-enoylamide. 
C6H13PMBO
H2N
OTBDPS
O
31
 
A solution of (+)-30 (224 mg, 0.4 mmol), NH4Cl (38 mg, 0.7 mmol) in dry DMF (5 mL) was cooled to 0 
°C. HOBT (73 mg, 0.5 mmol) and HBTU (205 mg, 0.5 mmol) were added followed by DIPEA (0.23 mL, 
1.4 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. Ice was added, and 
then the aqueous layer was extracted with ethyl acetate (2 × 25 mL). The combined organic extracts were 
washed with cold brine (3× 10 mL) and dried over Na2SO4. After removal of the solvent in vacuo, the 
residue was purified using flash column chromatography (0-30% ethyl acetate : petroleum ether) to 
furnish (-)-31 (180 mg, 73%) as a white sticky solid. 
Rf  (25% ethyl acetate : hexane) = 0.45.  
[α]D23 = -8.9 (c 1.4, MeOH).  
νmax (thin film) 3550, 3505, 3450, 3100, 1700, 1635, 1605, 1580, 1540, 1485, 1450, 1285, 1135, 850, 760 
cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.73-7.54 (m, 4H), 7.50-7.30 (m, 6H), 7.20 (d, J = 8.2 Hz, 2H), 6.85 (d, 
J = 8.2 Hz, 2H), 6.73 (brs, 1H), 5.78 (brs, 1H), 5.50-5.39 (m, 1H), 5.32-5.22 (m, 1H), 4.43 (d, J = 11.4 
Hz, AB, 1H), 4.33.4.25 (m, 1H), 4.17 (d, J = 11.4 Hz, AB, 1H), 3.98 (m, 1H), 3.80 (s, 3H), 1.94-1.83 (m, 
2H), 1.75-1.15 (m, 14H), 1.12 (s, 9H), 0.87 (t, J = 6.6 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 177.7, 160.5, 137.3 (×2), 137.1 (×2), 134.4, 134.0, 133.1, 132.7, 131.8 
(×2), 130.8 (×2), 129.5 (×4), 115.3 (×2), 75.5 (×2), 71.0, 56.8, 37.3, 35.6, 33.4, 31.3, 30.9, 29.0, 28.6 
(×3), 26.9, 25.1, 24.2, 20.8, 15.7 ppm.  
Elemental analysis calcd (%) for C38H53NO4Si: C 74.10, H 8.67, N 2.27; found: C 74.38, H 8.69, N 2.26. 
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3.3.2.20. (2R,8R)-2-((tert-butyldiphenylsilyl)oxy)-8-hydroxytetradecanoylamide. 
C6H13HO
H2N
OTBDPS
O
18
 
To a solution of (-)-31 (68 mg, 0.11 mmol) in methanol (6 mL) was added 10% Pd/C (20 mg). The 
suspension was evacuated under vacuum and flushed with H2 gas (4 times). The reaction mixture was 
stirred under H2 atmosphere for 12 h at room temperature, then filtered through a plug of celite and the 
residue was washed with ethyl acetate (10 mL). The filtrate was concentrated in vacuo and purified using 
flash column chromatography (0-40% ethyl acetate: petroleum ether to obtain (-)-18 (40 mg, 73%) as a 
pale yellow oil. 
Rf  (30% ethyl acetate : hexane) = 0.35.  
[α]D23 = -10.1 (c 1.0, MeOH).  
νmax (thin film) 3550, 3505, 3450, 3100, 1710, 1604, 1575, 1450, 1299, 930, 790, 740 cm-1.   
1H NMR (300 MHz, CDCl3) δ = 7.70-7.54 (m, 4H), 7.50-7.31 (m, 6H), 6.72 (brs, 1H), 5.67 (brs, 1H), 
4.27 (t, J = 4.6 Hz, 1H), 3.60-3.50 (m, 1H), 1.94-1.55 (m, 2H), 1.48-1.15 (m, 19H), 1.12 (s, 9H), 0.89 (t, J 
= 6.6 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 176.6, 135.8 (×4), 133.1, 132.6, 130.3 (×2), 128.0 (×4), 74.4, 72.0, 37.5, 
34.5, 32.0, 29.5, 27.2, 27.1 (×3), 25.7 (×2), 23.5, 22.8 (×2), 19.4, 14.1 ppm.  
Elemental analysis calcd (%) for C30H47NO3Si: C 72.38, H 9.52, N 2.80; found: C 72.19, H 9.54, N 2.79. 
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3.3.2.21. (7R,13R)-14-amino-13-((tert-butyldiphenylsilyl)oxy)-14-oxotetradecan-7-yl (S)-1-(2-((2-
methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
O
O
O
C6H13
H2N
O
TBDPSO
MEMO
32
 
To a stirred solution of pyrrolinecarboxylic acid (-)-14 (66 mg, 0.2 mmol) in dry dichloromethane (8 mL) 
was added EDC·HCl (52 mg, 0.3 mmol) and DMAP (5 mg, 0.04 mmol) at 0 °C. A solution of (-)-18 (69 
mg, 0.14 mmol) in dichloromethane (2 mL) was added dropwise at 0 °C. The reaction mixture was 
warmed to room temperature and stirred for 16 h, then it was poured into water (10 mL) and the organic 
layer was separated. The aqueous layer was extracted with dichloromethane (2 × 25 mL) and the 
combined organic extracts were washed with brine and dried over anhydrous Na2SO4. The solvent was 
removed in vacuo and the residue was purified using flash column chromatography (FCC) with 0-40% 
ethyl acetate : hexane to furnish (-)-32 (56 mg, 50%) as a pale yellow oil.  
Rf (40% ethyl acetate : hexane) = 0.35.  
[α]D23 = -44.9 (c 1.0, MeOH). 
νmax (liquid film) 3520, 3410, 3090, 1760, 1710, 1660, 1640, 1440, 1280, 1130, 1010, 920, 790 cm-1.   
1H NMR (600 MHz, acetone-d6) (mixture of conformers) δ = 7.74-7.65 (m, 4H), 7.53-7.41 (m, 7H), 7.31 
(dd, J = 1.6, 7.6 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.14-7.08 (m, 1H), 6.97 (brs, 1H), 6.72 (brs, 1H), 6.22-
6.18 (m, 1H), 5.30 (s, 2H), 5.114-5.10 (m, 1H), 4.95- 4.87 (m, 2H), 4.16 (t, J = 5.1 Hz, 1H), 3.80 (t, J = 
4.8 Hz, 2H), 3.51 (t, J = 4.8 Hz, 2H), 3.27 (s, 3H), 3.20-3.12 (m, 1H), 2.70-2.55 (m, 1H), 2.20-1.92 (m, 
2H), 1.67-1.11 (m, 18H), 1.11 (s, 9H), 0.87 (t, J = 7.3 Hz, 3H) ppm.  
13C NMR (150 MHz, acetone-d6,) δ  = 175.1, 170.5, 164.1, 153.5, 135.7 (×2), 135.6 (×2), 133.3, 132.8, 
131.0, 130.7, 130.0, 129.5, 128.6, 127.8 (×4), 126.5, 121.8, 115.5, 108.1, 93.7, 74.5, 74.3, 71.4, 67.9, 
58.1, 57.9, 34.5, 34.0, 34.0, 33.8, 31.5, 29.6, 29.5, 26.5 (×3), 25.0, 24.7, 23.4, 22.3, 18.9, 13.4 ppm.  
Elemental analysis calcd (%) for C46H64N2O8Si: C 68.97, H 8.05, N 3.50; found: C 69.20, H 8.03, N 
3.52. 
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3.3.2.22. (7R,13R)-14-amino-13-hydroxy-14-oxotetradecan-7-yl (1S)-9-oxo-1,2,3,3a-tetrahydro-9H-
benzo[e]pyrrolo[2,1-b][1,3]oxazine-1-carboxylate. 
N
O
O
O
C6H13
H2N
O
HO
O
*
33
 
2N HCl (0.7 mL) was added dropwise to stirred solution of MEM ether (-)-32 (40 mg, 0.049 mmol) in 
THF (0.7 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1h. THF was removed in 
vacuo; the aqueous layer was extracted with ethyl acetate (2 x 7 mL). The combined organic extracts were 
washed with brine (6 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The product was 
purified using flash column chromatography with 15-45 % EtOAc : Hexane to afford (-)-33 as a 
colourless oil (9 mg, 35 %, more polar diastereomer) and 2.5 mg (11%, less polar diastereomer), 
stereochemistry not assigned. 
Spectral data for the more polar diastereomer:  
Rf (50 % EtOAc : hexane) = 0.32.  
[α]D23 = -54.0 (c 0.75, CHCl3).  
1H NMR (600 MHz, CDCl3) δ = 7.83 (d, J = 7.6 Hz, 1H), 7.44 (dd, J = 7.6, 7.6 Hz, 1H), 7.09 (dd, J = 7.6, 
7.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.87 (s, 1H), 5.56 (dd, J = 6.2, 7.3 Hz, 1H), 5.48 (s, 1H), 4.99-4.93 
(m, 1H), 4.60 (d, J = 8.9 Hz, 1H), 4.29-4.26 (m, 1H), 4.13-4.08 (m, 1H), 2.50-2.44 (m, 1H), 2.40-2.23 (m, 
2H), 2.20-2.15 (m,1H), 1.84-1.04 (m, 20H), 0.85 (t, J = 7.3 Hz, 3H). 
13C NMR (150 MHz, CDCl3) δ = 177.3, 170.6, 161.4, 157.8, 134.4, 127.8, 122.8, 118.9, 116.9, 88.5, 
75.5, 71.0, 57.1, 34.4, 33.8, 33.7, 31.7, 30.2, 29.0, 27.7, 26.0, 25.3, 24.5, 24.0, 22.5, 14.0. 
Elemental analysis. Calcd. for C26H38N2O6 C, 65.80; H, 8.07; N, 5.90. Found: C, 65.87; H, 8.09; N, 5.91. 
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3.3.2.23. ethyl (S)-1-(2-hydroxybenzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
OEt
O
O
HO
34
 
To a stirred solution of ethyl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-5-oxopyrrolidine-2-
carboxylate (-)-13 (35 mg, 0.10 mmol) in CH2Cl2 (0.6 ml, 15 M) was added TiCl4 (0.2 mL, 0.2 mmol, 1M 
in CH2Cl2) at -20 °C under N2 atmosphere. The reaction mixture was stirred at -20 °C for 10 min; then 
aqueous ammonia (1.2 mL) was added. The aqueous layer was extracted with ethyl acetate (2 x 5 mL), 
and the combined organic extracts were washed with brine (5 ml) and dried over anhydrous Na2SO4 and 
the solvent was removed in vacuo. The purification using preparative TLC in 30 % EtOAc: Hexane, gave 
the title compound (-)-34 as a colourless oil (20 mg, 76 %). 
Rf (20 % EtOAc: hexane) = 0.3. 
[α]D23 = - 132.3 (c 1.00, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 9.76 (s, 1H), 7.46-7.34 (m, 2H), 7.00 (dd, J = 1.2, 8.3 Hz, 1H), 6.88 
(ddd, J = 8.3, 8.3, 1.2 Hz, 1H), 6.84-6.78 (m, 1H), 5.30-5.24 (m, 1H), 5.02 (dd, J = 5.2, 11.4 Hz, 1H), 
4.30-4.19 (m, 2H), 3.18-3.05 (m, 1H), 2.78-2.66 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ = 171.1, 167.8, 159.3, 133.7, 131.1, 128.5, 119.1, 118.2, 117.0, 110.9, 
61.9, 59.5, 33.6, 14.3.  
Elemental analysis  Calcd. for C14H15NO4: C, 64.36; H, 5.79, N, 5.36. Found: C, 64.52; H, 5.78; N, 5.34.  
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3.3.2.24. ethyl (1S)-9-oxo-1,2,3,3a-tetrahydro-9H-benzo[e]pyrrolo[2,1-b][1,3]oxazine-1-carboxylate. 
N
OEt
O
O
O
*
35
 
2N HCl (0.5 mL) was added dropwise to stirred solution of MEM ether (20 mg, 0.0572 mmol) in THF 
(0.5 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1h. THF was removed in 
vacuo; the aqueous layer was extracted with ethyl acetate (2 X 5 mL). The combined organic extracts 
were washed with brine (4 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The product 
was purified using flash column chromatography with 25 % EtOAc: Hexane to afford 35 as yellow oil (8 
mg, 35 %, major diastereomer, stereochemistry not assigned) 
Rf (30 % EtOAc: Hexane) = 0.3.  
1H NMR (300 MHz, CDCl3) δ =  1H-NMR: 7.93 (dd, J = 1.8, 7.7 Hz, 1H), 7.45 (m, 1H), 7.11 (td, J = 1.3, 
7.6 Hz, 1H), 6.99 (m, 1H), 5.64 (m, 1H), 4.65 (m,1H), 4.22 (m, 2H), 2.54 – 2.20 (m, 4H), 1.26 (t, J = 
7.10, 3H) 
13C NMR (150 MHz, CDCl3) δ = 171.2, 161.3, 158.0, 134.4, 128.3, 122.9, 119.5, 117.2, 88.5, 61.9, 56.9, 
30.4, 26.3, 14.4. 
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3.3.2.25. (7R,13R)-14-amino-13-hydroxy-14-oxotetradecan-7-yl (S)-1-(2-hydroxybenzoyl)-2,3-dihydro-
1H-pyrrole-2-carboxylate. 
N
O
O
O
C6H13
H2N
O
HO
HO
1
 
To a stirred solution of (-)-32 (28 mg, 0.03 mmol) in dichloromethane (1 mL) was added TiCl4 (0.13 mL, 
0.13 mmol, 1 M in dichloromethane) at -20 °C. The reaction mixture was stirred at -20 °C for 10 min; 
then aqueous ammonia (2 mL) was added. The aqueous layer was extracted with ethyl acetate (2 × 30 
mL), and the combined organic extracts were washed with brine (10 mL) and dried over anhydrous 
Na2SO4. The solvent was removed in vacuo. The crude compound (24 mg) was dissolved in dry THF (1 
mL) and cooled to 0 °C. TBAF (0.1 mL, 0.1 mmol, 1 M in THF) was added dropwise. The reaction 
mixture was warmed to room temperature and stirred for 1 h, then saturated NH4Cl (5 mL) was added. 
The aqueous layer was extracted with ethyl acetate (2 × 25 mL); and the combined organic extracts were 
washed with brine (10 mL) and dried over anhydrous Na2SO4. After removal of the solvent in vacuo, the 
residue was purified using preparative TLC in 5% methanol : dichloromethane to furnish 1 (10 mg, 70% 
over two steps) as colorless oil.  
 
Rf (3% methanol : dichloromethane) 0.33.  
 
[α]D23 = -33.4 (c 1.00, CHCl3).  
 
1H NMR (600 MHz, CDCl3) δ = 9.53 (brs, 1H), 7.40-7.34 (m, 2H), 6.97 (d, J = 8.2 Hz, 1H), 6.89 (dd, J = 
7.5, 7.5 Hz, 1H), 6.70 (brs, 1H), 6.59 (brs, 1H), 5.42 (brs, 1H), 5.36-5.26 (m, 1H), 5.00 (dd, J = 4.7, 11.3 
Hz, 1H), 5.02-4.95 (m, 1H), 4.08 (dd, J = 3.6, 8.1 Hz, 1H), 3.60-3.40 (m, 1H), 3.12 (ddd, J = 17.1, 11.3, 
2.5 Hz, 1H), 2.68 (m, 1H), 1.98-1.08 (m, 20H), 0.85 (t, J = 6.8 Hz, 3H) ppm.  
 
13C NMR (150 MHz, CDCl3) δ = 177.0, 171.3, 167.4, 158.0, 133.4, 130.8, 128.3, 119.4, 118.0, 117.8, 
111.0, 76.0, 71.4, 59.3, 34.5, 34.3, 34.1, 33.6, 31.8, 29.2, 28.3, 25.5, 24.8, 24.5, 22.6, 14.1 ppm.  
Elemental analysis calcd (%) for C26H38N2O6: C 65.80, H 8.07, N 5.90; found: C 66.02, H 8.05, N 5.91. 
HRMS Accurate mass (ES+) calculated for C26H37N2O6  (M -1)+ 473.26571, Found: 473.26487. 
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CHAPTER-4 
PART-A  
BIOLOGICAL INVESTIGATION OF PROMYSALIN 
4.1. INTRODUCTION: 
Historically, the discovery of antibiotics and innovative developments in the field of antibiotics has saved 
numerous lives. The success of antibiotics is mainly attributed to their wide-spectrum activity which is 
amenable for the treatment of diverse bacterial infections. Recent studies by Cox. et al.1 emphasize the 
prolonged effect of antibiotics on human physiology and health on early exposure, these findings 
underscore that some antimicrobials certainly damage the commensal host population. In fact, the 
perturbation of commensal microbiota by the use of oral antibiotics often allows the proliferation of 
pathogens, which results in elevated chances of gastrointestinal inflammations and allergies.2 These 
findings prompted the researchers to expand their interest for the development of new chemical scaffolds 
with narrow-spectrum antibiotic activity.  
Promysalin is reported as a narrow spectrum antibiotic with species-specific activity against 
Pseudomonas aeruginosa. It exhibits the species-specific activity also against other members of genus 
Pseudomonas,3,4 without affecting the other gram-positive and gram-negative bacteria. Furthermore, 
promysalin attracted more attention because of its ability to inhibit the production of pyoverdine,4 a 
siderophore which is often linked to the virulence. Due to its intrinsic specificity, promysalin could serve 
as an alternative to develop new anti-virulence therapy against opportunistic human pathogen 
Pseudomonas aeruginosa. Recently we have accomplished the total synthesis of promysalin;5 herein, we 
discuss the biological investigation of promysalin. This work was done in collaboration with Prof. Diego 
Mora (Department of Food, Environmental and Nutritional Sciences, University of Milan) 
4.2. PROMYSALIN- A BROAD SPECTRUM ANTIBIOTIC: 
Promysalin was tested against several gram-positive and gram-negative bacteria using standard 
microdilution methods. The surprising results obtained (table-1), indicate that promysalin is not species 
specific antibiotic (as reported by Wuest et. al), having a broad-spectrum of activity against gram-positive 
and gram-negative bacteria including some well known human pathogens. The compound significantly 
inhibited the growth of Pseudomonas aeruginosa ATCC 10145 and ATCC 27853, Staphylococcus aureus 
ATCC 29213 and Streptococcus thermophilus DSM 201617T with minimal inhibitory concentration 
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(MICs) of 16 µg/ml. Moreover, it is also active against several Lactobacillus species with MICs of 256 
µg/ml. MICs of 64 µg/ml were measured against Enterococcus durans NCDO956, E. faecalis ATCC 
29292, ATCC 19433 and LMG 19456, E. faecium ATCC 19434, Staphylococcus epidermidis ATCC 
14990T and Streptococcus pyrogenes ATCC 12344T. The minimal bactericidal concentration (MBCs) 
values were determined for all the strains tested. The value ranges from 64 µg/ml for S. thermophilus and 
S. pneumonia to 256 or > 256 µg/ml for all the other bacterial strains tested. In conclusion, these findings 
reveal that promysalin is more active against streptococci and lactococci than toward lactobacilli.  
Bacterial species Strains MIC MBC 
Escherichia coli ATCC 25922 64 256 
Pseudomonas aeruginosa ATCC 10145 16 128 
Pseudomonas aeruginosa ATCC 27853 16 128 
Enterococcus durans NDCO 956 64 >256 
Enterococcus faecalis ATCC 29212 64 >256 
Enterococcus faecalis ATCC 19433 64 >256 
Enterococcus faecalis LMG 19456 64 >256 
Enterococcus faecium ATCC 19434 64 >256 
Enterococcus italicus DSM 15952 32 >256 
Lactococcus cremoris DSM 20069 32 32 
Lactococcus garviae DSM 20684 64 >256 
Staphylococcus aureus ATCC 25923 32 >256 
Staphylococcus aureus ATCC 29213 16 >256 
Staphylococcus epidermidis ATCC 14990T 64 128 
Streptococcus pneumoniae ATCC 700669 32 64 
Streptococcus pneumoniae ATCC 49619 32 64 
Streptococcus pneumoniae Pen6 32 64 
Streptococcus pyogenes ATCC 12344T 64 128 
Streptococcus thermophilus DSM 20617 T 16 64 
Pediococcus acidilactici PA-1 128 128 
Lactobacillus acidophilus DSM 20079 256 >256 
Lactobacillus delbrueckii subsp.  bulgaricus ATCC 11842 256 >256 
Lactobacillus casei LMG 6904 256 >256 
Lactobacillus helveticus ATCC 15009T 256 >256 
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Lactobacillus paracasei subsp. Paracasei DSM 5622 T 256 >256 
Lactobacillus plantarum ATCC 4008 256 >256 
 
Table 1: The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) 
values of promysalin against Gram-negative and Gram-positive bacteria. 
 
The above results of the promysalin antibacterial activity against a wide range of gram-positive 
microorganisms are in contrast to the previous observations,3 where promysalin was described as a 
species-specific antibiotic. The reason for this disparity in data could be attributed to the screening 
method used by Li. et al.3 against promysalin sensitive bacteria, i.e. the agar diffusion test. We observed 
that the agar diffusion test (Figure-1) is not robust enough to detect the promysalin sensitive bacteria 
except for the sensitive strain P. stutzeri LMG 2333; on the contrary the microdilution was found to be a 
more effective and reliable method to identify promysalin-sensitive bacteria.  
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Figure1: Agar diffusion assay carried out using P. putida RW10S1 (promysalin producers), and P. 
stutzeri LMG 2333 (promysalin-sensitive) as reference strains3 inoculated in TSB agar. Promysalin 
production and activity was tested against the soft agar overlay containing Streptococcus thermophilus 
DSM 20617T (A), Pediococcus acidilactici PAC1.0 (B) and Pseudomonas stutzeri LMG 2333 (C). P and 
S represent the growth of the promysalin-producer RW10S1, and the promysalin-sensitive strain, 
respectively, in TSB agar. 
 
The probable explanation to the above conflicting results could be the following factors: 
1) The effective concentration of promysalin released by the producer in the solid medium is lower than 
the MIC of sensitive strain. 
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2) The amphipathic nature of the promysalin might limit its solubility in aqueous medium which in turn 
interferes with the susceptibility test. 
3) Promysalin was able to show its inhibitory effect against the gram-negative Pseudomonas stutzeri 
LMG 2333 in the agar diffusion test, whereas it was inactive against the gram-positive counterparts 
(figure-1). It could be hypothesized that promysalin might have a different mode of action against 
Pseudomonas sp. and gram-positive bacteria. 
 
4.3. MECHANISM OF ACTION: 
In order to understand the mode of action of promysalin against gram positive bacteria, S. thermophilus 
DSM 20617T was used as a model organism. The cells were exposed to promysalin and the cell viability 
was measured using flow cytometry. Interestingly, when the cells were treated with 100 µg/ml of 
promysalin they rapidly lost their viability with significant increase in their propidium iodide 
fluorescence. Similar results were obtained with the biocide chlorhexidine at 100 µg/ml (figure-2) but 
with a faster rate. 
 
Figure-2: Effect of promysalin on cell viability of S. thermophilus DSM 20617T. Flow cytometry density 
diagrams show SYBR Green I vs PI fluorescence of cells exposed to promysalin or chlorhexidine (100 
µg/mL). A) Cells before exposure to antimicrobials; B) Cells after 30 min of exposure to promysalin. C) 
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Cells after 60 min exposure to promysalin and D) Cells after 15 min exposure to chlorhexidine. Viable 
cells are gated in G1, and viable cells with slightly damaged cell membranes are gated in G2. Dead cells 
with damaged membranes are gated in G3. The transition of cell populations from gate G1 to gate G3 is 
correlated to cell membrane damage. 
 
In the case of chlorhexidine 75% of the cell population lost the viability in 15 min. However, similar 
effect was observed in 60 min when cells were exposed to promysalin, (figure-2). The significant loss of 
cell viability upon exposure of cells to promysalin and chlorhexidine was associated with the damage of 
cell membrane as it results in increased propidium iodide (PI) cell fluorescence with concomitant 
reduction of SYBR-green I cell fluorescence. In order to understand whether promysalin exerts the 
similar effect on gram-negative bacteria the same experiment was conducted with E. coli (Figure-3). To 
our delight, similar results were obtained to those previously obtained with S. thermophilus cells. In case 
of E. coli promysalin follows a different rate kinetics as the membrane damage was faster (evident after 
20 min of exposure and almost complete in 90 min).  
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Figure-3: Effect of promysalin and chlorhexidine on Escherichia coli ATCC 25922 cell-membrane 
integrity. Flow cytometry density diagrams show SYBR Green I vs PI fluorescence of cells exposed to 
promysalin or chlorhexidine (100 and 200 µg/mL, respectively). A) and B) Cells after 20 min of exposure 
to antibacterials. C) and D) Cells after 1.5 h-exposure to antibacterials. Viable cells are gated in G1, and 
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viable cells with slightly damaged cell membranes are gated in G2. Dead cells with damaged membranes 
are gated in G3. The movement of cell populations from gate G1 to gate G3 is linked to cell membrane 
damage. 
Chlorhexidine is a well known potent biocide, which exhibits its bactericidal effect by disrupting the cell 
membrane similar to antimicrobial peptides.6 Benzalkonium chloride is another biocide which belongs to 
the class of quaternary ammonium compounds (QACs); like chlorhexidine it is a cationic surfactant 
which destructs the lipid bilayer of bacterial cell membrane.7 Similar to chlorhexidine and promysalin, 
benzalkonium chloride induced the loss of membrane integrity on S. thermophilus and E. coli cells in 15 
min, figure-4. 
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Figure-4: The effect of benzalkonium chloride on Streptococcus thermophilus DSM 20617T and 
Escherichia coli ATCC 25922 cell membrane integrity. Flow cytometry density diagrams show SYBR 
Green I vs PI fluorescence of cells treated with promysalin or chlorhexidine (100 and 200 µg/mL, 
respectively). A) and C) Cells before exposure to benzalkonium chloride (100 µg/mL). B) and D) Cells 
after 15 min of exposure to benzalkonium chloride. Viable cells are gated in G1. Dead cells with damaged 
membranes are gated in G3. The transition of cell populations from gate G1 to gate G3 is correlated to 
cell membrane damage. 
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The amphipathic nature of promysalin is compatible with its potential to interact with the phospholipid 
bilayer. In this context, we therefore propose that promysalin, chlorhexidine and benzalkonium chloride 
could have similar mechanism of action.  
4.4. PROMYSALIN-MEDIATED CELL MEMBRANE DISRUPTION AND RELEASE 
OF INTRACELLULAR COMPONENTS: 
To understand the in detailed mechanism of action, we decided to verify whether the membrane damage 
is accompanied by release of intracellular material or not. We decided to use the fluorescence probe 5 
(and 6-)carboxyfluorescein succinimidyl ester (cFSE) using the cFDASE precursor.8 cFDASE can easily 
permeate the membrane and get cleaved by the intracellular esterases. The conjugation of cFSE with the 
aliphatic amine residues of intracellular proteins results in green fluorescent cell staining.9 Thus, S. 
thermophilus DSM 20617T cells were labeled with cFSE probe and exposed to promysalin and 
chlorhexidine. The cell membrane damage along with the leakage of cFSE fluorescence outside the cells 
was analyzed using flow cytometry and by standard fluorometer. 
 
Figure-5: cell membrane damage and leakage of cFSE fluorescence outside the cell. 
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As depicted in figure-5, both promysalin and, more effectively, chlorhexidine promoted a significant 
reduction of cFSE fluorescence inside the cells and subsequent increase of cFSE fluorescence outside the 
cells. These results lead us to conclude that phospholipid bilayer disruption is followed by release of 
intracellular components.  
These results indicate that the antibacterial effect of promysalin is linked to the disruption of the 
phospholipid membrane bilayer and not to the elevation of ion membrane permeability which is well 
characterized for the membrane uncoupling gramicidin.10 Noteworthy, gramicidin did not show a 
membrane damage or a cFSE-fluorescence leakage in S. thermophilus DSM 20617T (Figure-6). 
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Figure-6: Effect of promysalin and gramicidin on Streptococcus thermophilus DSM 20617T cell 
membrane integrity. Flow cytometry density diagrams show the cFSE vs PI fluorescence of cells exposed 
to promysalin or gramicidin (100 µg/mL and 100 mM, respectively). A) Cells before exposure to 
antimicrobials. B) Cells after 60 min of exposure to DMSO. C) Cells after 60 min of exposure to 
promysalin. D) Cells after 60 min of exposure to gramicidin. Viable cells are gated in G1. Dead cells with 
damaged membranes are gated in G3. The transition of cell populations from gate G1 to gate G3 is 
correlated to cell membrane damage. 
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4.5. EFFECT OF PROMYSALIN ON SACCHAROMYCES CEREVISIAE: 
To expand the activity spectrum of promysalin towards eukaryotic microorganisms, we tested the 
compound against the cells of the yeast Saccharomyces cerevisiae BC1. A partial cell membrane damage 
as compared to the bisbiguanide biocide chlorhexidine was observed when the cells were exposed to 
promysalin, figure-7. Considering the partial cell membrane damage observed, promysalin was unable to 
inhibit completely the growth of Saccharomyces cerevisiae at the highest concentration tested (128 
µg/ml). Instead, promysalin significantly delayed the lag phase of the growth by 8 h with respect to 
control (figure-8). This result underscores the potential of this molecule against yeast and fungi. 
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Figure-7: The effect of promysalin and chlorhexidine on Saccharomyces cerevisiae BC1 cell membrane 
integrity. Flow cytometry density diagrams show SYBR Green I vs PI fluorescence of cells exposed to 
promysalin and chlorhexidine (100 µg/mL). A) Cells before exposure to antimicrobials. B) Cells after 60 
min of exposure to promysalin. C) Cells after 60 min of exposure to chlorhexidine. Viable cells are gated 
in G1. Dead cells with damaged membranes are gated in G3. The transition of cell populations from gate 
G1 to gate G3 is correlated to cell membrane damage.  
 
Figure-8: Growth of Saccharomyces cerevisiae BC1 with varying concentrations of promysalin. The 
calculated lag time (h:min) for each growth condition is indicated. 
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PART-B 
PREPARATION OF ANALOGUES AND THEIR BIOLOGICAL STUDIES 
The broad-spectrum bioactivity of the natural compound and its proposed mechanism of action prompted 
us to gain insights into the most vital structural features responsible for the activity. The diverted total 
synthesis of promysalin analogues by Wuest et al.11 has demonstrated that the bioactivity of the molecule 
is sensitive to changes within its hydrogen bond network and also that the exact three-dimensional 
orientation of the molecule is mandatory for biological activity.4 Recently, we reported an 
enantioselective convergent synthesis of promysalin.5 The robust and modular nature of our synthetic 
route has enabled us to apply it easily for the synthesis of some representative analogs, figure-9.  
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Figure-9: Structure of promysalin (1) and analogues 2-11.  
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Our strategy was based on gradual modifications of three structural frameworks: the salicylate core, the 
dehydroproline fragment and the myristamide chain. To illuminate the role of the salicylate core, it was 
altered by removal of hydrogen bond donor phenolic OH (2) and introduction of a methoxy group (4). 
Whereas 3, 5, 6 were prepared to highlight the importance of the myristamide chain linked to 
dehydroproline system. The derivatives 9, 10, 11 were synthesized to test the antimicrobial potential of 
myristamide chain. Taking into account the susceptibility of promysalin to acidic conditions,5 the 
enamide moiety was replaced with a proline fragment (compound 7). The conformationally rigid cyclized 
analogue, having a tetrahydro-9-oxa-3a-aza-cyclopentanaphthalen-4-one ring (compound 8) was obtained 
by treatment with TFA using literature procedure.11 
The promysalin analogues were screened using microdilution assay and MIC and MBC values were 
determined against the following reference gram negative and gram positive strains: Pseudomonas 
aeruginosa ATCC 10145, Staphylococcus aureus ATCC 29213, S. thermophilus DSM 20617T. The 
results are described in the table-2. 
 
Compound Pseudomonas aeruginosa 
ATCC 10145 
Staphylococcus aureus 
ATCC 29213 
Streptococcus 
thermophilus DSM20617T 
 MIC MBC MIC MBC MIC MBC 
Promysalin 16 128 16 >256 16 64 
2 128 >256 64 >256 64 128 
3 32 512 32 >256 32 64 
4 32 >256 32 >256 64 128 
5 32 >256 >256 >256 128 >256 
6 128 >256 >256 >256 256 >256 
7 32 >256 >256 >256 64 128 
8 128 >256 64 >256 64 64 
9 128 >256 125 >256 128 >256 
10 128 >256 >256 >256 128 >256 
11 128 >256 >256 >256 128 >256 
 
Table-2: Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values 
of promysalin and analogues against Gram-negative and Gram-positive bacteria. 
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The subtle changes in the salicylate moiety deteriorated the activity as the elimination of the phenolic 
group (cpd. 2) led to 8-fold decreased antibacterial activity. However, the methyl ether 4 retained 
significant biological activity against both gram positive and gram negative organisms. The C-2 
dehydroxy compound 3 partially retained the activity, most likely due to the chain flexibility allowing the 
amide carbonyl to participate in the hydrogen bonding interaction. Surprisingly, the heptyl ester 5 
conserved its effect against Pseudomonas aeruginosa ATCC 10145 but failed to show significant 
inhibition of gram positive counterparts. As anticipated, further reduction of chain length, as in the ethyl 
ester 6, did not give promising results.  The proline derivative 7 maintains a modest activity; in contrast to 
the previous results by Wuest et al.11 The structurally rigid oxazinone analogue 8 retained a moderate 
activity against P. aeruginosa ATCC 10145, S. aureus 29213, and S. thermophilus DSM 20617T. 
Compounds 7 and 8 highlight the importance of the enamide moiety, as both the more flexible proline 
and the conformationally locked oxazinone analogues did not fully retain the activity. The myristamide 
fragments 9-11 did not show activity. In conclusion, analogs 2, 3, 4, 7 retained the activity although with 
higher MIC compared to promysalin, MBC values lower than 256 µg/ml were observed only against S. 
thermophilus in case of the analogues 2, 3, 4, 7 and 8. These results imply that promysalin and analogues 
have a bacteriostatic rather than bactericidal effect against the other species tested. The salicylate 
fragment was found more essential for the antibacterial activity as small changes in this region led to 
significant loss of activity. 
The analogs which retained MIC values below or equal to 128 µg/ml in S. thermophilus DSM 20617T 
were also evaluated for their ability to induce cell membrane damage by flow cytometry using the SYBR 
Green I/PI double staining assay (figure-10). In addition, the viability of the cells treated with promysalin 
and its derivatives was also evaluated using standard plating method. Surprisingly, the benzoylenamide 3 
in contrast to poor MIC displayed 88% membrane damage. The methyl ether 4 manifested a sounding 
98% membrane disruption almost equal to promysalin. Pertaining to its conformational rigidity, the 
oxazinone analogue 8 gave moderate reduction in cell viability. The fully functionalized myristamide 
chain appears to be necessary to produce a remarkable antibacterial effect, a similar trend was observed in 
case of 5 and 6 as the ester derivatives induced diminished reduction of cell viability (15% and 35% 
respectively). Noteworthy, the C-2 dehydroxylation to give compound 3 had a huge impact, enabling only 
negligible cell membrane damage, thus again highlighting the importance of hydrogen bonding groups. 
The proline derivative 7 having the intact hydrogen bonding atoms shows 92% reduction irrespective of 
the change in orientation due to the loss of the double bond. In summary, the oxygen network in the 
parent molecule seems to play a crucial role and only modifications in the salicylate fragment are 
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tolerated and conserved significant activity. On the contrary, alterations in myristamide chain were found 
to be detrimental. 
 
Figure-10: The effect of promysalin and analogs on S. thermophilus DSM 20617T cell membrane 
integrity and cell viability. Flow cytometry density diagrams show the SYBR Green I vs PI fluorescence 
of cells exposed to promysalin or to the analogs 2-8 (100 µg/ml). Viable cells are gated in G1, viable cells 
with slightly damaged cell membrane are gated in G2. Dead cells with damaged membrane are gated in 
G3. The transition of cell population from gate G1 to gate G3 is related to the entity of cell membrane 
damage. The reduction of cell viability measured by standard plating was shown in parenthesis. The 
reduction of cell viability was calculated using as reference (100% of viability reduction) the bactericidal 
effect of chlorhexidine. The differences in structure between promysalin and the analogs are indicated by 
the red arrows. 
87 
 
4.6. SUMMARY: 
In light of the results obtained, promysalin displays broad-spectrum antibacterial activity against gram-
positive and gram negative bacteria, thus it cannot be considered as a species-specific narrow-spectrum 
molecule. Damage of the phospholipid layer seems to be the most probable mechanism of action of 
promysalin. The broad-spectrum activity together with ability of promysalin to disrupt the phospholipid 
bilayer of the microbial cell membrane makes it a biocide rather than an antibiotic. Thus, the use of 
promysalin to treat human infections, such as those caused by Pseudomonas aeruginosa as proposed by 
Wuest et. al.11 needs a thorough investigation.  
The representative analogues of promysalin were synthesized and evaluated for their antimicrobial 
activity. The results obtained suggest that subtle alteration of the functional groups in the natural 
compound led to loss of activity. The three dimensional architecture and the hydrogen bonding network is 
mandatory to have significant antimicrobial activity. The analogues were also evaluated for their 
membrane disruption potential against S. thermophilus DSM20617T, which showed excellent to moderate 
reduction in cell viability. 
 
 
 
 
 
 
 
 
 
 
88 
 
4.7. EXPERIMENTAL SECTION: 
4.7.1. SYNTHESIS OF ANALOGUES: 
4.7.1.1. GENERAL INFORMATION:  
See chapter-3.3.1 for General information. 
4.7.1.2. GENERAL PROCEDURES: 
C6H13
O
O
NH2
N
O
O
HO
OHN
O
O
MEMO
OEtN
O
O
MEMO
OEtN
O
O
HO
HO
O
MEMO
OEtN
O
O
MEMO
C6H13
O
O
HO
NH2
N
O
O
HO ON
O
O
HO C6H13
C6H13
O
O
NH2
N
O
O
R
HO
OEtN
H
O
O
OEtN
O
O
R
C6H13
O
O
NH2
N
O
O
O
HO
3
6
7
2 R = H
4 R = OMeB, C, D
+
5
8
Ref-5
Ref-5
B, C, G
C, E
C, E
E
Ref-5
then H
A
F
1217
13 R = H
14 R = OMe
15
16
18
 
Scheme 1: Synthetic routes to compounds 2-8: a) i. aroyl chloride, NEt3, 0 ºC to 80 ºC, 3h, ii. LiBHEt3, 
toluene, -78 ºC, 1 h, then DIPEA, cat. DMAP, TFAA, -78 ºC to rt, 3 h; b) LiOH, EtOH : H2O, 0 ºC to rt, 5 
h; c) i) 2,4,6-trichlorobenzoyl chloride, NEt3, THF, 0 ºC to rt, 2h, ii) alcohol, DMAP, toluene, 0 ºC to rt, 
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12 h; d) TBAF, THF, 0 ºC to rt, 1 h; e) TiCl4, -20 ºC, 15 min.; f) L-proline ethyl ester.HCl, EDCI, HOBt; 
g) 1N HCl, THF, 0 ºC to rt; h) TFA, CH2Cl2, rt, 30 min. 
4.7.1.2.1. GENERAL PROCEDURE A: ACYLATION OF ETHYL l-PYROGLUTAMATE. 
NEt3 (2 eq.), followed by acid chloride (1.2 eq.) were added dropwise to a stirred solution of ethyl L-
pyroglutamate (1 eq.) in toluene (0.5 M) at 0 °C under N2 atmosphere. The mixture was stirred at 80 °C 
for 3 h and cooled to room temperature. Sat. NaHCO3 was added and the organic layer was separated. 
The aqueous layer was extracted with EtOAc (× 2). The combined organic extracts were washed with 
brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The product was purified using flash 
column chromatography in 0-30% EtOAc/hexane. 
 
4.7.1.2.2. GENERAL PROCEDURE B: REDUCTIVE ELIMINATION. 
To a stirred solution of acylated pyroglutamate (1 eq.) in dry toluene (0.2 M) was added Superhydride® 
(lithium triethylborohydride) (1.2 eq., 1M in THF) at -78 °C under N2 atmosphere. The mixture was 
stirred at -78 °C for 1h, then DMAP (0.1 eq.) and DIPEA (5.7 eq.) were added, followed by very slow 
addition of TFAA (1.2 eq.). The reaction mixture was gradually warmed to room temperature and stirred 
for 3 h. Water (× 10) was added and the organic layer was separated. The aqueous layer was extracted 
with ethyl acetate (× 2); the combined organic extracts were washed with brine, dried over anhydrous 
Na2SO4 and concentrated in vacuo. The residue was purified using flash column chromatography in 0-50 
% ethyl acetate: hexane. 
 
4.7.1.2.3. GENERAL PROCEDURE C: HYDROLYSIS OF THE ETHYL ESTER. 
To a solution of ethyl ester (1 eq.) was added dropwise a solution of LiOH (1.5 eq.) in water (EtOH : H2O 
2:1, 0.08 M) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 5 h. EtOH 
was removed in vacuo, the aqueous layer was washed with 40 % ethyl acetate in diethyl ether (× 2), 
cooled to 0 °C and acidified using 5% citric acid. The product was extracted using 5% CH3OH : CH2Cl2 
(× 3). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo to afford carboxylic acid. 
4.7.1.2.4. GENERAL PROCEDURE D: YAMAGOUCHI ESTERIFICATION. 
NEt3 (3 eq.) followed by 2,4,6-trichlorobenzoyl chloride (2 eq.) were added dropwise to a stirred solution 
of acid (1eq.) in THF (0.03 M) at 0 °C under N2 atmosphere. The mixture was warmed to room 
temperature and stirred for 2h. THF was removed in vacuo and the residue was dissolved in toluene 
(0.03M). DMAP (3 eq.) followed by alcohol (0.8 eq.) in toluene were added at 0 °C under N2 atmosphere. 
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The resulting suspension was stirred overnight at room temperature. EtOAc (× 15) was added, the organic 
layer was washed with sat. NH4Cl, brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The 
product was purified by flash column chromatography 0-70 % EtOAc: hexane. 
 
4.7.1.2.5. GENERAL PROCEDURE E: MEM DEPROTECTION 
To a stirred solution of MEM ether (1 eq.) in CH2Cl2 (0.15 M) was added TiCl4 (2 eq., 1M in CH2Cl2) at -
20 °C under N2 atmosphere. The reaction mixture was stirred at -20 °C for 10 min; then aqueous 
ammonia (20 times) was added. The aqueous layer was extracted with ethyl acetate (×2), and the 
combined organic extracts were washed with brine and dried over anhydrous Na2SO4. The solvent was 
removed in vacuo. The product was purified using preparative TLC. 
 
4.7.1.2.6. GENERAL PROCEDURE F: TBDPS DEPROTECTION. 
TBAF (3 eq. 1M in THF) was added dropwise to a stirred solution of silyl ether (1 eq.) in THF (0.2 M) at 
0 °C. The reaction mixture was stirred at room temperature for 1h. Sat. NH4Cl was added. The aqueous 
layer was extracted with ethyl acetate (× 2). The combined organic extracts were washed with brine, dried 
over anhydrous Na2SO4 and concentrated in vacuo. The product was purified using preparative TLC. 
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4.7.1.3. EXPERIMENTAL PROCEDURES: 
Promysalin (compound 1) was synthesized using literature procedure.5 
 
4.7.1.3.1. SYNTHESIS OF COMPOUND 2.  
4.7.1.3.1.1. ethyl (S)-1-benzoyl-5-oxopyrrolidine-2-carboxylate. 
 
NO
OEt
O
O
19
 
 
Using general procedure A, ethyl L-pyroglutamate (500 mg, 3.28 mmol) yielded ethyl (S)-1-benzoyl-5-
oxopyrrolidine-2-carboxylate (+)-19 as a creamy solid (620 mg, 74 %);  
Rf (25 % EtOAc: Hexane) = 0.25.  
[α]D23 = + 23.0 (c 1.00, CHCl3).  
mp = 79-80 °C. 
1H NMR (300 MHz, CDCl3) δ = 7.70-7.63 (m, 2H), 7.58-7.50 (m, 1H), 7.46-7.37 (m, 2H), 4.89 (dd, J = 
3.9, 8.9 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 2.83-2.68 (m, 1H), 2.66-2.38 (m, 1H), 2.23-2.09 (m, 1H), 1.30 
(t, J = 7.1 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 173.7, 171.2, 170.6, 134.0, 132.5, 129.3 (×2), 128.1 (×2), 62.1, 59.0, 
32.0, 22.1, 14.3 ppm.  
Elemental Analysis Calcd. for C14H15NO4: C, 64.36; H, 5.79; N, 5.36. Found: 64.25; H, 5.78; N, 5.37. 
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4.7.1.3.1.2. Ethyl (2S)-1-benzoyl-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
OEt
O
O
13
 
Using general procedure B, the ester (+)-19 (478 mg, 1.83 mmol) yielded the title compound ethyl (2S)-1-
benzoyl-2,3-dihydro-1H-pyrrole-2-carboxylate (-)-13 as a colourless oil (200 mg, 44 %).  
Rf (30 % EtOAc: Hexane) = 0.4.  
[α]D23 = - 138.6 (c 1.00, CHCl3). 
1H NMR (600 MHz, acetone-d6) δ = 7.60-7.31 (m, 5H), 6.57 (s, 1H); 5.17 (s, 1H); 4.95 (dd, J = 5.1, 11.7 
Hz, 1H), 4.28-4.12 (m, 2H), 3.20-3.12 (m, 1H), 2.70-2.63 (m, 1H), 1.35-1.19 (m, 3H) ppm.  
13C NMR (150 MHz, acetone-d6) δ = 170.5, 166.0, 135.6, 130.6, 130.4, 128.4 (× 2), 127.6 (× 2), 108.4, 
60.6, 58.4, 33.4, 13.5 ppm.  
Elemental Analysis Calcd. for C14H15NO3: C, 68.56; H, 6.16; N, 5.71. Found: C, 68.64; H, 6.15; N, 5.72. 
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4.7.1.3.1.3. (S)-1-benzoyl-2,3-dihydro-1H-pyrrole-2-carboxylic acid. 
N
OH
O
O
20
 
Using general procedure C the ester (-)-13 (170 mg, 0.69 mmol) was hydrolyzed to give (S)-1-benzoyl-
2,3-dihydro-1H-pyrrole-2-carboxylic acid (-)-20 as a pale yellow solid (130 mg).  
Rf (5 % MeOH : CH2Cl2) = 0.2.  
[α]D23 = - 85.3 (c 1.20, CHCl3).  
1H NMR (300 MHz, CD3OD) δ = 7.62-7.55 (m, 2H), 7.52-7.42 (m, 3H), 6.51-6.47 (m, 1H), 5.26-5.21 (m, 
1H); 4.84 (dd, J = 4.5, 11.2 Hz, 1H); 3.18-3.05 (m, 1H); 2.78-2.67 (m, 1H) ppm.  
13C NMR (150 MHz, CD3OD) δ = 177.3, 168.0, 135.4, 130.7, 130.2, 130.0 (× 2), 128.4, 127.66 (× 2), 
111.2, 60.6, 34.2, 26.5 ppm.  
Compound (-)-20 was used for the next step without further purification. 
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4.7.1.3.1.4. (7R,13R)-14-amino-13-hydroxy-14-oxotetradecan-7-yl-(S)-1-benzoyl-2,3-dihydro-1H-
pyrrole-2-carboxylate. 
C6H13
O
O
HO
NH2
N
O
O
2
 
NEt3 (0.09 mL, 0.69 mmol) followed by 2,4,6-trichlorobenzoyl chloride (0.07 mL, 0.46 mmol) were 
added dropwise to a stirred solution of the above acid (-)-20 (50 mg, 0.23 mmol) in THF (4.1 mL, 0.03 
M) at 0 °C under N2 atmosphere. The mixture was warmed to room temperature and stirred for 2 h. THF 
was removed in vacuo and the residue was dissolved in toluene (3 mL). DMAP (84 mg, 0.69 mmol) 
followed by (2R,8R)-2-((tert-butyldiphenylsilyl)oxy)-8-hydroxytetradecanamide5 (-)-29 (57 mg, 0.115 
mmol) in toluene was added at 0 °C under N2 atmosphere. The resulting suspension was stirred overnight 
at room temperature. EtOAc (8 mL) was added, the organic layer was washed with sat. NH4Cl (5 mL), 
brine (5 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude silyl ether (54 mg, 
0.076 mmol) was dissolved in THF (1 mL) and cooled to 0 °C; TBAF (0.22 mL, 0.23 mmol, 1M in THF) 
was added dropwise under N2 atmosphere. The reaction mixture was stirred at room temperature for 1 h. 
Sat. NH4Cl (7 mL) was added and the aqueous layer was extracted with ethyl acetate (2 × 7 mL) The 
combined organic extracts were washed with brine (5 mL), dried over anhydrous Na2SO4 and 
concentrated in vacuo. The product was purified preparative TLC in 6% MeOH: CH2Cl2, to afford the 
title compound (-)-2 as colourless oil (28 mg, 52 % over two steps).  
Rf (5 % MeOH: CH2Cl2) = 0.4.  
[α]D23 = -42.0 (c 0.45, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.57-7.36 (m, 5H), 6.85-6.72 (m, 1H), 6.53-6.46 (m, 1H), 5.20-5.14 (m, 
1H), 5.13-5.01 (m,1H), 4.97 (dd, J = 4.1, 12.1 Hz, 1H), 4.27 (m, 1H), 4.11-4.02 (m, 1H), 3.50 (brs, 1H), 
3.21-3.07 (m, 1H), 2.77-2.64 (m, 1H), 1.90-1.17 (m, 20H), 0.88 (t, J = 6.9 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 177.6, 170.7, 167.9, 134.8, 131.1, 130.9, 128.8 (× 2), 127.8 (× 2), 110.0, 
75.3, 70.7, 58.7, 34.9, 34.2, 34.1, 33.7, 31.9, 29.3, 27.6, 25.7, 24.8, 24.3, 22.8, 14.3 ppm.  
 
Elemental Analysis Calcd. for C26H38N2O5: C, 68.10; H, 8.35; N, 6.11. Found: C, 68.01; H, 8.33; N, 
6.12. 
 
HRMS: Accurate mass (ES+) calculated for C26H38N2O5Na (M + Na)+ 481.26729, Found: 481.26861. 
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4.7.1.3.2. SYNTHESIS OF COMPOUND 3.  
4.7.1.3.2.1 (R)-14-amino-14-oxotetradecan-7-yl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-
dihydro-1H-pyrrole-2-carboxylate. 
C6H13
O
O
NH2
N
O
O
MEMO
21
 
Using general procedure D, (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-
carboxylic acid5  (-)-16 (50 mg, 0.15 mmol) was reacted with (R)-8-hydroxytetradecanamide (11, see 
below) (32 mg, 0.139 mmol) to give (R)-14-amino-14-oxotetradecan-7-yl (S)-1-(2-((2-
methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate (-)-21 (40 mg, 54%) as a 
colourless oil. 
Rf  (4 % MeOH : CH2Cl2) = 0.3.  
[α]D23 = -54.5 (c 0.75, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.41-7.31 (m, 2H), 7.22 (dd, J = 8.2, 1.0 Hz, 1H), 6.30 (brs, 1H), 6.21-
6.14 (m, 1H), 5.28 (s, 2H), 5.09-4.91 (m, 3H), 3.84-3.78 (m, 2H), 3.57-3.50 (m, 2H), 3.36 (s, 3H), 3.20-
3.07 (m, 1H), 2.73-2.63 (m,1H), 2.42-2.34 (m,1H), 2.19 (t, J = 7.5 Hz, 2H), 1.72-1.18 (m, 20H), 0.87 (t, J 
= 6.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 176.3, 170.8, 165.3, 153.6, 131.6, 131.0, 128.9, 125.9, 122.4, 115.6, 
109.0, 94.0, 75.5, 71.7, 68.2, 59.2, 58.2, 36.1, 34.7, 34.4, 31.9, 29.4, 28.9, 28.6, 25.6, 25.2, 24.8, 22.8, 
14.3 ppm. 
Elemental Analysis Calcd. for C30H46N2O7: C, 65.91; H, 8.48; N, 5.12. Found: C, 65.83; H, 8.50; N, 
5.10. 
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4.7.1.3.2.1. (R)-14-amino-14-oxotetradecan-7-yl (S)-1-(2-hydroxybenzoyl)-2,3-dihydro-1H-pyrrole-2-
carboxylate. 
C6H13
O
O
NH2
N
O
O
HO
3
 
Using general procedure E, compound (-)-21 (85 mg, 0.159 mmol) was deprotected to afford the title 
compound (-)-3 as a colourless oil (38 mg, 52 %).  
Rf  (2 % MeOH:CH2Cl2) = 0.4.  
[α]D23 = -50.1 (c 1.5, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.45-7.33 (m, 2H), 6.99 (dd, J = 8.2, 1.0 Hz, 1H), 6.89 (ddd, J = 8.2, 8.2, 
1.0 Hz, 1H), 6.79 (brs, 1H), 5.67 (brs, 1H), 5.32-5.16 (m, 2H), 5.09-4.91 (m, 2H), 3.23-3.05 (m, 1H), 
2.76-2.62 (m, 1H), 2.20 (t, J = 7.6 Hz, 2H), 1.74-1.11 (m, 20H), 0.86 (t, J = 6.9 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 176.1, 171.1, 167.5, 158.8, 133.5, 131.1, 128.5, 119.2, 118.1, 117.5, 
110.8, 76.1, 59.6, 36.1, 34.4, 34.2, 31.9, 29.3, 29.1, 29.0, 25.5 (× 3), 25.0, 22.7, 14.3 ppm.  
Elemental Analysis Calcd. for C26H38N2O5: C, 68.10; H, 8.35; N, 6.11. Found: C, 68.02; H, 8.37; N, 
6.11.  
HRMS: Accurate mass (ES+) calculated for C26H38N2O5Na (M + Na)+ 481.26729, Found: 481.26829. 
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4.7.1.3.3. SYNTHESIS OF COMPOUND 4: 
4.7.1.3.3.1. ethyl (S)-1-(2-methoxybenzoyl)-5-oxopyrrolidine-2-carboxylate. 
N
O
OEt
O
O
OMe
22
 
Using general procedure A, ethyl L-pyroglutamate (500 mg, 3.28 mmol) afforded compound (+)-22 as a 
white solid (723 mg, 77 %). 
Rf (30 % EtOAc: Hexane) = 0.4.  
M.P = 93-94 °C.  
[α]D23 = + 65.5 (c 1.00, CHCl3).  
1H NMR (600 MHz, CDCl3) δ = 7.44 (ddd, J = 8.4, 7.7, 1.7 Hz, 1H), 7.33 (dd, J = 7.7, 1.7 Hz, 1H), 7.01 
(dd, J = 7.7, 7.7 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H); 4.92 (dd, J = 9.5, 2.8 Hz, 1H), 4.29 (q, J = 6.9 Hz, 2H), 
3.83 (s, 3H), 2.73-2.66 (m, 1H) 2.57-2.52 (m, 1H), 2.47-2.40 (m, 1H), 2.19-2.13 (m, 1H), 1.34 (t, J = 7.1 
Hz, 3H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 173.1, 171.4, 168.3, 157.2, 132.3, 129.0, 125.3, 120.8, 111.3, 62.1, 
58.6, 56.1, 53.8, 31.9, 22.1, 14.5 ppm. 
Elemental Analysis Calcd. for C15H17NO5 C, 61.85; H, 5.88; N, 4.81. Found: C, 61.95; H, 5.89; N, 4.80. 
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4.7.1.3.3.2.  ethyl (S)-1-(2-methoxybenzoyl)2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
O
OEt
O
OMe
14
 
Using general procedure B, ethyl (S)-1-(2-methoxybenzoyl)-5-oxopyrrolidine-2-carboxylate (+)-22 (723 
mg, 2.48 mmol) afforded compound (-)-14 as a clear oil (405 mg, 60 %).  
Rf (30 % EtOAc: Hexane) = 0.5.  
[α]D23 = - 117.8 (c 1.25, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.43-7.33 (m, 2H), 7.00 (ddd, J = 8.2, 8.2, 1.1 Hz, 1H), 6.94 (d, J = 8.2 
Hz, 1H), 6.18-6.12 (m, 1H), 5.08-5.03 (m, 1H), 5.00 (dd, J = 5.02, 11.7 Hz, 1H), 4.34-4.19 (m, 2H), 3.84 
(s, 3H), 3.20-3.05 (m, 1H), 2.76-2.65 (m, 1H), 1.32 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ = 171.2, 165.3, 156.1, 131.5, 131.0, 129.2, 125.1, 121.0, 111.6, 108.7, 
61.6, 58.2, 56.0, 34.3, 14.3 ppm.  
Elemental Analysis  Calcd. for C15H17NO4: C, 65.44; H, 6.22; N, 5.09. Found: C, 65.54; H, 6.21; N, 
5.08. 
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4.7.1.3.3.3. (S)-1-(2-methoxybenzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylic acid. 
N
O
OH
O
OMe
23
 
Using general procedure C, compound (-)-14 (250 mg, 0.908 mmol) was hydrolyzed to yield (-)-23 ((S)-
1-(2-methoxybenzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylic acid) as a yellow solid (185 mg, 82 %).  
Rf (4 % MeOH : CH2Cl2) = 0.4.  
M.P = 145-146 °C.  
[α]D23 = -82.8 (c 0.5, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.47-7.35 (m, 2H), 7.03 (ddd, J = 8.2, 8.2, 1.0 Hz, 1H), 6.96 (d, J = 8.2 
Hz, 1H), 6.07-6.02 (m, 1H), 5.26-5.20 (m, 1H), 5.13 (dd, J = 4.3, 10.8 Hz, 1H), 3.84 (s, 3H), 3.28-3.16 
(m, 1H), 3.11-2.96 (m, 1H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 173.1, 167.3, 156.0, 132.2, 130.0, 129.3, 124.0, 121.1, 111.6, 111.3, 
59.1, 56.0, 33.2 ppm.  
Elemental Analysis Calcd. for C13H13NO4: C, 63.15; H, 5.30; N, 5.67. Found: C, 63.23; H, 5.29; N, 5.66. 
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4.7.1.3.3.4. (7R,13R)-14-amino-13-((tert-butyldiphenylsilyl)oxy)-14-oxotetradecan-7-yl-(S)-1-(2-
methoxybenzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
C6H13
O
O
TBDPSO
NH2
N
O
O
MeO
24
 
Using general procedure D, the above acid (-)-23 (35 mg, 0.14 mmol) was reacted with (2R,8R)-2-((tert-
butyldiphenylsilyl)oxy)-8-hydroxytetradecanamide5 (-)-29 (56 mg, 0.112 mmol) to give (7R,13R)-14-
amino-13-((tert-butyldiphenylsilyl)oxy)-14-oxotetradecan-7-yl-(S)-1-(2-methoxybenzoyl)-2,3-dihydro-
1H-pyrrole-2-carboxylate (-)-24 as a pale yellow oil (42 mg, 50 %). 
Rf (50 % EtOAc : hexane) = 0.3.  
[α]D23 = -39.0 (c 0.4, CHCl3).  
1H NMR (600 MHz, CDCl3) δ = 7.67 (d, J = 7.0 Hz, 2H), 7.62 (d, J = 7.0 Hz, 2H), 7.50-7.34 (m, 8H), 
7.00 (dd, J = 7.0, 7.0 Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 6.74 (d, J = 4.5 Hz, 1H), 6.18-6.14 (m, 1H), 5.58-
5.54 (m, 1H), 5.06-4.92 (m, 3H), 4.27 (dd, J = 3.9, 5.2 Hz, 1H), 3.85 (s, 3H), 3.17-3.10 (m, 1H), 2.71-
2.66 (m, 1H), 1.70-1.12 (m, 29H); 0.98 (t, J = 7.1 Hz, 3H) ppm. 
13C NMR (150 MHz, CDCl3) δ = 176.2, 170.8, 164.9, 155.9, 135.7(× 2), 135.6(× 2), 133.0, 132.6, 131.2, 
130.9, 130.2, 130.1, 127.9 (× 2), 127.8(× 2), 125.1, 120.8, 111.3, 108.3, 75.4, 74.2, 58.1, 55.7, 34.3, 34.2, 
33.9, 33.8, 31.7, 29.7, 29.3, 29.2, 27.0 (× 2), 25.2, 24.8, 23.3, 22.6, 19.3, 14.0 ppm. 
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4.7.1.3.3.5. (7R,13R)-14-amino-13-hydroxy-14-oxotetradecan-7-yl (S)-1-(2-methoxybenzoyl)-2,3-dihydro-
1H-pyrrole-2-carboxylate. 
C6H13
O
O
HO
NH2
N
O
O
MeO
4
 
Compound (-)-24 (30 mg, 0.041 mmol) was deprotected using general procedure F to give the title 
compound 4 as a colourless oil (19 mg, 99 %).  
Rf (4 % MeOH : CH2Cl2) = 0.3. 
[α]D23 = -32.8 (c 0.5, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.44-7.37 (m, 1H), 7.33 (dd, J = 1.8, 7.6 Hz, 1H), 7.03-6.97 (m, 1H), 
6.95 (d, J = 8.2 Hz, 1H), 6.91 (brs, 1H), 6.18-6.12 (m, 1H), 5.14-4.99 (m, 3H), 4.96 (dd, J = 4.5, 11.6 Hz, 
1H), 4.36 (d, J = 5.4 Hz, 1H), 4.11-4.01 (m, 1H), 3.83 (s, 3H), 3.21-3.07 (m, 1H), 2.73-2.62 (m, 1H), 
1.91-1.17 (m, 20H), 0.88 (t, J = 6.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 177.9, 170.7, 166.0, 156.0, 131.9, 130.8, 129.0, 124.3, 121.1, 111.6, 
109.8, 75.1, 70.5, 58.2, 56.0, 35.0, 34.3, 33.7, 31.9, 29.9, 29.3, 27.5, 25.7, 24.8, 24.4, 22.8, 14.3 ppm.  
Elemental Analysis Calcd. for C27H40N2O6: C, 66.37; H, 8.25; N, 5.73. Found: C, 66.21; H, 8.26; N, 
5.72. 
HRMS: Accurate mass (ES+) calculated for C27H40N2O6Na (M + Na)+ 511.27786, Found: 511.28881. 
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4.7.1.3.4. SYNTHESIS OF COMPOUND 5: 
4.7.1.3.4.1. heptyl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
O
O
O
OMEM
C6H13
25
 
Using general procedure F, compound (-)-16 (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-
1H-pyrrole-2-carboxylic acid5 (50 mg, 0.15 mmol) was reacted with n-heptanol (0.026 mL, 0.19 mmol) to 
give heptyl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate (-)-25 
as a colourless oil (50 mg, 58 %).  
Rf (30 % EtOAc: hexane) = 0.2.  
[α]D23 = -85.7 (c 1.25, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.39-7.32 (m, 2H), 7.21 (dd, J = 1.2, 8.2 Hz, 1H), 7.04 (ddd, J = 1.2, 8.2, 
8.2 Hz, 1H), 6.18-6.13 (m, 1H), 5.28 (s, 2H), 5.05-5.01 (m, 1H) 4.99 (dd, J = 5.0, 11.8 Hz, 1H), 4.23-4.12 
(m, 2H), 3.83-3.76 (m, 2H), 3.56-3.48 (m, 2H), 3.35 (s, 3H), 3.19-3.03 (m, 1H), 2.74-2.63 (m, 1H), 1.71-
1.60 (m, 2H), 1.42-1.18 (m, 8H), 0.86 (t, J = 6.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 171.2, 165.1, 153.7, 131.4, 131.0, 129.1, 126.1, 122.3, 115.5, 108.7, 
93.9, 71.7, 68.1, 65.8, 59.2, 58.1, 34.4, 31.9, 29.1, 28.8, 26.0, 22.8, 14.3 ppm.  
Elemental Analysis Calcd. for C23H33NO6 C, 65.85; H, 7.93; N, 3.34. Found: C, 65.73; H, 7.91; N, 3.33. 
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4.7.1.3.4.1. heptyl (S)-1-(2-hydroxybenzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
O
O
O
OH
C6H13
5
 
Using general procedure E the above MEM ether (-)-25 (25 mg, 0.04 mmol) was deprotected to give the 
title compound 5 as a colourless oil (14 mg, 99 %).  
Rf (20 % EtOAc: hexane) = 0.4.  
[α]D23 = -112.7 (c 0.65, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 9.78 (s, 1H), 7.45-7.33 (m, 2H), 7.01 (dd, J = 1.2, 8.3 Hz, 1H), 6.88 
(ddd, J = 1.2, 8.3, 8.3 Hz, 1H), 6.84-6.80 (m, 1H), 5.31-5.23 (m, 1H), 5.03 (dd, J = 5.3, 11.4 Hz, 1H), 
4.27-4.09 (m, 2H), 3.20-3.04 (m, 1H), 2.78-2.67 (m, 1H), 1.72-1.61 (m, 2H), 1.40-1.16 (m, 8H), 0.87 (t, J 
= 7.1 Hz, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ = 170.9, 167.6, 159.2, 134.1, 130.9, 128.3, 118.8, 118.0, 116.8, 110.6, 
65.8, 59.3, 33.5, 31.7, 28.8, 28.5, 25.7, 22.5, 14.0 ppm.  
Elemental Analysis Calcd. for C19H25NO4: C, 68.86; H, 7,60; N, 4.23. Found: C, 68.68; H, 7,58; N, 4.24. 
HRMS: Accurate mass (ES+) calculated for C19H25NO4Na (M + Na)+ 354.16758, Found: 354.16798. 
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4.7.1.3.5. SYNTHESIS OF COMPOUND 6: 
4.7.1.3.5.1. ethyl (S)-1-(2-hydroxybenzoyl)-2,3-dihydro-1H-pyrrole-2-carboxylate. 
N
O
OEt
O
OH
6
 
Using general procedure E ethyl (S)-1-(2-((2-methoxyethoxy)methoxy)benzoyl)-2,3-dihydro-1H-pyrrole-
2-carboxylate5 (-)-15 (35 mg, 0.10 mmol) was deprotected to give the title compound (-)-6 as a colourless 
oil (20 mg, 76 %). 
Rf (20 % EtOAc : hexane) = 0.3. 
[α]D23 = - 132.3 (c 1.00, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 9.76 (s, 1H), 7.46-7.34 (m, 2H), 7.00 (dd, J = 1.2, 8.3 Hz, 1H), 6.88 
(ddd, J = 8.3, 8.3, 1.2 Hz, 1H), 6.84-6.78 (m, 1H) 5.30-5.24 (m, 1H), 5.02 (dd, J = 5.2, 11.4 Hz, 1H), 
4.30-4.19 (m, 2H), 3.18-3.05 (m, 1H), 2.78-2.66 (1H, m), 1.29 (3H, t, J = 7.1 Hz) ppm.  
13C NMR (75 MHz, CDCl3) δ = 171.1, 167.8, 159.3, 133.7, 131.1, 128.5, 119.1, 118.2, 117.0, 110.9, 
61.9, 59.5, 33.6, 14.3 ppm.  
Elemental Analysis Calcd. for C14H15NO4: C, 64.36; H, 5.79, N, 5.36. Found: C, 64.52; H, 5.78; N, 5.34.  
HRMS: Accurate mass (ES+) calculated for C14H15NO4Na (M + Na)+ 284.08933, Found: 284.08971. 
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4.7.1.3.6. SYNTHESIS OF COMPOUND 7: 
4.7.1.3.6.1. ethyl (2-((2-methoxyethoxy)methoxy)benzoyl)-L-prolinate. 
N
O
OEt
O
OMEM
18
 
HOBt (125 mg, 0.93 mmol) and EDC·HCl (168 mg, 0.93 mmol) were added sequentially to a stirred 
solution of 2-((2-methoxyethoxy)methoxy)benzoic acid5 17  (150 mg, 0.66 mmol) and L-proline ethyl 
ester·HCl (143 mg, 0.80 mmol) in DMF (2 mL, 0.3 M) at 0 °C under N2 atmosphere. DIPEA (0.54 mL, 
3.31 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 16 h. The 
reaction mixture was poured into ice cold water (15 mL) and the aqueous layer was extracted with ethyl 
acetate (2 × 10 mL). The combined organic extracts were washed with cold brine (2 × 5 mL), dried over 
anhydrous Na2SO4 and concentrated in vacuo. Purification using flash column chromatography in 2 % 
MeOH : CH2Cl2 afforded the compound (-)-18 as a colourless oil (185 mg, 79 %).  
Rf (2 % MeOH : CH2Cl2) = 0.2.  
[α]D23 = - 69.7 (c 1.2, CHCl3).  
1H NMR (300 MHz, CDCl3) mixture of rotamers (major) δ  = 7.34-7.12 (m, 3H), 7.07-7.00 (m, 1H), 5.29 
(s, 2H), 4.65 (dd, J = 4.3, 8.6 Hz, 1H), 4.23 (q, J = 6.9 Hz, 2H,), 3.86-3.76 (m, 2H), 3.57-3.51 (m, 2H), 
3.36 (s, 3H), 3.38-3.25 (m, 2H), 2.37-1.78 (m, 4H), 1.31 (t, J = 6.9 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = (major) 172.2, 168.0, 153.1, 130.2, 128.0, 127.7, 122.2, 115.4, 94.0, 
71.5, 67.9, 61.0, 59.0, 58.6, 48.2, 29.6, 24.7, 14.2 ppm.  
Elemental Analysis Calcd. for C18H25NO6: C, 61.52; H, 7.17; N, 3.99. Found: C, 61.39; H, 7.16; N, 4.00. 
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4.7.1.3.6.2. (2-((2-methoxyethoxy)methoxy)benzoyl)-L-proline. 
N
O
OH
O
OMEM
26
 
Using general procedure C ester (-)-18 (165 mg, 0.47 mmol) was hydrolyzed to (2-((2-
methoxyethoxy)methoxy)benzoyl)-L-proline (-)-26 as a colourless gummy mass (140 mg, 92 %).  
Rf (10 % MeOH : CH2Cl2) = 0.3.  
[α]D23 = -79.3 (c 1.7, CHCl3).  
1H NMR (300 MHz, CDCl3) mixture of rotamers (major) δ = 7.41-7.17 (m, 3H), 7.06 (dd, J = 7.8, 7.8 Hz, 
1H), 5.29 (s, 2H), 4.76 (dd, J = 4.2, 8.2 Hz, 1H) 3.83-3.77 (m, 2H), 3.57-3.52 (m, 2H), 3.37 (s, 3H), 3.40-
3.32 (m, 2H), 2.55-2.36 (m, 1H), 2.26-1.80 (m, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = major: 170.2, 168.5, 153.2, 131.4, 128.0, 126.6, 122.5, 115.5, 114.8, 
94.1, 71.7, 68.2, 59.7, 59.2, 49.0, 28.6, 24.8 ppm.  
Elemental Analysis Calcd. for C16H21NO6: C, 59.43; H, 6.55; N, 4.33. Found: C, 59.55; H, 6.54; N, 4.34. 
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4.7.1.3.6.3. (7R,13R)-14-amino-13-((tert-butyldiphenylsilyl)oxy)-14-oxotetradecan-7-yl(2-((2-
methoxyethoxy) methoxy)benzoyl)-L-prolinate. 
C6H13
O
O
TBDPSO
NH2
N
O
O
MEMO
27
 
Using general procedure F, the above acid (-)-26 was reacted with (2R,8R)-2-((tert-
butyldiphenylsilyl)oxy)-8-hydroxytetradecanamide5 (-)-29 (61 mg, 0.12 mmol) to give (7R,13R)-14-
amino-13-((tert-butyldiphenylsilyl)oxy)-14-oxotetradecan-7-yl-(2-((2-methoxyethoxy)methoxy)benzoyl)-
L-prolinate (-)-27 as a yellow sticky solid (58 mg, 59 %). 
Rf (3 % MeOH : CH2Cl2) = 0.4.  
[α]D23 = -25.1 (c 0.35, CHCl3).  
1H NMR (300 MHz, CDCl3) mixture of rotamers (major) δ = 7.69-6.98 (m, 14H), 6.72 (brs, 1H), 5.52 
(brs, 1H), 5.29 (s, 2H), 4.70-4.58 (m,1H), 4.29-4.20 (m, 1H), 3.87-3.72 (m, 3H), 3.58-3.47 (m, 2H), 3.35 
(s, 3H), 3.45-3.24 (m, 2H), 2.40-1.77 (m, 4H), 1.74-1.04 (m, 29H), 0.87 (t, J = 6.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = (major) 176.4, 172.1, 167.8, 153.3, 136.0 (× 2), 135.8 (× 4), 133.2, 
132.8, 130.7, 130.4, 128.2, 128.1 (× 4), 122.4, 115.2, 94.1, 75.3, 74.4, 71.8, 68.1, 59.2, 48.4, 34.5, 34.2, 
32.0, 31.9, 31.5, 30.0, 29.9, 29.5, 29.4, 29.3, 27.3, 25.4, 25.0, 23.0, 22.8, 22.78, 19.5, 14.3 ppm.  
Elemental Analysis Calcd. for C46H66N2O8Si: C, 68.79; H, 8.28; N, 3.49. Found: C, 68.67; H, 8.26; N, 
3.48. 
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4.7.1.3.6.4. (7R,13R)-14-amino-13-hydroxy-14-oxotetradecan-7-yl (2-hydroxybenzoyl)-L-prolinate. 
C6H13
O
O
HO
NH2
N
O
O
HO
7
 
2N HCl (0.5 mL) was added dropwise to a stirred solution of the (-)-27 (50 mg, 0.06 mmol) in THF (0.5 
mL) at 0 °C. The reaction mixture was stirred at room temperature for 1h. THF was removed in vacuo; 
the aqueous layer was extracted with ethyl acetate (2 × 7 mL). The combined organic extracts were 
washed with brine (5 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The product was 
purified using preparative TLC in 10% MeOH : CH2Cl2, to afford the title compound (-)-7 as a pale 
yellow oil (25 mg, 75 %).  
Rf (10 % MeOH : CH2Cl2) = 0.4.  
[α]D23 = -13.0 (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ = 10.66 (1H, s); 7.55-7.44 (m, 1H), 7.40-7.30 (m, 1H), 6.96 (dd, J = 1.0, 
8.2 Hz, 1H), 6.87 (dd, J = 8.2, 8.2 Hz, 1H), 6.59 (brs, 1H), 5.29 (brs, 1H), 4.98 (brs, 1H), 4.65 (dd, J = 
5.5, 8.6 Hz, 1H), 4.15-4.06 (m, 1H), 3.95-3.74 (m, 2H), 3.40-3.31 (m, 1H), 2.43-2.21 (m, 1H), 2.17-1.89 
(m, 3H), 1.83-1.07 (m, 20H), 0.87 (t, J = 6.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 177.3, 172.4, 170.4, 159.1, 133.3, 128.2, 118.9, 117.95, 117.87, 75.5, 
71.7, 60.7, 50.8, 34.6, 34.5, 34.4, 31.9, 29.4, 29.3, 28.6, 25.9, 25.6, 25.0, 24.7, 22.8, 14.3 ppm.  
Elemental Analysis Calcd. for C26H40N2O6: C, 65.52; H, 8.46; N, 5.88. Found: C, 65.63; H, 8.48; N, 
5.89. 
HRMS: Accurate mass (ES+) calculated for C26H40N2O6Na (M + Na)+ 499.27786, Found: 499.27697. 
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4.7.1.3.7. SYNTHESIS OF COMPOUND 8: 
4.7.1.3.7.1. (7R,13R)-14-amino-13-hydroxy-14-oxotetradecan-7-yl-(1S)-9-oxo-1,2,3,3a-tetrahydro-9H-
benzo[e]pyrrolo[2,1-b][1,3]oxazine-1-carboxylate. 
C6H13
O
O
HO
NH2
N
O
O
O
8
 
Compound 8 was synthesized as described in the Chapter-3, synthesis of Intermediate 33. 
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4.7.1.3.8. SYNTHESIS OF COMPOUND 9: 
4.7.1.3.8.1. (2R,8R)-2,8-dihydroxytetradecanamide 9. 
C6H13HO
H2N
O
OTBDPS
C6H13HO
H2N
O
OH
29 9
F
 
Using general procedure F, silyl ether (-)-295 (38 mg, 0.076 mmol) yielded the title compound (+)-9 as an 
off white solid (12 mg, 63 %).  
Rf (2 % MeOH : CH2Cl2) = 0.3.  
M.P = 100-102 ºC.  
[α]D23 = +15.0 (c 0.5, CHCl3).  
1H NMR (300 MHz, CH3OH - d4) δ = 3.97 (dd, J = 3.9, 7.7 Hz, 1H), 3.50 (brs, 1H), 1.83-1.67 (m, 1H), 
1.66-1.52 (m, 1H), 1.50-1.22 (m, 20H), 0.90 (t, J = 7.0 Hz, 3H) ppm.  
13C NMR (75 MHz, CH3OH - d4) δ = 179.5, 71.5, 71.2, 37.3, 37.2, 34.4, 31.9, 29.4, 29.4, 25.6, 25.5, 
24.9, 22.5, 13.2 ppm.  
Elemental Analysis Calcd. for C14H29NO3: C, 64.83; H, 11.27; N, 5.40. Found: C, 64.75; H, 11.29; N, 
5.41. 
HRMS: Accurate mass (ES+) calculated for C14H29NO3Na (M + Na)+ 282.20396, Found: 282.20448. 
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4.7.1.3.9. SYNTHESIS OF COMPOUND 10: 
4.7.1.3.9.1. (2R, 8R)- 2,8 dihydroxytetradecanol.  
C6H13PMBO
HO
OH
C6H13HO
HO
OH
H2, Pd/C
EtOH, rt, 16h,
71%
30 10
 
To a solution of diol 305 (100 mg, 0.274 mmol) in ethanol (7 mL) was added 10% Pd/C (10 mg). The 
suspension was evacuated under vacuum and flushed with H2 gas (4 times). The reaction mixture was 
stirred under H2 atmosphere at room temperature for 12 h. The reaction mixture was filtered through a 
plug of celite and the residue was washed with ethyl acetate (2 × 5 mL). The filtrate was concentrated in 
vacuo, the concentrate was triturated with diethyl ether (5 mL) to obtain alcohol 10 (50 mg, 74 %) as 
white solid.  
Rf (70 % ethyl acetate: hexane) = 0.2.  
M.P = 103-104 °C.  
[α]D23 = +8.0 (c 0.5, MeOH).  
1H NMR (300 MHz, 300 MHz, CH3OH - d4) δ = 3.62-3.34 (m, 4H), 1.60-1.22 (m, 20H), 0.90 (t, J = 6.9 
Hz, 3H) ppm.  
13C NMR (75 MHz, CH3OH - d4) δ = 72.1, 71.2, 66.2, 37.3, 37.2, 33.2, 31.9, 29.7, 29.3, 25.6 (× 2), 25.5, 
22.5, 13.2 ppm.  
Elemental Analysis Calcd. for C14H30O3: C, 68.25; H, 12.27. Found: C, 68.33; H, 12.29. 
HRMS: Accurate mass (ES+) calculated for C14H30O3Na (M + Na)+ 269.20872, Found: 269.20931. 
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4.7.1.3.10. SYNTHESIS OF COMPOUND 11: 
C6H13PMBO
HO
O
C6H13PMBO
H2N
O
C6H13HO
H2N
O
C6H13PMBO
HO
32
33 11
31
a
b c
 
Scheme-2: Synthesis of 11; a) TEMPO, BAIB, NaHCO3, ACN/ H2O, 0 °C, 4h, 65%; b) HBTU, HOBT, 
NH4Cl, DIPEA, DMF, 0 °C to rt, 1 h, 82%; c) H2, Pd/C, EtOH, rt, 16 h, 71%. 
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4.7.1.3.10.1. (R,Z)-8-(4-methoxybenzyloxy)tetradec-6-enoic acid. 
C6H13PMBO
HO
O
32
 
A suspension of alcohol (+)-315 (700 mg, 2.02 mmol), NaHCO3 (509 mg, 6.06 mmol) in CH3CN : H2O (1 
:1) (25 mL) was cooled to 0 °C and stirred for 10 min. TEMPO (63 mg, 0.40 mmol) and 
bis(acetoxy)iodobenzene (1.62 gm, 5.05 mmol), were added sequentially in one portion and the solution 
was stirred at 0 °C for 4 h in the dark. Saturated aq. NaHCO3 (20 mL) was added at 0 °C and the aqueous 
layer was extracted with ethyl acetate (2 × 25 mL). The combined organic extracts were washed with 
brine (20 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude oil was purified using 
flash column chromatography with 0-30% ethyl acetate: petroleum ether) to furnish (R,Z)-8-(4-
methoxybenzyloxy)tetradec-6-enoic acid (+)-32 (475 mg, 65 %) as white translucent oil.  
Rf  (30 % ethyl acetate: hexane) = 0.25.  
[α]D23 = +28.5 (c 1.00, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.24 (d, J = 9.1 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 5.58 (dt, J = 11.2, 7.4 
Hz, 1H), 5.32 (dd, J = 11.2, 9.5 Hz, 1H), 4.50 (d, J = 12.3 Hz, 1H), 4.26 (d, J = 12.3 Hz, 1H), 4.11-4.02 
(m, 1H), 3.80 (s, 3H), 2.35 (t, J = 7.3 Hz, 2H), 2.16-1.93 (m, 2H), 1.74-1.18 (m, 14H), 0.87 (t, J = 7.3 Hz, 
3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 179.7, 159.2, 132.6, 131.9, 131.3, 129.5 (× 2), 113.9 (× 2), 74.0, 69.6, 
55.5, 35.9, 34.1, 32.1, 29.5, 29.4, 27.7, 25.6, 24.6, 22.8, 14.3 ppm.  
Elemental Analysis Calcd. for C22H34O4: C, 72.89; H, 9.45. Found: C, 72.77; H, 9.44. 
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4.7.1.3.10.2. (R,Z)-8-(4-methoxybenzyloxy)tetradec-6-enamide. 
C6H13PMBO
H2N
O
33
 
A solution of carboxylic acid (+)-32 (475 mg, 1.31 mmol), NH4Cl (282.3 mg, 5.27 mmol) in dry DMF 
(18 mL, 0.07 M) was cooled to 0 °C. HOBT (534 mg, 3.93 mmol) and HBTU (1.5 gm, 3.93 mmol) were 
added, followed by DIPEA (1.87 mL, 5.27 mmol). The reaction mixture was warmed to room 
temperature and stirred for 1 h. Ice pieces were added, and then the aqueous layer was extracted with 
ethyl acetate (2 × 20 mL). The combined organic extracts were washed with cold brine (3 × 15 mL) and 
dried over anhydrous Na2SO4. After removal of the solvent in vacuo, the residue was purified using flash 
column chromatography with 0-50% ethyl acetate: petroleum ether to furnish (R,Z)-8-(4-
methoxybenzyloxy)tetradec-6-enamide (+)-33 (389 mg, 82 %) as a colourless oil.  
Rf  (50 % ethyl acetate: hexane) = 0.33.  
[α]D23 = +17.4 (c 0.5, CHCl3).  
1H NMR (300 MHz, CDCl3) δ = 7.24 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 5.58 (dt, J = 11.2, 7.4 
Hz, 1H), 5.45 (brs, 2H), 5.31 (dd, J = 11.2, 9.3 Hz, 1H), 4.49 (d, J = 11.7 Hz, 1H), 4.26 (d, J = 11.7 Hz, 
1H), 4.12-4.00 (m, 1H), 3.80 (s, 3H), 2.20 (t, J = 7.6 Hz, 2H,), 2.15-1.93 (m, 2H), 1.74-1.17 (m, 14H), 
0.87 (t, J = 7.7 Hz, 3H) ppm.  
13C NMR (75 MHz, CDCl3) δ = 175.4, 159.2, 132.7, 131.8, 131.3, 129.5 (× 2), 113.9 (× 2), 74.0, 69.6, 
55.5, 35.9, 35.8, 32.0, 29.5 (× 2), 27.7, 25.6, 25.4, 22.8, 14.3 ppm.  
Elemental Analysis Calcd. for C22H35NO3: C, 73.09; H, 9.76; N, 3.87. Found: C, 73.17; H, 9.73; N, 3.87. 
 
 
 
 
115 
 
4.7.1.3.10.3. (R)-8-hydroxytetradecanamide. 
C6H13HO
H2N
O 11
 
To a solution of (+)-33 (389 mg, 1.083 mmol) in ethanol (30 mL) was added 10% Pd/C (200 mg). The 
suspension was evacuated under vacuum and flushed with H2 gas (× 4). The reaction mixture was stirred 
under H2 at room temperature for 12 h, then it was filtered through a plug of celite and the residue was 
washed with ethyl acetate (2 × 20 mL). The filtrate was concentrated in vacuo; the concentrate was 
triturated with diethyl ether (10 mL) to obtain (R)-8-hydroxytetradecanamide (+)-11 (150 mg, 71 %) as a 
white solid.  
Rf  (50 % ethyl acetate: hexane) = 0.15.  
M.P = 97-99 ºC. 
[α]D23 = +9.0 (c 1.0, CHCl3).  
1H NMR (300 MHz, CD3OD) δ = 3.49 (brs, 1H), 2.49-2.40 (m, 1H), 2.22-2.15 (s, 3H), 1.66-1.22 (m, 
20H), 0.90 (t, J = 6.7 Hz, 3H) ppm. 
13C NMR (75 MHz, CD3OD) δ = 178.1, 71.2, 37.3, 35.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.1, 25.7, 25.6, 
22.5, 13.3 ppm.  
Elemental Analysis Calcd. for C14H29NO2: C, 69.09; H, 12.01; N, 5.75. Found: C, 69.15; H, 12.03; N, 
5.74. 
HRMS: Accurate mass (ES+) calculated for C14H29NO2Na (M + Na)+ 266.20905, Found: 266.20960. 
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4.7.2. MATERIALS AND METHODS RELATED TO MICROBIOLOGICAL ASSAYS: 
4.7.2.1. MICROBIOLOGICAL MEDIA AND CULTURE CONDITION: 
Bacteria strains and yeast were maintained at -80 °C and cultivated in M17 broth (Difco, Laboratories, 
Detroit, MI) for Streptococcus and Lactococcus species, and in MRS broth (Difco) for all Lactobacillus, 
Pediococcus, and Enterococcus species. Staphylococcus species were cultivated in Brain Heart Infusion 
broth (Difco). Streptococcus pneumoniae was routinely maintained in Trypticase Soy Broth (TSB) 
(Difco, Laboratories, Detroit, MI) with 3% (v/v) defibrinated horse blood in a 5% CO2 incubator. E. coli 
and Pseudomonas species were cultivated in TSB (Difco, Laboratories, Detroit, MI). Cultures were 
incubated at 30 °C and 37 °C for mesophilic and thermophilic species, respectively. 
 
4.7.2.2. AGAR DIFFUSION ASSAY.  
An agar diffusion assay was carried out using P. putida RW10S1 (promysalin producers), and P. stutzeri 
LMG 2333 (promysalin sensitive) as reference strains.3 Strains RW10S1 and LMG 2333 were spotted on 
the surface of agar Trypticase Soy Broth (TSB) (Difco, Laboratories, Detroit, MI) and incubated for 10-
18 h at 30 °C. After growth, the surface of the Petri plate was exposed to a saturated atmosphere of 
chloroform for 10 min, and an overlay containing a suspension of 107 CFU/mL of the target strain in the 
appropriate soft agar medium was poured onto the surface. The soft agar overlay, containing agar 7.5 g/L, 
was prepared in M17 medium (Difco, Laboratories, Detroit, MI) for Streptococcus thermophilus DSM 
20617T, and in MRS medium (Difco, Laboratories, Detroit, MI) for Pediococcus acidilactici 
DSM20284T. After solidification, the plates were incubated at the appropriate temperature for 18 h, and 
the presence or the absence of an inhibition halo around the P. putida RW10S1 was verified. 
 
4.7.2.3. EVALUATION OF MINIMAL INHIBITORY CONCENTRATION (MIC) AND MINIMAL 
BACTERICIDAL CONCENTRATION (MBC) OF PROMYSALIN AND DERIVATIVES AGAINST GRAM-
POSITIVE AND GRAM-NEGATIVE BACTERIA. 
Minimum inhibitory concentration (MIC) was determined using the broth microdilution method: after 
overnight growth on Mueller-Hinton broth-II (MHB-II) (Sigma-Aldrich, Milan, Italy) plates, strains were 
suspended in MHB-II to a standardized OD590 of 0.5. Three 10-fold dilutions were performed, and each 
cell suspension was inoculated in the presence of promysalin or its derivative analogues at the indicated 
concentrations. Determination of the minimum bactericidal concentration (MBC) was performed by 
subculturing 10 µL from each well without visible microbial growth. After 48 hours of incubation, the 
promysalin or analogue dilutions yielding three colonies or less were scored as the MBC for starting 
inocula of 105 CFU/mL. The experiments were performed in triplicate. MIC and MBC were performed 
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according to CLSI (Clinical and Laboratory Standards Institute) methods for dilution antimicrobial 
susceptibility tests for aerobic bacteria (approved standard, Wayne, PA, USA: CLSI; 2009).  
 
4.7.2.4. FLOW CYTOMETRY EVALUATION OF CELL MEMBRANE DAMAGE AND MEASUREMENT OF 
cFSE FLUORESCENCE CELL LEAKAGE. 
To evaluate whether membrane damage was linked to cell leakage of intracellular components, microbial 
cells grown for 18 h in the appropriate medium in Petri dishes were collected and diluted in sterile filtered 
(0.2 µm) phosphate-buffered saline (PBS) (NaCl 8 g/L; KCl 0.2 g/L; Na2HPO4 1,44 g/L; KH2PO4 0.24 
g/L; pH 7.4) to a final concentration of 108 events per mL. The cell suspension was diluted to 106 
events/mL and then exposed to promysalin (100 µg/mL) or its derivative analogues (100 µg/mL), 
chlorhexidine (100 µg/mL) (Sigma-Aldrich) or benzalkonium chloride (100 µg/mL) (Sigma-Aldrich) at 
37 °C. The cell suspension was also exposed to a DMSO control. At the time requested, a sample was 
collected and subjected to SYBR Green I/PI double staining and analysis by flow cytometry and, when 
necessary, to a standard plate count in the appropriate medium. In flow cytometry, particles/cells that pass 
through the beam will scatter light, which is detected as forward scatter (FSC) and side scatter (SSC). 
FSC correlates with cell size, cell shape and cell aggregates, whereas SSC depends on the density of the 
particles/cells (i.e., the number of cytoplasmic granules and membrane size). In this manner, cell 
populations can often be distinguished based on differences in their size and density. Cell suspensions 
were subjected to dual nucleic acid staining with cell permeate SYBR Green I (1X) and cell impermeant 
propidium iodide (PI) (5 µg/mL) (Sigma-Aldrich, Milan, Italy). SYBR Green I permeate the membrane of 
total cells and stains nucleic acids with green fluorescence. After incubation at room temperature for 15 
min, the labeled cell suspensions were diluted to approximately 106 events per mL, and analyzed by flow 
cytometry. Cell suspensions that were prepared as described above were analyzed using a flow cytometer 
with the following threshold settings: FSC 5,000, SSC 4,000, and 20,000 total events collected. All 
parameters were collected as logarithmic signals, and a 488-nm laser was used to measure the FSC 
values. The rate of events in the flow was generally lower than 2,000 events/s. The obtained data were 
analyzed using BD AccuriTM C6 software 1.0 (BD Biosciences, Milan, Italy). Cell-membrane damage 
was carried out by applying double staining with SYBR Green I and PI. The SYBR Green I fluorescence 
intensity of stained cells was recovered in the FL1 channel (excitation 488 nm, emission filter 530/30 
nm). PI fluorescence was recovered in the FL3 channel (excitation 488 nm, emission filter 670 nm long 
pass). PI penetrates only bacteria with damaged membranes, causing a reduction in SYBR Green I 
fluorescence when both dyes are present. Thus, live bacteria with intact cell membranes fluoresce bright 
green (defined as active fluorescent cells), bacteria with slightly damaged membranes exhibit both green 
118 
 
and red fluorescence (defined as slightly membrane damaged cells) and cells with broken membranes 
fluoresce red (defined as non-active fluorescent cells) (ISO 19344:2015; IDF 232:2015). Active 
fluorescent cells, damaged cells and non-active fluorescent cells were electronically gated in density plots 
of green fluorescence (FL1) versus red (FL3) fluorescence. Green and red fluorescence allowed for 
optimal distinction between stained microbial cells and instrument noise or sample background. Active 
fluorescent cells were gated in G1, cells with a slightly damaged membrane were gated in G2, and cells 
with broken membranes fluoresce red were gated in G3. To evaluate whether membrane damage was 
linked to cell leakage of intracellular components, microbial cells grown for 18 h in the appropriate 
medium in Petri dishes were collected and diluted in PBS to a final concentration of 108 per mL. The 
obtained cell suspension was supplemented with 4 µM cFDASE (Sigma-Aldrich, Milan, Italy), which is a 
precursor molecule of cFSE. The suspensions were incubated for 30 min at 37 °C. During this incubation, 
membrane-permeating cFDASE was cleaved by intracellular esterases, and the resulting cFSE molecules 
were conjugated to the aliphatic amines of intracellular proteins. After centrifugation at 15,000 x g for 1 
min and washing with PBS solution, the cells were suspended in an equal volume PBS. To ensure that 
unconjugated and free probes were eliminated by the cells, we periodically monitored cell fluorescence 
by flow cytometry as described below. The stability of the cell fluorescence was assessed; stained cells 
kept on ice in PBS after staining maintained a stable fluorescence, indicating that no free cFSE was inside 
the cells. Cell suspensions, prepared as described above and diluted to 106 events/mL, were analyzed 
using a flow cytometer with the previously described threshold settings. The cFSE fluorescence intensity 
of stained cells was recovered in the FL1 channel (excitation 488 nm, emission filter 530/30, provided by 
BD Biosciences, Milan, Italy). The cFSE-labeled cell suspension was then exposed to promysalin (100 
µg/mL) or its derivative analogues (100 µg/mL), chlorhexidine (100 µg/mL) (Sigma-Aldrich) or 
benzalkonium chloride (100 µg/mL) (Sigma-Aldrich) at 37 °C. As a control, the cFSE-labeled cell 
suspension was also exposed to a volume of DMSO solvent equal to that used for promysalin and its 
derivative analogues. At the time point, two samples of each cell suspension were collected: i) one sample 
was labeled with PI as described above, incubated at room temperature for 15 min, and analyzed by flow 
cytometry. The second sample was used to measure cFSE-fluorescence cell leakage. In flow cytometry, 
density plots of cFSE-green fluorescence (FL1) and FSC allowed for optimal distinction between cFSE-
stained microbial cells and instrument noise or sample background. Active cells showing only cFSE 
fluorescence were gated in G1, and cells with a slightly or heavily damaged membrane showing cFSE and 
PI fluorescence were gated in G2 and G3. Electronic gates on the green fluorescence/FSC density plot 
were used to select the measured bacterial concentration expressed as a % equal to the number of events 
in the gate divided by the total events counted. The sample for the measurement of cFSE-fluorescence 
119 
 
cell leakage was centrifuged (13000 rpm, 2 min), and the cell-free supernatant transferred to a 96-
microtiter plate for measurement of cFSE-fluorescence in a Victor 3 fluorometer (PerkinElmer). The 
fluorescence data were calculated as the average of three independent assays and expressed in arbitrary 
units of fluorescence ± the standard deviation. 
 
4.7.2.6. EVALUATION OF GROWTH KINETIC PARAMETERS OF SACCHAROMYCES CEREVISIAE BC1 
IN THE ABSENCE OF PROMYSALIN.  
S. cerevisiae BC1 growth was monitored in 96-well plates that were filled using an automatic liquid 
handling system (EpMotion, Eppendorf, Italy) to a final volume of 200 µL in the presence and absence of 
promysalin at different concentrations (4-128 µg/mL). A set of promysalin solutions at different 
concentrations in DMSO was prepared to add the same volume to each well, regardless of the final 
promysalin concentration. The growth of S. cerevisiae BC1 in the presence of promysalin was compared 
to its growth in the presence of a DMSO control added to the medium. Microbial growth was monitored 
using a spectrophotometer (MicroWave RS2, Biotek, USA) programmed for 145 readings (O.D.600 nm) 
every 10 min for 24 h at 37 °C. At the end of the incubation, the growth curve and lag time (h:min) were 
obtained using Gen5 software (Biotek, USA). The data were calculated as the average of three 
independent assays ± the standard deviation. 
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CHAPTER-5 
TOTAL SYNTHESIS OF LEOPOLIC ACID A 
5.1. INTRODUCTION: 
Plant associated actinomycetes have proven to be rich sources of biologically active secondary 
metabolites and therefore have attracted increasing attention in recent years. The secondary metabolites 
isolated from these sources represent a group of chemically diverse small molecules with wide range of 
bioactivity such as antibacterial, antifungal, cytotoxic and plant growth promoter. Few of these 
metabolites are shown in Figure-1.1, 2    
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Figure-1: Plant associated actinomycetes metabolites. 
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In 2012, through the chemical analysis of a terrestrial-derived Streptomyces sp. isolated from the 
rhizosphere of the plant Juniperus excelsa, Raju and coworkers3 elucidated the structure of a new 
metabolite, leopolic acid A (1, Figure-1). Leopolic acid has unprecedented structural features consisting 
of an aliphatic side chain attached to a 2,3-pyrrolidinedione residue, which in turn, is connected to the 
ureido dipeptide L-Phe-L-Val. The compound showed antifungal and antibacterial activity against Mucor 
hiemalis and Staphylococcus aureus with a MIC of 32 and 16 µg/mL respectively. Recently, our research 
group has been engaged in the total synthesis of this intriguing metabolite. For this purpose, it has been 
developed the synthesis of the pyrrolidine-2,3-dione scaffold outlined in Scheme 1.4  The pyrrolidine-2,3-
dione 9 was obtained in good yield by the Michael addition of p-methoxybenzylamine on ethyl acrylate 
followed by Dieckmann cyclisation with diethyl oxalate. The alkylation of enolic group using K2CO3 and 
benzyl bromide in dry DMF produced O-benzyl lactam 10, which was subsequently deprotected using 
CAN in CH3CN : water to furnish PMB deprotected lactam 11 in good yields. 
 
 
N
OH
COOEt
O
PMB
OEt
O
a, b
N
OBn
COOEt
O
PMB
HN
OBn
COOEt
O
c d
9 10 11
 
Scheme 1: Synthesis of pyrrolidine-2,3-dione. Reagents and Conditions: a) p-methoxybenzylamine, 
EtOH, rt, 12 h, 98 %; b) diethyl oxalate, NaOEt, EtOH, reflux, 3h, 83%; c) BnBr, K2CO3, DMF, 0 °C to 
rt, 1 h, 50 %; d) CAN, CH3CN:H2O, 0 °C to rt, 3 h, 73 %. 
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5.2. SYNTHESIS OF LEOPOLIC ACID A: 
Part of my research activity was focused on the development of the synthetic pathway from the 
intermediate 11 onwards (scheme-2). The acylation of lactam 11 using n-BuLi and the pentafluorophenol 
ester of Boc-valine gave N-acyl lactam (+)-12 in 73% yield.5 
HN
O
OBn
COOEt
N
O
OBn
COOEt
O
BocHN
N
O
OBn
CH2OH
OH
BocHN
N
O
OBn
CHO
O
BocHN
N
O
OBn
O
BocHN
7
N
O
OBn
O
H3N
7
TFA
N
O
OBn
O
N
H
7
N
H
O
BnO
O
Ph
N
O
OH
C10H21
O
N
H
N
H
O
HO
O
Ph
a b
c d e
f g
11 12 13
14 15 16
17 1
 
Scheme-2: Synthesis of leopolic acid A. Reagents and Conditions: a) 2-tert-butoxycarbonylamino-3-
methylbutyric acid pentafluorophenyl ester, n-BuLi, THF, -78 °C, 0.5 h, 71%; b) DIBAL-H, CH2Cl2, -78 
°C, 2 h, 30%; c) PCC, CH2Cl2, 0 °C to rt, 12 h, 46%; d) n-nonyltriphenylphosphonium bromide, n-BuLi, 
THF, -78 °C to 0 °C, 2 h; e) TFA, CH2Cl2, 0 °C to rt, 1 h; f) L-phenylalanine benzyl ester, DIPEA, 
triphosgene, CH2Cl2, rt, 1 h, 60% over three steps; g) H2, Pd/C, EtOAc, rt, 2 h, 77%. 
The selective reduction of ester to primary alcohol using equivalent amounts of LAH, NaBH4, LiBH4, 
Superhydride® did not gave the fruitful results. Finally, the treatment of lactam (+)-12 with 3 equivalents 
of DIBAL-H in CH2Cl2 at -78 °C chemoselectively reduced the ester and exocyclic amide to yield the 
diol (-)-13 in acceptable yield. The oxidation of diol (-)-13 was found to be nontrivial as under mild acidic 
condition and at room temperature the lactamol underwent cleavage to the corresponding lactam with 
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concomitant oxidation of primary alcohol to aldehyde. The oxidation under Swern condition and with 
Dess-Martin periodinane did not give the oxidized product in good yields. The PCC promoted one pot 
oxidation of diol (-)-13 furnished the aldehyde (+)-14 in moderate yield.  
The Wittig olefination of the resultant aldehyde with n-nonyltriphenylphosphonium bromide and n-BuLi 
at -78 °C facilitated the installation of decyl chain to furnish 15 as mixture of E/Z isomers.  
The intermediates 14 and 15 were susceptible to the mildest basic conditions and give rise to the 
hydrolysed products. Thus, the Boc deprotection of crude 15 followed by treatment with triphosgene and 
phenylalanine benzyl ester at room temperature produced urea 17. Finally, the global deprotection using 
catalytic hydrogenation generated the target molecule leopolic acid A (+)-1. We published these results in 
Beilstein J. Org. Chem. 2016, 12, 1624-1628.  
5.3. CONCLUSIONS: 
In conclusion, the Leopolic acid synthesis was accomplished in 11 steps. Although the molecule 
structurally looks simple, the 2,3-pyrrolidinone core was quite troublesome to install and several attempts 
were made to find the right pathway. The main problem we faced was the instability of a number of 
intermediates containing the 2,3 pyrrolidinedione moiety. The NH-free pyrrolidinedione scaffold, for 
instance, was found to be stable only in the presence of the ester group in position 4. The instability of the 
majority of the compounds resulting from the 2,3-pyrrolidinone core might be the probable reason for the 
rare presence of this structure in the literature.  
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5.4. PRELIMINARY ANTIMICROBIAL ACTIVITY EVALUATION STUDIES ON 2,3-
PYRROLIDINEDIONE CONTAINING MOLECULES: 
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Figure-2: Tetramic acid (18) and 2,3-pyrrolidinedione (19) scaffolds. 
 
A literature survey revealed that more than one hundred compounds containing the 2,4-pyrrolidinedione 
ring system (18, tetramic acids) have been isolated from a variety of natural sources.6 Most of these 
molecules have attracted considerable attention for their biological activities (i.e. antibacterial, antiviral, 
antifungal and anticancer). Compared to the numerous studies on bioactivities of tetramic acids, 
compounds with a 2,3-pyrrolidinedione skeleton (19) have been considerably less investigated. Even 
though this core can be considered as an attractive target, synthetic studies directed to find new 
biologically active compounds are very few.7  
 
N
OBn
COOEt
OO
N
H
Boc
HN
OBn
COOEt
O
N
OH
COOEt
O
PMB
N
OBn
COOEt
O
PMB
9 10
11 12
 
Figure-3: Structure of 2,3-pyrrolidinedione containing molecules tested. 
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Thus, while accomplishing the total synthesis of leopolic acid, we planned the biological screening of 
intermediates in order to investigate their antimicrobial and antifungal activities. In particular, in the 
perspective of a potential application for the development of new molecules for oral healthcare, we tested 
the antimicrobial activity of representative compounds (Figure-3) on Streptococcus mutans and Candida 
albicans. The results are shown in Table 1. 
Derivative (concentration) 
S. mutans  
inihibition (%) 
C. albicans  
inhibition (%) 
PBS + EtOH (10%) +  
DMSO 10% (negative control) 0.0  0.0  
9(0.2%)a 51.3  10.7  
9(1%) 25.6  45.5  
10 (0.2%) 2.7  23.1  
10 (1%) 0.0  32.3  
11 (0.2%) 4.8  27.9  
11(1%) 3.4  43.2  
12(0.2%) 48.6  16.7  
12 (1%) 89.5  50.7  
CHX (0.2%) (positive control) 93.6  49.9  
 
 
Table-1: MTT assay (data are expressed as % growth inhibition of microbial cells viable biomass after 1 
h exposure to different concentrations of the tested derivatives). 
 
A 0.2% solution of compound 9, containing a free enolic OH, gave a 51.3% inhibition of S. mutans 
growth. On C. albicans, however, the inhibition rate did not reach 50%, even at the highest concentration 
tested (1%). The protection of the enolic OH by a benzyl group (10) totally deprived the compound of any 
antibacterial activity. 
The effect of substituent on the nitrogen atom was also investigated. Removal of the PMB group from 
compound 10 to obtain compound 11 did not significantly change its antibacterial and antifungal 
activities. An unexpected gain in antibacterial activity was observed with the introduction of the protected 
amino acidic moiety to obtain compound 12.  
 
5.5. CONCLUSIONS: 
In conclusion, based on the results obtained, the compounds having 2,3-pyrrolidinedione nucleus can be 
considered promising lead structures for the development of structurally simplified and novel 
antimicrobial agents.  
We published these results in Bioorg. Med. Chem. Lett. 2016, 26, 1376-1380. 
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5.6. EXPERIMENTAL SECTION: 
5.6.1. GENERAL INFORMATION:  
As per chapter 3.3.1. GENERAL INFORMATION. 
5.6.2: EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA: 
5.6.2.1. ethyl 1-(4-methoxybenzyl)-2,5-dihydro-4-hydroxy-5-oxo-1H-pyrrole-3-carboxylate. 
N
OH
COOEt
O
PMB
9
 
Ethyl 3-(4-methoxybenzylamino)propanoate. A mixture of 4-methoxybenzylamine (10.00 g, 72.89 
mmol) in ethanol (100 mL) and ethyl acrylate (6.27 g, 62.62 mmol) was stirred at room temperature for 
12 h. After completion of reaction, the mixture was concentrated in vacuo to give ethyl 3-(4-
methoxybenzylamino)propanoate (16.88 g, 98%) as a pale yellow liquid. Rf ( 75% EtOAc/ Hexane) = 0.5. 
1H-NMR (CDCl3) δ = 7.23 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 4.13 (q, J = 7.2 Hz, 2H), 3.80 (s, 
3H), 3.74 (s, 2H), 2.88 (t, J = 6.6 Hz, 2H), 2.52 (t, J = 6.6 Hz, 2H), 1.25 (t,  J = 7.2 Hz, 3H) ppm.  
A mixture of ethyl 3-(4-methoxybenzylamino) propanoate (15.00 g, 63.21 mmol), NaOEt (6.40 g, 94.21 
mmol) and diethyl oxalate (10.99 g, 75.85 mmol) was refluxed for 3h. After removal of all the volatiles 
under vacuum, the solid residue obtained was dissolved in boiling water and filtered while hot. 
Neutralization of the filtrate with 2 N HCl gave a precipitate, which was filtered, washed with water and 
dried in vacuum to give the desired product 9 (18.01 g, 83%) as a white solid.  
Rf = (10% MeOH : CH2Cl2 ) = 0.5.  
m.p. = 132-133 °C.  
1H NMR (300 MHz, CDCl3) δ = 7.18 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 4.60 (s, 2H), 4.26 (s, 
2H), 3.83 (s, 2H), 3.79 (s, 3H), 1.29 (t, J = 7.0 Hz, 3H) ppm.  
Elemental Analysis calcd. (%) for C15H17NO5: C, 61.85; H, 5.88; N, 4.81. Found: C, 61.60; H, 5.90; N, 
4.82. 
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5.6.2.1. ethyl 1-(4-methoxybenzyl)-4-(benzyloxy)-2,5-dihydro-5-oxo-1H-pyrrole-3-carboxylate.  
N
OBn
COOEt
O
PMB
10
 
To a stirred solution of 9 (15.02 g, 51.56 mmol) in dry DMF (150 mL) was added anhydrous K2CO3 
(21.45 g, 154.0 mmol) at 0 °C and the reaction was stirred for 15 min, and then BnBr (9.52 g, 56.00 
mmol) was added. The reaction mixture was allowed to warm up and stirred for further 1h. After 
completion of the reaction, the mixture was diluted with EtOAc and washed with a cold brine solution. 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was 
purified by flash column chromatography (25% EtOAc : Hexane) to afford 10 (10.03 g, 50%) as a white 
solid.  
Rf (30% EtOAc : Hexane) = 0.5. 
mp = 72-74 °C.  
1H NMR (600 MHz, CDCl3) δ = 7.54-7.45 (m, 2H), 7.42-7.31 (m, 3H), 7.18 (d, J = 8.5 Hz, 2H), 6.88 (d, 
J = 8.5 Hz, 2H), 5.82 (s, 2H), 4.57 (s, 2H), 4.24 (q, J = 7.0 Hz, 2H), 3.86 (s, 2H), 3.82 (s, 3H), 1.30 (t, J = 
7.0 Hz, 3H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 164.9, 162.3, 159.3, 153.2, 136.7, 129.5 (× 2), 128.3 (× 2), 128.2, 
128.0, 127.6 (× 2), 114.5, 114.2 (× 2), 72.5, 60.6, 55.2, 46.5, 46.2, 14.1ppm. 
Elemental Analysis calcd. (%) for C22H23NO5: C, 69.28; H, 6.08; N, 3.67. Found: C, 69.05; H, 6.10; N, 
3.66. 
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5.6.2.2. ethyl 4-(benzyloxy)-2,5-dihydro-5-oxo-1H-pyrrole-3-carboxylate.  
 
HN
OBn
COOEt
O
11
 
A stirred solution of 10 (5.00 g, 13.10 mmol) in ACN:Water (3:1) (40 mL) was added with Cerium 
ammonium nitrate (28.74 g, 52.43 mmol) at 0 °C, then it was stirred for 1h at room temperature. After the 
completion of reaction, the mixture was diluted with EtOAc and washed with water and brine solution. 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product was 
purified by flash column chromatography (50% EtOAc : Hexane) to afford 11 (2.50 g, 73%) as a white 
solid.  
Rf (50% EtOAc : Hexane) = 0.3. 
mp = 160-161 °C.  
1H NMR (600 MHz, CDCl3) δ = 7.51-7.42 (m, 2H), 7.41-7.30 (m, 3H), 6.71 (brs, 1H), 5.77 (s, 2H), 4.29 
(q, J = 7.0 Hz, 2H), 4.06 (s, 2H), 1.34 (t, J = 7.0 Hz, 3H) ppm.  
13C NMR (150 MHz, CDCl3) δ = 168.4, 162.4, 153.1, 136.5, 128.4 (× 2), 128.1, 127.6 (× 2), 116.8, 72.9, 
60.7, 43.0, 14.1 ppm.  
Elemental Analysis Calcd. (%) for C14H15NO4: C, 64.36; H, 5.79; N, 5.36. Found: C, 64.60; H, 5.77; N, 
5.35. 
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5.6.2.3 4-Benzyloxy-1-(2-tert-butoxycarbonylamino-3-methylbutyryl)-5-oxo-2,5-dihydro-1H-pyrrole-3-
carboxylic ethyl ester. 
 
N
OBn
COOEt
OO
N
H
Boc
12
 
To a stirred solution of 11 (1.01 g, 3.86 mmol) in anhydrous THF (30 mL) was added n-BuLi (1.6 M in 
hexane, 2.6 mL, 4.17 mmol) at -78 °C over 10 min. 2-tert-Butoxycarbonylamino-3-methyl-butyric acid 
pentafluorophenyl ester5 (1.62 g, 4.25 mmol) in THF (2 mL) was then added, and the mixture was stirred 
for 30 min at the same temperature. The reaction was quenched by addition of sat. NH4Cl and extracted 
with EtOAc (3 ×15 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. 
The crude product was purified by flash column chromatography (12% EtOAc : Hexane) to afford 12 
(6.05 g, 86%) as a colorless viscous oil.  
Rf (80% EtOAc : Hexane) = 0.5. 
1H NMR (600 MHz, CDCl3) δ = 7.50-7.31 (m, 5H), 5.67 (s, 2H), 5.41 (m, 1H), 4.35 (AB, 1H), 4.31 (q, J 
= 7.0 Hz, 2H), 4.30 (AB, 1H), 4.14 (q, J = 7.0 Hz, 2nd rotamer, 2H), 2.15 (m, 1H), 1.46 (s, 9H), 1.34 (t, J 
= 7.0 Hz, 3H), 1.28 (t, J = 7.0 Hz, 2nd rotamer, 3H), 1.11 (d, J = 7.0 Hz, 3H), 0.84 (d, J = 7.0 Hz, 2nd 
rotamer, 3H) ppm.  
13C NMR (150 MHz, CDCl3) mixture of rotamers (major) δ = 172.5, 164.2, 161.7, 155.9, 150.8, 135.9, 
128.6 (× 2), 128.5, 128.4 (× 2), 118.3, 79.8, 73.6, 61.3, 58.5, 44.6, 30.2, 28.2 (× 3), 19.8, 16.0, 14.1 ppm. 
Elemental Analysis calcd. (%) for C24H32N2O7: C, 62.59; H. 7.00; N, 6.08. Found: C, 62.80; H. 7.02; N, 
6.09. 
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5.6.2.4. (1S, 1’S) {1-[(3-Benzyloxy-4-hydroxymethyl-2-oxo-2,5-dihydropyrrol-1-yl)-hydroxymethyl]-2-
methyl-propyl}-carbamic acid tert-butyl ester. 
N
O
OBn
CH2OH
OH
BocHN
13
 
A solution of 12 (1.00 g, 2.17 mmol) in dry CH2Cl2 (20 mL) was added with diisobutylaluminium hydride 
(1.0 M in CH2Cl2, 5.42 mL, 5.42 mmol) at -78 °C and stirred for 2.5 h at the same temperature. After 
completion of reaction, the mixture was quenched by addition of sat. Rochelle salt (20 mL) and EtOAc 
(40 mL) was added. The thick slurry obtained was stirred vigorously till the two layers became 
transparent. The organic phase was separated and the aqueous phase was extracted with EtOAc (3 × 25 
mL). The combined organic extracts were washed with brine (35 mL) and dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column chromatography 
(40% EtOAc : Hexane) to afford 13 (0.27 g, 30%) as a yellowish solid;  
Rf (40% EtOAc : Hexane) = 0.3.  
mp = 60-62 °C. 
[α]D23 = -0.52 (c 1.00, MeOH). 
1H NMR (300 MHz, CDCl3) δ = 7.49-7.28 (m, 5H), 5.44 (dd, J = 4.6, 9.5 Hz, 1H), 5.25 (d, J = 11.3 Hz, 
1H), 5.11 (d, J = 11.3 Hz, 1H), 4.62 (d, J = 11.0 Hz, 1H), 4.46 (d, J = 4.6 Hz, 1H), 4.31 (d, J = 14.5 Hz, 
1H), 4.12 (d, J = 14.5 Hz, 1H), 4.04 (s, 2H), 3.77 (ddd, J = 3.5, 9.5, 11.0 Hz, 2H), 2.35 (brs, 1H), 2.28-
2.15 (m, 1H), 1.33 (s, 9H), 0.97 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 6.7 Hz, 3H) ppm. 
13C NMR (75 MHz, CDCl3) δ = 168.3, 156.6, 143.4, 136.8, 133.9, 128.8 (× 2), 128.6, 128.4 (× 2), 79.8, 
75.9, 73.2, 56.9, 56.2, 43.9, 28.5 (× 2), 28.4, 28.0, 20.3, 15.6 ppm.  
Elemental Analysis calcd. (%) for C22H32N2O6, C 62.84, H 7.67, N 6.66%, Found C 62.93, H 7.65, N 
6.67%. 
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5.6.2.5. (1S) [1-(3-Benzyloxy-4-formyl-2-oxo-2,5-dihydropyrrole-1-carbonyl)-2-methyl-propyl]carbamic 
acid tert-butyl ester. 
N
O
OBn
CHO
O
BocHN
14
 
To a stirred solution of compound 13 (0.22 g, 0.50 mmol) in CH2Cl2 (5 mL) PCC (1.12 g, 5.23 mmol) 
was added at 0 °C, then the solution was allowed to stir for 12 h at rt. After completion, the reaction 
mixture was filtered through a pad of celite and washed with CH2Cl2. The filtrate was concentrated in 
vacuo. The crude product was purified by flash column chromatography (20% EtOAc : Hexane) to afford 
14 (0.100 g, 46%) as a colourless viscous oil.  
Rf (20% EtOAc : Hexane) = 0.5. 
[α]D23 = + 8.32 (c 1.00, MeOH). 
1H NMR (600 MHz, CDCl3) δ = 10.14 (s, 1H), 7.51-7.35 (m, 5H), 5.73-5.60 (m, 2H), 5.39 (dd, J = 2.8, 
9.5 Hz, 1H), 5.17 (d, J = 9.5 Hz, 1H), 4.39 (d, J = 18.9 Hz, 1H), 4.24 (d, J = 18.9 Hz, 1H), 2.19-2.05 (m, 
1H), 1.44 (s, 9H), 1.09 (d, J = 7.1 Hz, 3H), 0.84 (d, J = 7.1 Hz, 3H) ppm. 
13C NMR (150 MHz, CDCl3) δ = 185.3, 173.0, 164.6, 156.1, 153.8, 135.0, 129.3, 129.1, 128.4 (× 2), 
125.0 (× 2), 80.1, 74.3, 58.7, 43.0, 30.5, 28.5 (× 3), 20.1, 16.3.  
Elemental Analysis calcd. (%) for C22H28N2O6, C 63.45, H 6.78, N 6.73%. found: C 62.56, H 6.75, N 
6.71%,  
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 5.6.2.6. (1S) [1-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-
methylpropyl]carbamic acid tert-butyl ester.  
N
O
OBn
O
BocHN
7
15
 
To an ice cold solution of (1-nonyl)triphenylphosphonium bromide (0.07 g, 0.14 mmol) in 3 mL of dry 
THF under nitrogen n-BuLi (1.6 M in hexane, 0.18 mL, 0.18 mmol) was added dropwise and the mixture 
was allowed stir for 45 min at the same temperature. The red solution was cooled to -78 °C and aldehyde 
14 (0.03 g, 0.07 mmol) in anhydrous THF (2 mL) was added dropwise. The reaction was stirred for 1 h at -
78 °C, warmed to 0 °C and quenched with sat. NH4Cl (10 mL). The aqueous phase was extracted with 
EtOAc (2 × 15 mL). The combined organic extracts were washed with brine (10 mL) and dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to give crude 15 which was used for the next step 
without further purification and characterization. 
Rf (10% EtOAc : Hexane) = 0.2. 
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5.6.2.7. (1S) 1-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methylpropyl 
ammonium trifluoro-acetate. 
N
O
OBn
O
H3N
7
TFA
16
 
To a stirred solution of compound 15 (0.02 g, 0.04 mmol) in dry CH2Cl2 (1 mL) TFA (0.5 mL) was added 
at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mixture 
was concentrated in vacuo. The residue was triturated with diethyl ether (3 ×5 mL) and dried to afford 16. 
The crude product was used for the next step without further purification.  
Rf (10% MeOH : CH2Cl2) = 0.2. 
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5.6.2.8. (2S, 1’S) 2-{3-[1-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-
propyl]ureido}-3-phenyl-propionic acid benzyl ester.  
N
O
OBn
O
N
H
7
N
H
O
BnO
O
Ph
17
 
A mixture of L-phenylalanine benzyl ester (0.02 g, 0.04 mmol) and diisopropylethylamine (0.01 g, 0.08 
mmol) in dry CH2Cl2 (2 mL) was added dropwise to a stirred solution of triphosgene (0.004 g, 0.013 
mmol) in dry CH2Cl2 (2 mL) at rt. After 15 min. stirring, a solution of 16 (0.03 g, 0.05 mmol) and DIEA 
(0.02 mL, 0.13 mmol) in dry CH2Cl2 (2 mL) was added dropwise. The reaction mixture was stirred for 1 h 
at room temperature and the solvent was removed in vacuo. The residue was diluted with ethyl acetate (10 
mL). The organic layer was washed with 10% aqueous KHSO4 (5 mL), 5% aqueous NaHCO3 (5 mL), 
brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The product was purified using PLC 
(35% EtOAc : Hexane) to give 17 (31 mg, 60% over three steps) as a white viscous liquid.  
Rf (30% EtOAc : Hexane) = 0.4.  
1H NMR (300 MHz, CDCl3) (mixture of stereoisomers) δ 7.53-6.88 (m,15H), 6.36 (d, J = 16.9 Hz, 1H), 
6.15-5.97 (m, 2H), 5.82-5.20 (m, 4H), 5.16-4.77 (m, 3H), 4.02 (d, J = 19.1 Hz, 1H), 3.61 (d, J = 19.1 Hz, 
1H), 3.20-2.90 (m, 2H), 2.21-2.07 (m, 3H), 1.78-1.63 (m, 2H), 1.52-0.64 (m, 19H) ppm. 
13C NMR (75 MHz, CDCl3) (major stereoisomer) δ 174.0, 172.6, 165.7, 157.1, 141.3, 139.1, 137.0, 
136.1, 135.4, 135.0, 129.7 (× 2), 128.8 (× 2), 128.75 (× 2), 128.7(× 2), 128.6 (× 2), 128.57 (× 2), 128.5 (× 
2), 127.0, 119.5, 73.1, 67.1, 57.6, 53.8, 44.6, 39.3, 33.8, 32.1, 31.2, 29.6, 29.5, 29.46, 29.1, 22.9, 20.1, 
16.6, 14.3 ppm.  
Elemental Analysis calcd. (%) for C43H53N3O6, C 72.96, H 7.55, N 5.94%, found: C 72.83, H 7.56, N 
5.95%. 
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5.6.2.9. (2S, 1’S) 2-{3-[1-(4-Decyl-3-hydroxy-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-propyl]-
ureido}-3-phenyl-propionic acid. 
N
O
OH
C10H21
O
N
H
N
H
O
HO
O
Ph
1
 
To the solution of 17 (0.03 g, 0.04 mmol) in EtOAc (5 mL) was added a catalytic amount of 10% Pd/C (6 
mg, 20% w/w). The reaction mixture was evacuated and flushed with H2 gas (3 times), then stirred for 2h 
at rt under H2 atmosphere. The reaction mixture was filtered through a celite pad and the pad was washed 
with EtOAc (3 ×5 mL). The filtrate was concentrated in vacuo. The crude product was purified by reverse 
phase PLC (25% H2O : MeOH) to afford 1 (0.02 g, 77 %) as a clear oil. 
Rf (25% H2O : MeOH) = 0.4.  
1H NMR (600 MHz, DMSO-d6)  δ = 12.62 (s, 1H), 9.42 (s, 1H), 7.27 (dd, J = 7.6, 7.4 Hz, 2H), 7.21 (dd, 
J = 7.6, 7.6 Hz, 1H), 7.19 (d, J = 7.4 Hz, 2H), 6.47 (d, J = 9.2 Hz, 1H), 6.34 (d, J = 8.0 Hz, 1H), 5.37 (1H, 
dd, J = 9.2, 3.7 Hz, 1H), 4.28 (m, 1H), 4.10 (d, J = 18.0 Hz, 1H), 4.00 (d, J = 18.0 Hz, 1H), 2.99 (dd, J = 
13.7, 5.1 Hz, 1H), 2.85 (dd, J = 13.7, 7.5 Hz, 1H), 2.31 (m, 2H), 2.00 (m, 1H), 1.54-1.10 (m, 16H), 0.91 
(d, J = 6.9 Hz, 3H), 0.86 (t, J = 6.4 Hz, 3H), 0.76 (d, J = 6.9 Hz, 3H) ppm. 
13C NMR (150 MHz, DMSO-d6) δ = 174.2, 172.7, 166.5, 157.9, 141.4, 138.0, 129.8 (× 2), 129.1, 128.6 
(× 2), 126.8, 57.1, 54.6, 46.7, 38.0, 31.8, 30.3, 29.5 (× 2), 29.4 (× 2), 29.2, 27.3, 25.3, 22.6, 20.2, 16.8, 
14.5 ppm.  
Elemental Analysis  calcd. (%) for C29H43N3O6, C 65.76, H 8.18, N 7.93%, Found: C 65.84, H 8.16, N 
7.91%. 
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CHAPTER-6 
TOTAL SYNTHESIS OF RESORMYCIN 
6.1. INTRODUCTION: 
In 1997, Takeuchi et. al. while screening Streptomyces platensis MJ953-SF5 isolated from the soil 
collected at Yokohama kawakawa, Japan, isolated a novel tripeptide cinnamic acid-containing metabolite, 
resormycin1 (1). The molecule showed remarkable growth inhibition of monocotyledonous and 
dicotyledonous weeds. The metabolites of cinnamic acid such as 3,5-dihydroxy cinnamic acid,2 
raphanusols,3 lespedazole4 from plants are known for their plant growth regulatory activity but they are 
not reported for the herbicidal activity. Moreover, resormycin also inhibits the growth of phytopathogenic 
fungi.   
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Figure-1: Structures of Resormycin (1), Androprostamine A (2), Androprostamine B (3). 
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The molecule is composed of three rare unnatural amino acid residues, hydroxyvaline, β-homolysine and 
an unusual chlorinated resorcyl-2,3-dehydro propenoic amino acid at C terminus.5 The structure of the 
molecule was elucidated by spectroscopic techniques. The resorcyl fragment is attached to the di-peptide 
unit via a Z-alkene. In 2015, Momose et. al. isolated two novel peptide metabolites androprostamine A 
(2) and B (3) produced by Streptomyces Sp. MK932-CF8.6 The compounds 2 and 3 display  anti-prostate 
cancer activity by inhibiting the function of androgen receptor. The prostate cancer is very prevalent 
among men in western countries and is a second leading reason for male fatalities in USA.7 Furthermore, 
in developing countries changes in life style and food habits have marked significant increase of prostate 
cancer cases. The androprostamine A (2) and B (3) share the tripeptide backbone core with resormycin.  
The intriguing biological profile of resormycin spanning from herbicidal, fungicidal to anticancer activity 
and the distinctive structural architect makes it an interesting synthetic target, which could serve as lead 
structure for the development of new active compounds.  
To explore the therapeutic potential of resormycin (1), we planned to develop a convergent synthetic 
approach, which in principle could be modulated for the generation of analogues to perform structure- 
activity relationship (SAR) studies. The synthetic strategy developed for resormycin can also be extended 
for the synthesis of androprostamine A (2) and B (3). The strong interest in these molecules is confirmed 
by the recent synthesis of resormycin (1) and androprostamine A (2) by Shibasaki et. al.8 reported in the 
literature during the last part of this work. 
6.2. SHIBASAKI APPROACH: 
The Shibasaki strategy (Figure-2) is based on the use of Horner-Wadsworth-Emmons (HWE) olefination 
as a key reaction to install the 2,3-dehydroamino acid moiety, but the olefination step proceeds with poor 
yield and E/Z selectivity. The synthesis of resormycin is achieved in 10 steps with overall yield of 3%. 
The synthetic route involves some unstable intermediates, poor yielding synthetic steps and it also lacks 
use of orthogonal protecting groups which is essential to develop substantial structure activity relationship 
studies.  
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Figure-2: Shibasaki approach. 
 
 
6.3. PRESENT PLAN: 
Our retrosynthetic plan is depicted in Figure-3. We envisioned that the Z-olefin could be obtained by Z-
selective elimination of alcohol 10. The advantage of this method over HWE olefination is to selectively 
obtain the Z-olefin without the formation of undesired E-isomer under neutral condition. The aldol 
condensation of the N-(diphenylmethylene)glycine tert-butyl ester with appropriately protected aldehyde 
is expected to furnish amino alcohol 11. The amino alcohol in turn could be produced starting from 4-
chloro-3,5-dihydroxybenzoic acid. The acid (-)-12 could be synthesized by coupling of NHS ester of 
protected β-homolysine with the hydroxyvaline 13. The di-alloc protected NHS ester can be smoothly 
obtained starting from β-homolysine 14. 
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Figure-3: Our retrosynthetic approach to resormycin. 
6.4. SYNTHESIS OF DIPEPTIDE 12: 
The shortest approach for the synthesis of dipeptide (-)-12 is the amide coupling of NHS ester of di-
Alloc-β-homolysine with the hydroxyvaline 13. Thus, the di-alloc protection of β-homolysine 14 using 
allyl chloroformate and K2CO3 in H2O afforded di-Alloc-β-homolysine (-)-15 in 73% yield.9 (Scheme 1). 
The treatment of compound (-)-15 with N-hydroxysuccinimide and EDC·HCl in DMF cleanly furnished 
NHS ester.10 The NHS ester obtained was pure enough and was used immediately upon water workup. 
The coupling of NHS ester with hydroxyvaline in dioxane: water using NEt3 produced acid (-)-12 in 86% 
yield over two steps.6 The acid was pure enough and was used for the next step without purification.  
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Scheme-1: Synthesis of dipeptide acid; Reagents and condition: a) Allyl chloroformate, K2CO3, H2O, 0 
°C to rt, 16 h, 73%; b) i) NHS, EDC-HCl, DMF, rt 16 h, ii) (S)-2-amino-3-hydroxy-3-methylbutanoic 
acid, NEt3, dioxane : H2O (2:1), rt, 2 h, 86% over two steps. 
6.5. SYNTHESIS OF THE ARYL CORE: 
The synthesis of the aryl core is depicted in scheme-2. The shortest and easiest approach for the synthesis 
of aldehyde 17 was the regioselective chlorination of 3,5-dihydroxybenzaldehyde at C-4 position. Initially 
several attempts using NCS/PTSA/NaCl,11 NaOCl/KOH,12 NCS/AcOH,13 NCS/MeOH,14 
NaOCl/piperidine15 were tried for the selective chlorination of 3,5-dihydroxybenzaldehyde to give 4-
chloro-3,5-dihydroxybenzaldehyde but the results were not encouraging in all the cases either 
chlorination went exclusively at C-2 position or there was no product formation at all. The chlorination 
using NaOCl/KOH12 gave formation of multiple spots on TLC. The chlorination of 3,5-bis(allyloxy) 
benzaldehyde also did not gave the regioselective C-4 chlorination. After several futile attempts we 
decided to begin with the synthesis of aldehyde 17 starting from commercially available 4-chloro-3,5-
dihydroxy benzoic acid. The triallyation of acid 5 using K2CO3/DMF16 at room temperature gave the ester 
16 in 86% yield. The ester 16 was subjected to reduction using LAH at 0 °C in dry diethyl ether, but the 
reaction gave incomplete conversion with formation of impurities. The treatment of ester 16 with DIBAL-
H in CH2Cl2 at -78 °C cleanly furnished the benzyl alcohol which was used without further purification. 
The crude benzyl alcohol was oxidized using PCC/NaOAc system in CH2Cl2 giving the aldehyde 17 in 
80% yield over two steps.17 Having the aldehyde 17 in hand we decided to use the Zu’s protocol18 i.e. the 
condensation of aldehyde 17 with glycine tertiary butyl ester using Cs2CO3 in NMP at 100 °C which 
selectively gave the title enamine 18 with Z-stereochemistry. 
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Scheme-2: Synthesis of aryl core; Reagents and condition: a) Allyl bromide, K2CO3, DMF, 0 °C to rt, 2 
h, 86 %; b) i) DIBAL-H, CH2Cl2, -78 °C, 1 h, ii) PCC, NaOAc, 10 °C- rt , 2 h, 80% over two steps c) 
Cs2CO3, glycine tert-butyl ester hydrochloride, NMP,100 °C, 6 h. 51%; d) i) DIPA, n-BuLi, THF, 0 °C, 
30 min, then N-(Diphenylmethylene)glycine-tert-butyl ester in THF, -78 °C, 30 min; ii) TMS-Cl, -78 °C- 
rt over 1h, then Cat. ZnCl2 and 17 in THF, rt, 2 h, iii) 10 % citric acid, rt, 16 h, 81%. 
Unfortunately, the coupling of enamine 18 with acid (-)-12 using HOBt/EDCI, HATU, HBTU, Ghosez 
reagent, oxalyl chloride and mix anhydride using ethyl chloroformate did not give the formation of amide 
product. The most plausible explanation for the unreactivity of enamine 18 under standard coupling 
conditions may be the poor nucleophilicity of the amine. The unsatisfactory results made us to change our 
synthetic strategy. Alternatively, we planned to convert the aldehyde 17 into corresponding amino 
alcohol, which can be readily coupled to the carboxylic acid counter parts. Thus, LDA was generated 
using DIPA and n-BuLi in THF at 0 °C, and was added to the THF solution of N-
(diphenylmethylene)glycine tert-butyl ester at -78 °C. The anion was quenched to generate the TMS 
enolate, which was condensed with the aldehyde 17 in presence of cat. ZnCl2 to furnish the O-TMS- N-
(diphenylmethylene)glycine tert-butyl ester imine intermediate. The intermediate obtained was cleaved 
using 10% citric acid to produce amino alcohol 11 in excellent yields.29 
The amide coupling of amino alcohol 11 and acid 12 using HBTU/DIPEA and HBTU/NMM gave the 
amide 10 in 50% and 61% yield, respectively (scheme 3). The O-acylation was the major side reaction 
with DIPEA and NMM as base. The best results were obtained when DMAP was employed as a base 
furnishing the amide 10 in 73% yield. The stereospecific elimination of alcohol 10 using DAST/pyridine20 
and DAST/NEt3 combination did not give good results. The O-DAST adduct formed did not undergo 
elimination at room temperature. The replacement of DAST with Martin sulfurane led to the formation of 
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Z-alkene 19 in 60% yields.21 The one pot-deprotection of allyl and alloc groups using Pd(PPh3)4 catalyst 
in combination with N-methyl aniline and dimedone22 as an allyl scavenger gave the partially deprotected 
compound. The palladium catalyzed hydrostanylation of alloc and allyl groups using SnBu3H and AcOH 
in CH2Cl2 results in clean deprotection to furnish diamine 20 in 60% yield.23 
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Scheme-3: Synthesis of resormycin; Reagents and condition: a) HBTU, DMAP, DMF, 0 °C for 2 h then 
at rt for 1 h. 73%, b) Martin sulfurane, CH2Cl2, 0 °C to rt, 16 h, 60 %; c) SnBu3H, AcOH, PdCl2(PPh3)2, 
CH2Cl2, rt, 12 h, 66 %; d) TFA, CH2Cl2, 0 °C to rt, 2 h, 97%. 
The diamine 20 was treated carefully with TFA in CH2Cl2 at 0 °C to furnish the title compound 
resormycin.  
6.6. CONCLUSIONS: 
In conclusion, we have designed and accomplished the total synthesis of resormycin in longest linear 
sequence of 8 steps with overall yield of 16%. The key steps in our synthetic approach include the late 
stage stereospecific dehydration of alcohol to install the Z-olefin and palladium catalyzed one-pot 
deprotection of allyl and alloc groups. The current synthetic strategy gains some advantages over the 
Shibasaki approach8 in terms of improved yields and orthogonality of protecting groups. The orthogonal 
nature and simplified synthetic approach makes it amenable for easy modifications of synthetic routes to 
generate the diverse analogues for biological investigation.  
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6.7. EXPERIMENTAL SECTION 
6.7.1. GENERAL INFORMATION:  
As per chapter 3.3.1. GENERAL INFORMATION. 
6.7.2: EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA: 
6.7.2.1. (S)-3,7-bis-allyloxycarbonylaminoheptanoic acid. 
HO
O NHAlloc
AllocHN
15
 
To a solution of β-homolysinedihydrochloride (320 mg, 1.37 mmol) in H2O (2 mL) at 0 °C, a cold 
solution of K2CO3 (948 mg, 6.86 mmol) in H2O (2 mL) followed by allyl chloroformate (0.36 mL, 3.432 
mmol) were added dropwise. After complete addition, reaction mixture was stirred at room temperature 
for 16 h. The reaction mixture was cooled to 0 °C and acidified using 2N HCl and the aqueous layer was 
extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were washed with brine (7 mL), 
dried over anhydrous Na2SO4 and concentrated in vacuo. The purification using flash column 
chromatography in 7-10% MeOH : CH2Cl2 yielded compound (-)-15 (330 mg, 73%) as a colorless solid. 
Rf (10 % MeOH : CH2Cl2) = 0.4.   
mp = 77-78 °C. 
[α]D23 = -12.8 (c 1.15, CHCl3) 
1H NMR (300 MHz, CD3OD) δ = 5.95-5.85 (m, 2H), 5.28 (dd, J = 17.1, 1.4 Hz, 2H), 5.16 (dd, J = 10.5, 
1.4 Hz, 2H), 4.53-4.48 (m, 4H), 4.02-3.84 (m, 1H), 3.09 (t, J = 6.7 Hz, 2H), 2.44 (dd, J = 6.9, 2.0 Hz, 
2H), 1.66-1.27 (m, 6H) ppm. 
13C NMR (75 MHz, CD3OD) δ = 175.2, 158.8, 158.2, 134.6, 134.5, 117.3 (× 2C), 66.2 (× 2C), 49.4, 41.5, 
40.9, 35.3, 30.6, 24.2 ppm.  
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6.7.2.2. (S)-2-((S)-3,7-bis(((allyloxy)carbonyl)amino)heptanamido)-3-hydroxy-3-methylbutanoic acid. 
N
H
O NHAlloc
OH
HO
O
AllocHN
12
 
To a stirred solution of compound (-)-15 (508 mg, 1.548 mmol) in dry DMF (5.1 mL, 0.3 M), N-
hydroxysuccinimide (409 mg, 3.562 mmol) and EDC·HCl (682 mg, 3.562 mmol) were sequentially 
added under N2 atmosphere. The clear solution obtained was stirred overnight at room temperature. The 
reaction mixture was poured in ice water (30 mL) and the aqueous layer was extracted with ethyl acetate 
(2 × 10 mL). The combined organic extracts were washed with cold brine (5 × 5 mL), dried over 
anhydrous Na2SO4 and concentrated in vacuo to give NHS ester (785 mg). The crude NHS ester was used 
further without purification. To a solution of (S)-2-amino-3-hydroxy-3-methylbutanoic acid (269 mg, 2.02 
mmol) in dioxane: H2O (26.6 mL, 1:1 ratio) was added NEt3 (0.64 mL, 4.60 mmol) followed by dropwise 
addition of solution of above NHS ester (785 mg, 1.84 mmol) in dioxane (13.4 mL). The resultant 
solution was stirred at room temperature for 2 h. The solvent was removed in vacuo and diluted with aq. 
NaHCO3 (5 mL) and the aqueous layer was washed with ethyl acetate (2 ×10 mL). The aqueous layer was 
cooled to 0 °C and acidified using 2N HCl, then it was extracted with ethyl acetate (2 × 20 mL), washed 
with brine (10 mL) and dried over anhydrous Na2SO4. The solvent was concentrated in vacuo to yield (-)-
12 (595 mg, 86%) as a pale yellow solid. 
Rf (10 % MeOH : CH2Cl2) = 0.1.   
mp = 63-65 °C. 
[α]D23 = -18.4 (c 1.0, CHCl3). 
1H NMR (300 MHz, CD3OD) δ = 6.00-5.83 (m, 2H), 5.28 (dd, J = 17.4, 1.8 Hz, 2H), 5.20-5.13 (m, 2H), 
4.53-4.47 (m, 4H), 4.42 (s, 1H), 3.95-3.91 (m, 1H), 3.09 (t, J = 6.4 Hz, 2H), 2.45 (dd, J = 6.9, 2.6, 2H), 
1.68-1.29 (m, 6H), 1.29 (s, 3H), 1.26 (s, 3H) ppm. 
13C NMR (75 MHz, CD3OD) δ = 178.2, 173.3, 158.7, 158.3, 134.6, 134.5, 117.5, 117.4, 73.4, 66.4, 66.2, 
62.7, 49.9, 42.8, 41.5, 35.5, 30.6, 27.8, 26.1, 24.1 ppm. 
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6.7.2.3. allyl 3,5-bis(allyloxy)-4-chlorobenzoate. 
OAllyl
O
AllylO
OAllyl
Cl
16
 
A suspension of 4-chloro-3,5-dihydroxy benzoic acid 5 (0.50 gm, 2.65 mmol) and anhydrous K2CO3 
(2.50 gm, 18.55 mmol) in dry DMF (5 mL, 0.5 M) was stirred for 10 minutes and cooled to 0 °C. Ally 
bromide (0.80 ml, 9.28 mmol) was added dropwise at 0 °C and the mixture was stirred for 1 h at room 
temperature. Then, the reaction mixture was poured in ice water (25 mL) and the aqueous layer was 
extracted with diethyl ether (2 × 10 mL); the combined organic extracts were washed with brine (5 mL) 
and dried over anhydrous Na2SO4. The solvent was removed in vacuo. Purification using flash column 
chromatography in 3% EtOAc :  petroleum ether afforded compound 16 (650 mg, 79 %) as a colorless oil. 
Rf (5 % EtOAc : petroleum ether) = 0.3.   
1H NMR (300 MHz, CDCl3) δ = 7.29 (s, 2H), 6.18-5.94 (m, 3H), 5.53-5.28 (m, 6H), 4.82 (dt, J = 5.9, 1.3 
Hz, 2H), 4.67 (dt, J = 5.2, 1.6 Hz, 2H) ppm. 
13C NMR (75 MHz, CDCl3) δ = 165.7, 155.0 (×2), 132.4 (×2), 132.2, 128.9, 118.7, 118.3 (×3), 107.3 
(×2), 70.1 (×2), 66.1 ppm. 
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6.7.2.4. 3,5-bis(allyloxy)-4-chlorobenzaldehyde. 
H
O
AllylO
OAllyl
Cl
17
 
DIBAL-H (4.30 mL, 1 M in CH2Cl2, 4.30 mmol) was added dropwise at -78 °C under N2 atmosphere to a 
stirred solution of allyl 3,5-bis(allyloxy)-4-chlorobenzoate 16 (532 mg, 1.72 mmol) in CH2Cl2 (11.4 mL, 
0.15 M). After complete addition, the reaction mixture was stirred at -78 °C for 1 h. A solution of aq. 
Saturated Rochelle’s salt (1 mL) was added followed by 2N HCl (5 mL), the reaction mixture was stirred 
vigorously till two layers became clear. The organic layer was separated and the aqueous layer was 
extracted with dichloromethane (10 mL); the combined organic extracts were washed with brine (6 mL), 
dried over anhydrous Na2SO4 and concentrated in vacuo to afford 418 mg of benzyl alcohol as colorless 
oil.  
To a stirring suspension of PCC (709 mg, 3.29 mmol) and NaOAc (67 mg, 0.82 mmol) in dry 
dichloromethane (3 mL) cooled to 10 °C, benzyl alcohol (418 mg, 1.64 mmol) in dichloromethane (5 mL) 
was added dropwise. The reaction mixture was stirred 2 h at room temperature. In vacuo concentration 
followed by flash column chromatography furnished the 3,5-bis(allyloxy)-4-chlorobenzaldehyde 17 (346 
mg, 80 % over two steps) as a white solid. 
Rf (5 % EtOAc : petroleum ether) = 0.2. 
mp = 88-89 °C 
1H NMR (300 MHz, CDCl3) δ = 9.88 (s, 1H), 7.09 (s, 2H), 6.15-5.99 (m, 2H), 5.55-5.43 (m, 2H), 5.37-
5.31 (m, 2H), 4.71-4.67 (m, 4H) ppm. 
13C NMR (75 MHz, CDCl3) δ = 191.2, 156.1 (× 2C), 135.2, 132.3 (× 2C), 118.6 (×3C), 107.0 (× 2C), 
70.3 (× 2C) ppm. 
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6.7.2.4. tert-butyl 2-amino-3-(3,5-bis(allyloxy)-4-chlorophenyl)-3-hydroxypropanoate. 
OH
AllylO
OAllyl
NH2
OtBu
O
Cl
11
 
LDA generation: n-BuLi (1.3 mL, 1.6 M, 1.37 mmol) was added dropwise to a stirred solution of 
diisopropyl amine (0.20 mL, 1.43 mmol) in anhydrous THF (4 mL) at 0 °C under N2 atmosphere. The 
pale yellow solution obtained was stirred at 0 °C for 30 minute.  
The above generated LDA solution was added dropwise to a solution of tert-butyl 2-
(diphenylmethyleneamino)acetate (0.37 gm, 1.25 mmol) in THF (4 mL) cooled to -78°C under N2 
atmosphere. The wine red solution obtained was stirred at -78 °C for 30 minutes. TMS-Cl (0.47 mL, 3.75 
mmol) was added dropwise (color changes from wine red to pale yellow); after complete addition the 
reaction mixture was warmed to room temperature over 1 h. The yellow solution obtained was added 
dropwise to a stirred solution of 17 (0.316 g, 1.25 mmol) and ZnCl2 (0.16 mL, 0.16 mmol) in dry THF (4 
mL) at room temperature and stirred for 2 h. The reaction mixture was cooled to 0 °C and quenched by 
dropwise addition of 10% citric acid (6 mL), after complete addition, the reaction mixture was stirred 
overnight at room temperature. THF was removed in vacuo and the aqueous layer was cooled to 0 °C and 
basified using saturated aq. NaHCO3 and extracted with ethyl acetate (2 × 25 mL). The combined organic 
extracts were washed with brine (15 mL) and dried over anhydrous Na2SO4 and the solvent was removed 
in vacuo. The crude was purified using flash column chromatography in 0.5% MeOH: CH2Cl2 to give 11 
(0.393 gm, 81%) as a colorless oil. 
Rf (2 % MeOH: CH2Cl2) = 0.25.   
1H NMR (300 MHz, CDCl3) major stereoisomer δ = 6.61 (s, 2H), 6.15-5.98 (m, 2H), 5.551-5.42 (m, 2H), 
5.34-5.26 (m, 2H), 4.72 (d, J = 4.9 Hz, 1H), 4.65-4.58 (m, 4H), 3.49 (d, J = 4.9 Hz, 1H), 1.40 (s, 9H) 
ppm. 
13C NMR (75 MHz, CDCl3) major stereoisomer δ = 172.2, 155.2 ( x 2C), 140.7, 132.7 (x 2C), 118.0 (x 
3C), 104.5 (x 2C), 82.2, 74.2, 70.0 (x 2C), 60.9, 28.0 (x 3C) ppm. 
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6.7.2.4. tert-butyl (Z)-2-amino-3-(3,5-bis(allyloxy)-2-chlorophenyl)acrylate. 
AllylO
OAllyl
NH2
OtBu
O
Cl
18
 
To a stirring suspension of glycine tert-butyl ester hydrochloride (29.8 mg, 0.178 mmol) and Cs2CO3 
(76.8 mg, 0.236 mmol) in N-methylpyrrolidinone (0.2 mL), a solution of 3,5-bis(allyloxy)-4-
chlorobenzaldehyde 17 (30 mg, 0.118 mmol) in N-methyl pyrrolidinone (0.6 mL) was added dropwise. 
The reaction mixture was stirred at 100 °C for 5 h. The reaction mixture was poured in cold water (2 mL) 
and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic extracts were 
washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was 
purified using flash column chromatography in 3% ethyl acetate: hexane to afford enamine 18 (22 mg, 
51%) as colorless oil. 
Rf (5 % EtOAc : Hexane) = 0.3.   
1H NMR (300 MHz, CDCl3) δ = 7.26 (s, 1H), 6.35 (s, 2H), 5.99-5.83 (m, 2H), 5.39-5.26 (m, 2H), 5.26-
5.15 (m, 2H), 4.44-4.39 (m, 4H), 1.39 (s, 9H) ppm. 
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6.7.2.5. tert-butyl(5S,9S)-9-(((allyloxy)carbonyl)amino)-2-((3,5-bis(allyloxy)-4-
chlorophenyl)(hydroxy)methyl)-5-(2-hydroxypropan-2-yl)-4,7,15-trioxo-16-oxa-3,6,14-triazanonadec-18-
enoate. 
OH
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A stirred solution of acid 12 (201 mg, 0.453 mmol) and amino alcohol 11 (190 mg 0.498 mmol) in dry 
DMF (4.5 mL, 0.1 M) was cooled to 0 °C. HBTU (188.8 mg, 1.583 mmol) and DMAP (60.8 mg, 0.498 
mmol) were sequentially added at 0 °C under N2 atmosphere. The reaction mixture was stirred at 0 °C for 
2 h and then 1 h at room temperature. The reaction mixture was poured into cold water (30 mL) and the 
aqueous layer was extracted with ethyl acetate (2 x 15 mL). The combined organic extracts were washed 
with brine (10 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified 
using column chromatography in 1.5 to 2.5 % MeOH : CH2Cl2 to afford amide 10 (270 mg, 73%, mixture 
of rotamers and conformers) as a white solid. 
Rf (3 % MeOH : CH2Cl2) = 0.25.  
mp = 61-62 °C 
1H NMR (300 MHz, CD3OD) Major diastereomer δ  =  6.77 (s, 2H), 6.17-6.00 (m, 2H), 5.98-5.83 (m, 
2H), 5.54-5.43 (m, 2H), 5.34-5.11 (m, 6H), 4.74-4.37 (m, 10 H), 3.98-3.80 (m, 1H), 3.15-3.05 (m, 2H), 
2.41 (d, J = 7.0 Hz, , 2H), 1.60-1.39 (m, 15H) ppm. 
13C NMR (75 MHz, CD3OD) Major diastereomer δ = 173.2, 172.5, 172.2, 170.6, 170.4, 156.3 (×2), 
142.4, 134.4 (×4), 117.6 (×4), 117.4, 105.3 (×2), 83.2, 73.6, 72.9, 70.7 (×4), 66.2, 61.2, 60.4, 50.0, 42.4, 
41.5, 35.2, 30.5, 28.3 (×5) ppm. 
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6.7.2.6. tert-butyl (5S,9S)-9-(((allyloxy)carbonyl)amino)-2-((Z)-3,5-bis(allyloxy)-4-chlorobenzylidene)-5-
(2-hydroxypropan-2-yl)-4,7,15-trioxo-16-oxa-3,6,14-triazanonadec-18-enoate. 
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To a stirred solution of alcohol 10 (30 mg, 0.037 mmol) in anhydrous CH2Cl2 (0.6 mL) was added 
dropwise at 0 °C a solution of Martin sulfurane (49.8 mg, 0.074 mmol) in anhydrous CH2Cl2 (0.4 mL) 
under N2 atmosphere. The reaction mixture was stirred at room temperature for 3 h. Another 0.074 mmol 
of Martin sulfurane were added and the reaction mixture was stirred at room temperature for 12 h. The 
reaction mixture was concentrated in vacuo and the crude material was purified using flash column 
chromatography in 1.5 % of MeOH in CH2Cl2 to furnish enamide 19 (17.5 mg, 60%) as a white solid. 
Rf (2 % MeOH : CH2Cl2) = 0.20.  
mp = 72-73 °C 
1H NMR (300 MHz, CDCl3) δ = 8.09 (s, 1H), 7.22 (s, 1H), 6.71 (s, 2H), 6.65 (1H, d, J = 6.4 Hz), 6.16 – 
5.98 (m, 2H), 5.94 – 5.75 (m, 2H), 5.53- 5.41 (m, 3H), 5.35-5.12 (m, 6H), 4.95-4.79 (m, 1H), 4.72-4.43 
(m, 8H), 4.38 (1H, d, J = 6.4 Hz), 3.98- 3.67 (m, 2H), 3.20-2.97 (m, 2H), 2.56-2.38 (m, 2H), 1.58-1.30 
(m, 6H), 1.53 (s, 9H), 1.25 (s, 3H), 1.22 (s, 3H) ppm. 
13C NMR (150 MHz, DMSO-d6) δ = 171.6, 170.0, 164.1, 156.5, 156.0, 155.2 (× 2), 132.9, 132.6 (× 4), 
132.1, 125.8, 117.9 (× 4), 117.6, 107.5 (× 2), 82.9, 71.8, 70.0 (× 3), 65.5, 60.0, 48.8, 40.6, 40.2, 33.7, 
29.3, 28.0 (× 3), 27.5, 25.6, 22.9.  
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6.7.2.7. tert-butyl-(Z)-3-(4-chloro-3,5-dihydroxyphenyl)-2-((S)-2-((S)-3,7-diaminoheptanamido)-3-
hydroxy-3-methylbutanamido)acrylate. 
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To a stirred solution of enamide 19 (23 mg, 0.029 mmol), AcOH (0.02 mL, 0.348 mmol) and 
PdCl2(PPh3)2 (2 mg, 0.0029 mmol) in dry CH2Cl2 (0.8 mL, 0.035 M) under N2 atmosphere SnBu3H 
(0.045 mL, 0.17 mmol) was added in one portion. The reaction proceeded with fast evolution of CO2 and 
slight warming. The reaction mixture was stirred at room temperature for 2 h and again SnBu3H (0.045 
mL, 0.17 mmol) was added in one portion. The reaction mixture was stirred overnight at room 
temperature, then it was concentrated in vacuo to dryness and the solid obtained was purified using 
reverse phase column chromatography in 2 % aq. NH3 in MeOH : H2O (1:1) to yield diamine 20 (10 mg, 
66 %) as a yellow solid.  
Rf (3 % NH3 in (MeOH : H2O, 1:1) = 0.2.  
1H NMR (300 MHz, CH3OH-d4) δ = 7.07 (s, 1H), 6.46 (s, 2H), 4.52 (s, 1H), 3.01-2.86 (m, 1H), 2.74 (t, J 
= 5.7 Hz, 2H), 2.37 (d, J = 6.6 Hz, 2H), 1.51 (s, 9H), 1.6-1.36 (6H, m), 1.37 (s, 3H), 1.34 (s, 3H) ppm. 
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6.7.2.8. (Z)-3-(2-chloro-3,5-dihydroxyphenyl)-2-((S)-2-((S)-3,7-diaminoheptanamido)-3-hydroxy-3-
methylbutanamido)acrylic acid. TFA salt. 
HO
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A solution of diamine 20 (10 mg) in CH2Cl2 (0.5 mL) was cooled to 0 °C, TFA (0.2 mL) was added 
dropwise and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was 
concentrated to dryness and the residue was triturated with diethyl ether to afford the title compound 1 
(13 mg, 97%) as a white solid. 
Rf (5 % NH3 in (MeOH : H2O, 1:1)) = 0.8.  
1H NMR (300 MHz, DMSO-d6) δ = 9.42 (brs, 1H), 8.38 (1H, d, J = 9.6 Hz), 8.02-7.60 (brs, 6H), 7.03 (s, 
1H); 6.73 (s, 2H), 4.51 (1H, d, J = 9.6 Hz), 3.45-3.30 (m, 1H), 2.75 (t, J = 7.2 Hz, 2H), 2.68 (dd, J = 6.0; 
15.6 Hz, 1H), 2.54 (dd, J = 6.0, 15.6 Hz, 1H), 1.63- 1.42 (m, 4H), 1.41- 1.29 (m, 2H), 1.22 (s, 6H) ppm. 
13C NMR (75 MHz, DMSO-d6) δ = 169.8, 169.6, 166.2, 154.0 (x 2 C), 132.2, 131.0, 126.7, 108.8 (x 2 C), 
108.5, 71.4, 60.5, 47.7, 38.3, 37.3, 31.2, 27.1, 26.4, 26.1, 21.3 ppm. 
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